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ABSTRACT  
   
Vaccination remains one of the most effective means for preventing infectious 
diseases. During viral infection, activated CD8 T cells differentiate into cytotoxic effector 
cells that directly kill infected cells and produce anti-viral cytokines. Further T cell 
differentiation results in a population of memory CD8 T cells that have the ability to self-
renew and rapidly proliferate into effector cells during secondary infections. However 
during persistent viral infection, T cell differentiation is disrupted due to sustained 
antigen stimulation resulting in a loss of T cell effector function. Despite the 
development of vaccines for a wide range of viral diseases, efficacious vaccines for 
persistent viral infections have been challenging to design. Immunization against virus T 
cell epitopes has been proposed as an alternative vaccination strategy for persistent viral 
infections, such as HIV. However, vaccines that selectively engage T cell responses can 
result in inappropriate immune responses that increase, rather than prevent, disease.  
Quantitative models of virus infection and immune response were used to 
investigate how virus and immune system variables influence pathogenic versus 
protective T cell responses generated during persistent viral infection. It was determined 
that an intermediate precursor frequency of virus-specific memory CD8 T cells prior to 
LCMV infection resulted in maximum T cell mediated pathology. Increased pathology 
was independent of antigen sensitivity or the diversity of TCR in the CD8 T cell response, 
but was dependent on CD8 T cell production of TNF and the magnitude of initial virus 
exposure. The threshold for exhaustion of responding CD8 T cells ultimately influences 
the precursor frequency that causes enhanced disease. 
 In addition, viral infection can occur in the context of co-infection by 
heterologous pathogens that modulate immune responses and/or disease. Co-infection 
of two unrelated viruses in their natural host, Ectromelia virus (ECTV) and Lymphocytic 
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Choriomeningitis virus (LCMV) infection in mice, were studied. ECTV infection can be a 
lethal infection in mice due in part to the blockade of antiviral cytokines, including Type 
I Interferons (IFN-I). It was determined that ECTV/LCMV co-infection results in 
decreased ECTV viral load and amelioration of ECTV-induced disease, presumably due 
to IFN-I induction by LCMV. However, immune responses to LCMV in ECTV co-infected 
mice were also lower compared to mice infected with LCMV alone and biased toward 
effector-memory cell generation. Thus, providing evidence for bi-directional effects of 
viral co-infection that modulate disease and immunity. Together the results suggest 
heterogeneity in T cell responses during vaccination with viral vectors may be in part due 
to heterologous virus infection or vaccine usage and that TNF-blockade may be useful for 
minimizing pathology while maintaining protection during virus infection. Lastly, 
quantitative mathematical models of virus and T cell immunity can be useful to generate 
predictions regarding which molecular and cellular pathways mediate T cell protection 
versus pathology. 
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CHAPTER 1 
INTRODUCTION 
Historical perspectives of immune memory  
 The concept of immune memory was utilized long before the understanding of 
microbiology or immunology. Early understanding (400 BCE) of immune memory was 
due to the observation that people who survived a disease rarely became sick from the 
same disease more than once(1, 2). In the 16th century the first expansive attempts at 
purposeful induction of immune memory against smallpox was attempted through the 
process of variolation(3). Variolation consisted of subcutaneously introducing smallpox 
pustules from infected patients into healthy individuals to prevent mortality during 
smallpox epidemics. However, variolation resulted in disseminated smallpox in a small 
proportion of recipients resulting in 2-3% mortality following inoculation(1, 3). 
 In 1796, the English physician Edward Jenner utilized his knowledge that 
dairymaids exposed to cowpox appeared to be immune to smallpox in order to 
deliberately transmit protection from one person to another. Jenner inoculated an 8–
year-old boy with a lesion from a dairymaid infected with cowpox, waited two months, 
and then inoculated the boy with smallpox. The boy did not demonstrate any disease 
symptoms leading Jenner to conclude cowpox infection mediated protection from 
smallpox. Jenner named the procedure vaccination after the Latin word for cowpox, 
vaccinia(4, 5). The English farmer Benjamin Jesty has now been recognized as the first to 
vaccinate against smallpox using cowpox lesions in 1774(6). However, Edward Jenner is 
widely acknowledged as the pioneer of vaccination due to his lifelong pursuit to 
scientifically promote smallpox vaccination.  
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The modern definition of immunological memory is the ability of a diverse 
population of purposely developed and pre-programmed immune cells to respond to 
secondary infection of a pathogen faster, and with greater magnitude, resulting in 
protection from either infection or disease(7-9). One of the most relevant contributions 
of immunology to human health is the ability to utilize immune memory for the design of 
vaccines against infectious diseases(7, 10). Four of the top ten leading global causes of 
premature death in humans are diseases due to infectious pathogens(11). However, in 
the past decade there has been a global shift away from premature death due to 
infectious diseases, except in Africa where 70% of calculated years of life lost are due to 
infectious diseases, maternal, neonatal, and nutritional causes(11). One of the main 
reasons for this transition is that expanded vaccination coverage has significantly 
enhanced our ability to elicit effective memory immune responses to fight and prevent 
human diseases caused by infectious pathogens(12, 13). Vaccines designed against 
smallpox, polio and measles are only a few examples of the remarkable impact 
vaccination has made towards the reduction of the global disease burden(1, 14).  
Despite the success of current vaccines, there are many remaining challenges for 
vaccines designed to prevent viral infections, such as human immunodeficiency virus 
(HIV)(15-17), hepatitis C virus (HCV)(18) and respiratory syncytial virus (RSV)(19). In 
2013, 35 million people were estimated to be living with HIV resulting in an estimated 
1.5 million deaths due to HIV-related causes(11). Effective antiretroviral therapy has 
increased the quality and longevity of life in HIV-infected individuals(20). However, in 
2o13, 2.1 million people worldwide became newly infected with HIV(11), emphasizing the 
need for a vaccine that prevents infection in order to eliminate HIV/AIDS in 
humans(21).  
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The traditional approaches for vaccine design against HIV have been hampered by the 
safety concerns for immunizing with attenuated HIV and the lack of efficacy of vaccines 
designed using inactivated virus (17, 21-23). Vaccination for T cell responses using 
recombinant vectors has been proposed as an alternative strategy to elicit immune 
responses and continues to be the focus of future vaccine candidates(21, 24, 25). 
Therefore, it is important to continue to study the intricacies of immunological 
memory in order to inform the safe design of vaccines through defining the magnitude, 
functionality, and specificity of immune responses to viral infection(9, 12). The 
generation of immunological memory to infectious pathogens involves the interaction 
and communication of almost all of the different types of cells in the immune 
system(26). In order to study adaptive memory responses, the function of the innate 
immune system must be understood. The innate immune system is critical for the 
detection of invading agents, initial control of overwhelming replication of pathogens, 
and informing adaptive immune cells(27).  
 
Fundamentals of innate immunity 
The immune system is composed of two very different yet equally important parts 
labeled as either innate or adaptive components. Innate immunity is characterized by a 
rapid, but fixed, response to a large, but limited number of stimuli. Innate immunity is 
composed of physical, chemical and biological barriers including specialized cells and 
soluble molecules that are present in all healthy individuals regardless of past exposure 
to pathogens(27). The main effector cells of the innate immune system are macrophages, 
granulocytes, natural killer (NK) cells, and dendritic cells (DCs)(16, 28, 29).  
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The main function of these cells is phagocytosis of invading pathogens, release of 
inflammatory cytokines and chemokines, activation of complement proteins, and 
presentation of foreign antigen to adaptive immune cells(30-32).  
Innate immune cell effector mechanisms are stimulated by detection of specific 
foreign molecular structures ubiquitous in microorganisms, such as lipopolysaccharides 
and nucleic acids, collectively termed pathogen associated molecular patterns 
(PAMPs)(31, 33, 34). PAMP recognition by specific receptors known as pattern 
recognition receptors (PRRs), including the families of Toll like receptors (TLRs) and 
retinoic acid inducible gene I (RIG-I) like receptors, result in signal transduction and 
activation of innate cell effector functions such as phagocytosis and production of 
inflammatory proteins(32, 33, 35, 36). One of the most important innate responses to 
PAMP detection of viral pathogens is the synthesis of type I interferons (IFN-I)(37, 38). 
 
Type I interferons mediate antiviral defense 
Type I interferons (alpha/beta) are a multi-member cytokine family whose 
function is to signal the presence of intracellular infections and facilitate communication 
among cells that provide defense against viruses and intracellular bacteria(39, 40). The 
preservation of type I interferons throughout the vertebrate lineage suggest that IFN-I 
has a vital role in anti-viral defense(37). In both mice and humans there are more than 
20 interferon alpha genes and one interferon beta gene. IFN-I provides a rapid and 
direct response to invading pathogens within hours, limiting viral replication days before 
activation of a pathogen-specific adaptive immune response(41). Two specific receptor 
families are primarily responsible for coupling viral recognition via detection of viral 
nucleic acids and synthesis of IFN-I.  
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These families include TLRs expressed on innate immune cells and the ubiquitously 
expressed cytosolic receptors exemplified by RIG-I and MDA-5(42, 43).  
Several members of the TLR family of receptors expressed in macrophages and 
dendritic cells detect the presence of viral nucleic acids in the endosome after 
phagocytosis(44, 45). One example, TLR3, recognizes a common feature of viral 
infection not normally present in healthy cells, double-stranded RNA (dsRNA)(46). The 
intracellular expression of TLR3 in the endosome allows TLR recognition of viral nucleic 
acids entering from outside the cell, separating viral infection from viral recognition in 
order to produce interferon(44, 46). Almost all nucleated cells respond to viral infection 
via the production of IFN-I(37). In addition to TLR recognition of viral nucleic acids by 
macrophages and dendritic cells, ubiquitous expression of cytosolic receptors 
exemplified by RIG-I and MDA-5 allow for the detection of viral nucleic acids in infected 
non-immune cells(36, 42, 47). RIG-I and MDA-5 both utilize the adapter protein IPS-1 
leading to IRF3 phosphorylation and dimerization resulting in activation of transcription 
of the IFNγ gene(36, 48-50) (Figure 1.1A). 
IFN-I produced by infected cells can signal in both an autocrine and paracrine 
manner to indicate the presence of viral infection within the cell(37). IFN-I binds to a 
heterodimeric receptor composed of IFNAR1 and IFAR2 subunits (IFNAR) on 
neighboring cells(51). Receptor binding leads to activation of Janus protein tyrosine 
kinases leading to the formation and activation of the heterotrimeric interferon 
stimulated gene factor 3 complex (ISGF3) that ultimately binds to interferon stimulated 
response elements in the nucleus promoting the transcription of hundreds of interferon-
stimulated genes(52, 53). Signaling via IFNAR in uninfected cells results in the 
establishment of the “anti-viral” state(54) (Figure 1.1B).  
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Figure 1.1: Viral detection leads to production of Type I interferons to 
promote anti-viral defenses in neighboring cells. [A] Viral nucleic acid is 
detected by cytosolic pattern recognition receptors such as RIG-I or MDA-5 in infected 
cells leading to activation of IRF-3 and production of IFN-I. [B] IFN-I ligation to 
IFNAR-1 results in signaling via ISGF3 complex leading to induction of pattern 
recognition receptors, induction of proteins to block protein synthesis (PKR) and 
induction of proteins to cleave viral RNA (OAS) resulting in an anti-viral state. 
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 IFN- induced proteins with broad anti-viral effects include 2’5’ oligoadenylate 
synthase (OAS) that, upon activation via viral dsRNA, in turn activate the nuclease 
RNase L leading to degradation of viral RNA transcripts(55). IFN-induced protein PKR 
can undergo activation via viral dsRNA leading to eIF2a phosphorylation resulting in the 
obstruction of translation of viral and cellular mRNA(56). Additionally, the viral nucleic 
acid sensors RIG-I and MDA-5 are IFN inducible, thereby increasing the sensitivity of 
neighboring cells to detect viral infection(57). Collectively, the action of IFN-I signaling 
is to sensitize the cell to apoptosis upon subsequent viral infection. This action results in 
inhibition of virus replication, elimination of virally infected cells, and prevention of viral 
spread(54).  
 In addition, IFN-I also has a critical role in the functional linkage of innate cell 
detection and adaptive cell response(40, 58). The finding that all vertebrates contain 
genes that encodes IFNα and IFNβ in addition to the presence of NK cells and adaptive 
T and B cells supports a connection between interferon and effector cell generation(37). 
Other than the cell intrinsic effects of IFN-I, two important effector cell populations are 
regulated by IFN-I, IFN-I can directly activate NK cells to enhance cytotoxic activity(59) 
and it can influence differentiation and function of CD8 T cells(60). Consequently, IFN-I 
has both pro-apoptotic and anti-apoptotic activities since IFN-I can directly impact viral 
replication in infected cells (pro-apoptotic) and provide stimulation of anti-viral immune 
responses (anti-apoptotic), depending on the differentiated state of the signaled cell(58). 
Therefore, innate immune cells have greater significance than only the early detection 
and control of invading pathogens. Innate immunity is critical for the subsequent 
generation of adaptive immune responses, which are the primary focus of the following 
investigations. 
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 Adaptive immunity provides immunological memory 
Adaptive immune cells are responsible for providing immunological memory to 
pathogens after previous exposures. The adaptive immune system is composed of three 
separate but cooperative compartments: B cells, CD4 helper T cells and CD8 cytotoxic T 
cells(61). It was not until the mid 1960s that B and T lymphocytes were determined to be 
primarily responsible for the basic functions of antibody production and cell mediated 
immune responses(62). The first scientists to suggest a division of labor between cells 
responsible for antibody production and cell mediated delayed type hypersensitivity 
were Max Cooper and Robert Good. They found that cells derived from the chicken bursa 
of fabricius were required for antibody production (B cells), while cells mediating graft 
versus host reactions (T cells) required an intact thymus(63). 
 
B-lymphocytes produce antibodies 
B cells are modestly defined as a population of lymphocytes that express clonally 
diverse cell surface immunoglobulin receptors, B cell receptor (BCR), that recognize 
specific antigenic epitopes(64). Antibodies (Ig) produced by activated B cells are simply 
the secreted version of the membrane bound BCR(65). Antibodies consist of two 
different polypeptide chains designated as heavy (50kDa) and light (25kDa). Antibodies 
are roughly “Y-shaped” in structure with two matching antigen binding sites due to each 
Ig consisting of two identical heavy chains connected by disulfide linkages in addition to 
one identical light chain linked to each heavy chain by disulfide bonds(66, 67). In order 
to generate a diverse array of B cell receptors or antibodies capable of recognizing any 
potential pathogen, a developing B cell in the bone marrow undergoes combinatorial 
rearrangements of multiple gene segments in the heavy and light chain loci.  
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The heavy chain rearranges variable (V), diversity (D) and joining (J) gene segments and 
the light chain locus rearranges only V and J segments prior to linkage with a selected 
constant(C) region resulting in the generation of unique and diverse antigen binding 
sites on individual B cells(68, 69). Moreover, the discovery of somatic gene 
rearrangements to generate diverse Ig receptors by Susumu Tonegawa made such an 
enormous contribution to the understanding of immunology that he was awarded the 
Nobel Prize in physiology or medicine in 1987(64). 
 Pre-existing antibodies are immensely important for immune protection against 
extracellular pathogens because B cells, unlike T cells that require pathogen antigens to 
be presented on host proteins for recognition, directly bind to the invading free virus 
particle, bacteria or parasite(70). B cell activation after BCR antigen recognition results 
in dynamic changes to the responding B cell including localization to the germinal center 
in secondary lymphoid tissues, clonal expansion, class switch recombination, somatic 
hypermutation and affinity maturation(71, 72). CD4 follicular helper cells and follicular 
dendritic cells in the germinal center are particularly important to trap antigens and 
provide co-stimulatory signals leading to the generation of memory B cells and long lived 
plasma cells that produce very high affinity antibodies of the desired isotype(73, 74). 
Neutralizing antibodies are important for the prevention of viral infection at the sites of 
viral entry, especially in mucosal tissues(8, 75)  
 
T-lymphocytes significantly influence control of viral infection 
The clinical observation that patients without functioning T cells experience an 
increased frequency and severity of viral infections, suggests T cells are critical for anti-
viral defense(76-78).  
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Additionally, children with Bruton’s a-gammaglobulinemia present with undetectable 
serum antibody titer, yet resist subsequent infections to the majority of viruses(79-82). 
Thus, suggesting T cell responses are critical for the control, clearance, and subsequent 
memory of viral infections.  
Similar to B cells, in order to generate a T cell response to a broad array of 
infectious pathogens, T cells express clonally distributed T cell receptors (TCR) on their 
cell surface(83). The structure of the TCR consists of a membrane bound heterodimer of 
T cell alpha and beta polypeptide chains(84). In order to generate a broad repertoire of 
TCR capable of responding to any and all invading viral pathogens, T cells undergo 
combinatorial rearrangements of gene segments in both the alpha (V and J) and beta (V, 
D, J) loci joined to a randomly selected constant region during T cell development in the 
thymus(85). In contrast to the BCR, a TCR has only one antigen-binding site that 
primarily contains the regions of the alpha and beta chains encoding the V-J or V-D-J 
junctions. This is due to the diversity generated by selection of random gene segments 
and by the random incorporation or removal of junctional nucleotides during somatic 
gene rearrangement(83, 85, 86). Both the alpha and beta chains form the TCR antigen-
binding site(84). Therefore increased diversity is also due to random alpha and beta 
chain pairing in each T cell(87). The diversity of potential T cell receptors is estimated to 
range from 107 to 1015 unique TCR(85, 88-90). 
 
T-lymphocytes require recognition of both self-protein and foreign peptide  
In contrast to B cells, T cell recognition of pathogen infection requires foreign 
antigens to be bound to host proteins on the cell surface. T cells simultaneously 
recognize both foreign peptides and host major histocompatibility complex (MHC) 
proteins. 
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Foreign peptides can be presented by infected cells or “professional” antigen presenting 
cells (APCs), such as dendritic cells and macrophages(91). CD8 T cells, primarily 
responsible for cytolysis of infected cells, recognize short (8-10 amino acid) foreign 
peptides presented on MHC-class I (MHC-I) proteins that consist of a single polypeptide 
associated with the B2M structural protein that are expressed on virtually all cells 
types(92). Whereas CD4 helper T cells recognize slightly longer foreign peptides (12-16 
amino acids) presented on MHC-class II proteins (MHC-II) that consist of two 
associated polypeptides, alpha and beta, expressed primarily on “professional” antigen 
presenting cells(93). A unique characteristic of MHC proteins is that they are both 
polygenic and polymorphic. Humans have three genes that express classical MHC class I 
proteins, HLA-A, HLA-B and HLA-C, and three genes that express classical MHC class II 
proteins, HLA-DR, HLA-DQ and HLA-DP(94). In addition, different peptide-binding 
grooves due to polymorphisms of MHC proteins result in variations in antigen 
presentation and immune responses between individuals(95). The Nobel Prize wining 
discovery of MHC restriction in 1974 by Rolf Zinkernagel and Peter Doherty revealed 
that CD8 T cells could only lyse virally infected target cells that presented the same type 
of MHC as the originating mouse strain(96, 97).  
One of the main causes for the functional differences between CD8 and CD4 T 
cell subsets is due to the divergent origins of the foreign peptide that bind to MHC-I and 
MHC-II proteins(92). CD8 peptides that bind to MHC-I are generated from foreign 
proteins degraded by cytoplasmic proteasomes(98), which are then transported to the 
endoplasmic reticulum, via TAP protein, where they bind MHC-I(99). Furthermore, 
MHC-I:peptide complexes undergo vesicle transportation to the cell surface in order to 
activate TCR on CD8 T cells, allowing adaptive immune detection of intracellular 
infections(100). 
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 In contrast, CD4 peptides that bind to MHC-II are generated from foreign proteins 
taken up from the extracellular space into intracellular vesicles(101). Phagosome fusion 
with endosomes, containing proteases activated by acidification, generate peptide 
fragments that are subsequently loaded onto MHC-II. MHC-II:peptide complexes are 
then transported to the cell surface in order to activate TCR on CD4 T cells, allowing 
adaptive immune detection of extracellular infections(102, 103). 
There are also circumstances in which CD8 T cells can recognize peptides derived 
from extracellular sources. Mike Bevan initially observed this phenomenon in 1976 when 
he found that CD8 T cells could recognize peptides derived from other cells (extracellular 
sources) presented on MHC-I proteins(104). Cross-presentation of extracellular sources 
of foreign proteins can happen either when phagosomes disintegrate (depositing 
proteins into the cytoplasm) or phagosomes fuse with the ER and foreign proteins are 
transported back to the cytoplasm by the host protein Sec61(105, 106). In both cases, 
extracellular derived proteins are then processed into peptides by cytoplasmic proteases 
and undergo MHC-I loading(107). Cross presentation is a critical component in the 
induction of CD8 T cell immune responses since activation of naïve CD8 T cells requires 
antigen presentation via professional APCs that may or may not be directly infected. 
Thus, APCs must acquire exogenous antigens from infected cells and present them on 
MHC-I using cross-presentation. Dendritic cells positive for CD8 expression have been 
identified as the main type of cross-presenting cell during in vivo T cell activation(108).  
Additionally, CD4 T cells can respond to peptides derived from intracellular 
pathogens via autophagy(109). Autophagy is a cellular process normally used for the 
degradation or recycling of host cytoplasmic proteins(110).  
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In the event of a viral or intracellular bacterial infection, foreign proteins in the 
cytoplasm can be collected into vesicles via autophagy followed by similar peptide 
generation and loading onto MHC-II proteins seen after phagocytosis(103, 109). 
 
T cells undergo positive and negative selection during development 
T cell development in the thymus involves an initial stepwise process of TCR 
alpha and beta chain rearrangement followed by positive selection for host MHC binding 
and negative selection for auto reactive T cells(111). After successful TCR expression on 
the cell surface, double positive T cells expressing both CD8 and CD4 co-receptor 
proteins (CD8+ CD4+) undergo “positive” selection for their ability to recognize host 
MHC-I or MHC-II proteins expressed on cortical epithelial cells(112). The majority of 
double positive T cells express a recombined TCR that interacts poorly with host MHC 
proteins failing to provide the necessary intracellular signaling to promote cell 
survival(113). Depending on the strength of the TCR interaction to MHC-I or MHC-II, 
double positive T cells become lineage committed to either CD8 or CD4 populations(113, 
114). Expression of CD8 or CD4 co-receptor proteins is critical for mature T cells due to 
the importance of co-receptor engagement with MHC to strengthen MHC:peptide:TCR 
interactions(115, 116).  
Following successful TCR:MHC interaction, lineage committed CD8 and CD4 T 
cells undergo “negative” selection during which auto-reactive cells are deleted(117). 
Strongly reactive T cells to self-peptides presented on MHC proteins expressed by 
medullary epithelial cells or bone marrow derived macrophages and dendritic cells 
undergo apoptosis and are eliminated from the T cell repertoire(118, 119).  
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Weak TCR ligation with self-peptide after positive selection in the thymus results in 
continued survival and migration of mature T cells to secondary lymphoid tissues(117). 
Central tolerance of T cells reactive to self-peptides is critical to limit potentially harmful 
autoimmune reactions to self-proteins(120, 121). 
 
T cell activation requires co-stimulation  
T lymphocytes in the periphery that recirculate between secondary lymphoid 
tissues and the blood consist mainly of two functionally discrete subpopulations: CD4 
helper T cells and CD8 cytotoxic T cells. In order for a T cell to respond to an infection, it 
must first undergo three signals of activation by dendritic cells migrating from sites of 
infection to draining lymph nodes(122). The first step of T cell activation is recognition 
between the TCR and its cognate antigen presented on MHC by APCs. TCR and 
peptide:MHC ligation results in the formation of the immunological synapse resulting in 
the activation of ITAM motifs on the zeta chain of the TCR associated protein CD3, 
leading to the activation of Zap-70(123-125). Zap-70 activation results in the 
phosphorylation of the adaptor protein LAT, leading to the recruitment of different 
components of several signaling pathways and ultimately activating the transcription 
factors NFATc, AP-1 and NF-kB(126-129).  
In addition, T cells need a second signal, such as co-stimulation via CD28 ligation 
to CD80 or CD86 expressed on the activating APC that results in potentiation of TCR 
signaling above a threshold in which full activation occurs(130, 131). This leads to IL-2 
driven survival and proliferation(130, 132).  
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Furthermore, a third signal via pro-inflammatory cytokines such as IL-12 or IFN-I is 
required for differentiation into effector T cell subsets and sustained proliferation(133-
136). TCR ligation without co-stimulation leads to a state of unresponsiveness defined as 
T cell anergy(137, 138). 
 
CD4 helper T cell differentiation 
CD4 T cells further differentiate into distinct subpopulations after activation that 
play a major role in mediating immune response via the secretion of specific cytokines 
and expression of co-stimulatory proteins including CD40-L(139-141). CD4 T cell 
subsets, such as T-helper 1 (Th1), T-helper 2(Th2), T-helper 17 (Th17) and T follicular 
helper (Tfh), carry out a broad array of functions(140, 142, 143). These functions include 
activation of innate immune cells, stimulation of B cells to undergo isotype switching and 
somatic hypermutation, and stimulation of CD8 T cells(139, 142, 144-147). Additionally, 
natural regulatory CD4 T cells (Treg) and inducible Treg subsets are critical components 
of immune regulation that are capable of suppressing immune responses(148-150).  
Naïve CD4 differentiation into distinctive helper cell lineages is dependent on the 
specific cytokines secreted by the activating APCs, which in turn are determined by the 
particular PRR activated by the infecting pathogen(139, 151). Differential cytokine 
signaling in the naïve CD4 T cell during TCR:peptide:MHC ligation results in the 
induction of specific transcription factors that lead to a defined cytokine profile of the 
responding helper cell(142, 151, 152) . For example, intracellular PAMP receptor 
signaling via detection of viral nucleic acids in the endosome condition DCs to secrete IL-
12 resulting in the differentiation of Th1 helper cells(140, 153).  
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IL-12 binding to the IL-12 receptor on the CD4 T cell induces the activation of STAT4, 
leading to the activation of the transcription factor Tbet that promotes the production of 
IFNγ(146, 147, 154). IFNγ is a critical cytokine for the control of intracellular pathogens 
because it can directly inhibit viral replication and activate macrophages to fuse 
endosomes with lysosomes, resulting in enhanced microbial killing and activation of NK 
cells and CD8 T cells to directly lyse infected cells(155, 156). CD4 helper T cells are a 
complex and interconnecting element of the immune system due to their broad ability to 
modulate innate cell subsets, antibody production and CD8 cytotoxic responses to 
invading pathogens(142, 151). 
 
CD8 T cell effector function 
In contrast to the defined subpopulations of CD4 helper T cells, the primary 
effector function of CD8 T cells is to kill pathogen infected or transformed tumor target 
cells(157, 158). Activated CD8 T cells exit lymph nodes and migrate into infected tissues 
or infiltrate tumor(159, 160). There, TCR ligation of foreign peptides presented by MHC-
I causes directed cytolysis of the target cells via two different mechanisms(161). One 
mechanism is accomplished by the directed release of granules containing the effector 
proteins perforin and granzyme B(162). Perforin mediated entry of granzyme B into 
target cells results in the activation of caspase 3 and BID proteins and the subsequent 
release of mitochondrial cytochrome C, leading to fragmentation of cellular DNA and 
apoptosis(163-166). The second mechanism of directed cytolysis requires engagement of 
T cell expressed Fas-ligand to Fas resulting in FADD mediated caspase activation leading 
to DNA fragmentation and apoptosis(167, 168). In both scenarios, CD8 T cell cytolysis is 
antigen-specific, controlled by TCR recognition, and does not damage surrounding 
cells(169, 170).  
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CD8 T cells can also directly inhibit viral infection and stimulate immune 
responses via production of the inflammatory cytokines IFNγ and TNF(157, 171). Tumor 
necrosis factor (TNF) was originally discovered as the soluble factor mediating tumor 
regression in mice after LPS stimulation(172). TNF signaling is currently recognized as 
causing two very different effects since it can either induce apoptosis via caspase 
activation or promote differentiation and proliferation via activation of transcription 
factor NF-kB(173-175). TNF has two identified receptors with varying levels of 
expression between cell types(176). TNFR1 has been identified on all human cell types 
whereas TNFR2 is mainly expressed on immune cells and endothelial cells(177). 
However, genetic deletion of either receptor eliminates the majority of signals 
transduced by TNF. Furthermore, TNFR1 may mediate apoptotic signals and TNFR2 
may mediate proliferation(178-180). In addition, TNF and TNFR1 have both been 
discovered to be critical for the protective effects of TNF during infection. The genetic-
deficiency of TNF or TNFR1 in mice leads to increased susceptibility of intracellular 
bacteria infection(181, 182). However, deletion of TNF signalizing also provides 
resistance to LPS-mediated septic shock, indicating a crucial balance between the 
protective potential of TNF produced during infection by effector CD8 T cells and the 
unintended damage of tissues due to overwhelming inflammation(183-185). 
CD8 T cells also produce the type II interferon, IFNγ that can either directly limit 
viral replication or modulate multiple components of the immune response(186). IFNγ 
signaling through the heterodimeric IFNGR1 receptor can result in the expression of 
viral resistance genes that increase a cell’s ability to recognize viral infection and signal 
infection to the immune system(187-189). Additionally, IFNγ signaling can stimulate the 
development of immune effector cells via activation of macrophages, increased antigen 
presentation and MHC protein expression, and activation NK cell cytolysis(156, 190). 
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CD8 T cells are important for the control of viral infections due to their sensitivity 
to respond to an array of viral structural and non-structural proteins and ability to 
directly limit viral replication by elimination of virally infected cells(191). However, the 
direct killing of infected cells combined with the release of large amounts of 
inflammatory cytokines by CD8 T cells can lead to unintended and severe 
immunopathology(192-194). Immunopathology is especially common during infection 
with non-cytolytic viruses that do not directly kill host cells, thus clinical disease 
symptoms are a direct result of the immune response and not due to pathogen 
burden(195). To ensure host survival there must be a balance between an effective anti-
viral response and limiting unintended immunopathology.  
 
Dynamics of the T cell response during acute viral infection 
Naïve antigen-specific CD8 T cell frequency has been estimated to be around 1 in 
every 200,000 CD8 T cells in a mouse spleen(196). A major component to the effector 
phase of the T cell response after activation is clonal expansion of stimulated antigen-
specific naive cells(197, 198). This leads to a greater frequency of antigen-specific effector 
cells during the peak response. Antigen-specific naïve T cells can divide up to 14 times 
before reaching the peak of their expansion, which usually occurs between 7-10 days post 
infection(199). The greater than 10,000 fold expansion results in antigen-specific 
effector cells reaching a potential frequency of 1 in every 2 CD8 T cells in the 
spleen(200). The massive expansion of antigen-specific T cells after stimulation is one of 
three distinct phases of the T cell response during a viral infection(159, 201) (Figure 
1.2).  
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Following the peak response, 90-99 percent of effector cells die during a contraction 
phase of the response until the remaining 1-10 percent of responding cells become long-
lived CD8 memory cells(9, 160, 202, 203). The ratio of the number of cells at the peak of 
the response versus the number of formed memory cells characterizes the extent of 
contraction(202). 
At the peak of the effector T cell response, there is a heterogeneous population of 
both terminally differentiated effector cells and memory precursors(9, 160, 203). The 
contraction of effector T cells is not impacted by the kinetics of pathogen clearance but 
can be influenced by the magnitude of inflammation in the environment during 
priming(204, 205). The homeostatic cytokines, IL-7 and IL-15, promote memory cell 
formation(206, 207) while the contraction of effector cells may be co-regulated by IL-2- 
family members, TNF-family members, perforin and IFNγ(9, 203). Contraction of short-
lived effector cells is required to maintain flexibility in the T cell compartment but it 
must be limited in order t0 increase the precursor frequency of memory antigen-specific 
cells for potential secondary exposures(202).   
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Figure 1.2: Dynamics of CD8 T cell response during viral infection. Naïve CD8 
T cells clonally expand into effector cells during viral infection. Following viral clearance, 
the majority of effector cells die during a contraction phase that culminates in the 
formation of memory T cells. Memory cell differentiation is a linear process resulting in 
long-term viral-specific cells maintained the in central lymphoid tissues and the 
periphery without continued antigen stimulation. 
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CD8 T cell memory differentiation 
It has been found that the subset of memory precursor effector cells that 
preferentially become long-lasting memory CD8 cells after acute infections are 
characterized by high expression of IL-7αR and low expression of KLRG1(9, 160, 208). 
Furthermore, the transcription factor T-bet has been found to be critical for the 
regulation of effector and memory cell differentiation. Overexpression of T-bet in 
effector cells leads to enhanced generation of short-lived terminal effectors(209, 210). 
One of the major determinants of the short lived effector versus memory precursor cell 
fate decision is the level of inflammation that CD8 T cells are exposed to during priming. 
In particular, IL-12 can modulate expression of T-bet resulting in more short-lived 
effector cells with high expression of KLRG1 and low expression of IL-7R. Accordingly, 
lower levels of IL-12 promote the formation of KLRG1low/IL-7Rhigh memory 
precursors(160, 211, 212).  
Additionally, epigenetic modifications such as DNA methylation or histone 
acetylation occur in CD8 T cells during the effector phase that are maintained after 
memory cell formation(211). Epigenetic modifications of genes involved in T cell 
survival, metabolism, proliferation and effector functions are the molecular basis for the 
propagated ability of CD8 T cells to rapidly respond to antigen stimulation, even after 
antigen-independent homeostatic cell division of memory cells(209, 213). For example, 
genes for IFNγ, IL-2, granzyme B and perforin become transcriptionally up-regulated 
due to the proximal promoter region losing repressive epigenetic markers resulting in 
these loci becoming epigenetically poised for polymerase accessibility and transcriptional 
activation in memory cells(214, 215).  
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Thus, there is a distinct transcriptional profile between short-lived effector and memory 
precursor cells during the effector phase that impacts contraction and memory 
formation. This is, in part, regulated by restriction of access to chromatin via DNA and 
histone modifications(209, 213-215).  
CD8 T cells require CD4 helper responses to form effective functional memory 
cells that can rapidly respond to secondary infection(216). Memory CD8 T cells primed 
in the absence of CD4 T cells do not the lose protective ability to clear acute viral or 
bacterial infections, but do demonstrate reduced expansion following secondary acute 
infections with or without continued CD4 T cell help(216-219). The requirement for CD4 
T cell help during priming to generate fully functional differentiated memory cells 
highlights the importance of CD4 T cell responses during primary infection due to their 
production of inflammatory cytokines, activation of APCs, or direct CD40:CD40L 
interactions between CD4 and CD8  T cells(142, 216, 217). Memory CD8 T cells and CD4 
T cells are one of the key components of protective immunity against viral infections. 
CD8 memory T cell numbers are stable and long-lasting after infection, whereas CD4 T 
memory cells slowly erode, as measured by tetramer-monitoring of CD8 T cell clones 
and CD4 T cell clones 20 to 900 days post infection(201, 220).  
Memory CD8 T cells undergo additional changes in phenotype, function and gene 
expression during differentiation 1-2 months after infection. This results in the 
establishment of a pool of antigen-specific T cells that can be maintained without 
continued antigen stimulation(9). Homeostatic turnover of memory T cells driven by IL-
7 and IL-15 results in the slow and steady cellular division of antigen-specific T cells that 
can respond faster to subsequent infection(221, 222). Memory CD8 T cells can rapidly 
respond to secondary infection primarily due to a simple increase in precursor frequency 
of antigen-specific cells and the retained potential to rapidly kill infected cells(223). 
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Memory CD8 T cells can release perforin/granzyme B and produce large amounts of 
IFNγ and TNF after exposure to an antigen without the activation and proliferation via 
traditional stimulation from APCs in draining lymph nodes(9, 211, 224). Chapter 2 
focuses on memory CD8 T cell secondary responses to viral infection. Specifically, the 
impact of the precursor frequency and the number of epitopes targeted by memory 
virus-specific CD8 T cells on disease outcomes including protection from disseminated 
viral infection and resulting T cell mediated pathology.  
 
Heterogeneity exists in memory CD8 T cell populations  
As in effector cells during expansion, there is heterogeneity in the population of 
memory cells formed after an acute infection(225). There are two main subsets 
of memory CD8 T cells, central and effector memory CD8 T cells, defined by the 
expression of cell surface proteins and tissue distribution(9, 160, 226). Central memory 
(TCM) cells are defined by the high expression of lymph node homing receptors CD62L 
and CCR7. TCM are known to have increased proliferative capacity as well as the ability to 
rapidly produce IFNγ, TNF and IL-2 after antigen stimulation. In contrast, the effector 
memory (TEM) cell subset is defined by low expression of CD62L and CCr7(227). 
Therefore, TEM are found enriched in non-lymphoid tissues and are important for the 
rapid recall of effector function as a first line of dense at peripheral sites of 
infection(228). Effector memory cells also have the ability to rapidly perform effector 
functions after antigen stimulation, but they do not have the same proliferative potential 
of central memory subsets(227, 229).  
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Central memory cells are associated with better protective immunity due to their 
ability to proliferate into a larger pool of secondary effector cells(230). However, both 
subsets contribute to protective immunity that is dependent on the nature and route of 
infection(228). Moreover, memory cell subsets do not arise as separate linages, but 
rather they move along a continuum of differentiation. Over time, CD62L expression on 
“effector” subsets increases(9, 231, 232). This results in a greater proportion of central 
memory cells that can self-renew via homeostatic turnover and rapidly proliferate into 
effector cells during secondary infections. Chapter 3 investigates, in part, the outcome of 
T cell expansion and memory differentiation of viral specific CD8 T cells in the context 
of viral co-infection. Specifically, the differences in effector memory and central 
memory CD8 T cell formation of virus specific T cells due to variations in inflammation 
during T cell activation via the secondary virus’s modulation of type I interferon 
production and signaling. 
 
Differences in T cell response following persistent viral infection  
 The fundamentals of T cell expansion, contraction and memory formation 
described above were elucidated from studies of the T cell response to acute viral 
infections. Acute viral infections such as influenza virus are characterized by short time- 
points of high antigen load (viremia) in the host followed by viral clearance(233). 
However, there are persistent viral infections such as hepatitis B virus (HBV), or HIV in 
which the virus is not controlled in the host following primary infection(234-236). This 
results in chronic antigen stimulation and persistent inflammation due to continued viral 
replication over time(234, 237).  
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Under conditions of chronic antigen stimulation, CD8 T cells do not undergo traditional 
differentiation into functional memory cells(232, 238). There are multiple alterations to 
the T cell response that occur under situations of chronic antigen stimulation such as T 
cell localization, functionality, and breadth of response(232, 239). For example, there 
may be preferential localization of antigen-specific T cells in non-lymphoid tissues due to 
sustained high antigen loads in infected organs or alteration in the expression of homing 
molecules on the CD8 T cell(232).  
 
Persistent viral infection induces CD8 T cell exhaustion  
One of the key differences between the T cell response to chronic and acute viral 
infection is the impaired effector function of responding T cells. The dysfunction of 
responding T cells during chronic viral infection due to sustained antigen stimulation is 
referred to as an exhaustive state of the T cell. The state of exhaustion of CD4 or CD8 T 
cell responses has been observed in a number of clinical and experimental viral 
infections in humans, non-human primates, and mice, such as HIV, HCV and HBV(240-
247). Additionally, bacterial infections, parasitic infections, and progressive tumor 
settings have all described responding T cells demonstrating a state of dysfunction(240-
246). This suggests that exhaustion is a conserved mechanism for limiting T cell 
immunopathology during antigen persistence. 
 A unique molecular signature markedly different from naïve, effector or memory 
T cells, can characterize exhausted CD8 T cells. However, T cell exhaustion is not an all-
or-nothing phenomenon. During chronic infection, CD8 T cells progressively lose 
effector functions with the degree of dysfunction directly correlating with the levels of 
virus or antigen present and the absence or loss of CD4 T cell help (Figure 1.3) (238).  
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Figure 1.3: Progressive increase in T cell exhaustion during viral infection. 
Persistent viral infection can result in dysfunction CD8 T cell differentiation in which 
chronic antigen stimulation drives exhaustion of CD8 T cells. As infection or antigen load 
increases, T cells undergo higher degrees of dysfunction. Initially, T cells lose the ability 
to produce IL-2 and proliferate, followed by lose of cytotoxic ability and inflammatory 
cytokine production. Higher expression of inhibitory receptors correlates with the degree 
of dysfunction of the exhausted cell. Lastly, virus-specific T cells can undergo apoptosis 
and be eliminated from the response. 
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Initially, T cells lose the ability to proliferate in response to antigen stimulation  
concurrent with the loss of production of the T cell growth factor, interleukin-2 (IL-2). 
Subsequently, T cells lose the ability to secrete the inflammatory cytokine tumor necrosis 
factor (TNF).  
The highest level of T cell exhaustion correlates with impaired cytolytic killing of 
infected target cells and the inability to produce the important anti-viral cytokine 
interferon-γ (IFN-γ)(248, 249). Lastly, critically exhaustive T cells may undergo clonal 
deletion as a final step of the exhausted phenotype summarized in Figure 1.3. Clonal 
deletion may further result in a change in the hierarchy of viral epitope-specific T cells 
responding to persistent viral infection as compared to an acute viral infection. This is 
due to the findings that CD8 T cells responding to immunodominant viral epitopes may 
be more susceptible to T cell exhaustion and deletion, resulting in the skewing of the T 
cell response to subdominant viral epitopes(238, 250). 
 Exhausted CD8 T cells maintain phenotypic and functional properties associated 
with exhaustion even after transfer into antigen-free hosts(251-253). Therefore, 
maintenance of the exhausted state must be mediated in part by regulatory mechanisms 
independent of external cues. The progressive loss of function during chronic viral 
infection is exacerbated by the loss of CD4 T cell help(250, 252). This increases with 
continuous antigen stimulation, indicating there must also be regulation by external 
cues. The varying levels of T cell exhaustion are regulated both by extrinsic and intrinsic 
mechanisms(249). Extrinsic mechanisms include the inhibition of CD8 T cells by 
regulatory CD4 T cell subsets and signaling via the inhibitory cytokines IL-10 and 
transforming growth factor-beta (TGF-β)(254, 255). Intrinsic mechanisms include the 
loss of expression of cytokines/cytokine receptors and increased expression of surface 
inhibitory receptors (249, 256).  
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The transient expression of inhibitory receptors such as Programmed cell death-1  
(PD-1) or cytotoxic T lymphocyte-associated antigen (CTLA-4) after T cell activation is 
presumably a mechanism used to control T cell responses in order to prevent hyper-
activation and autoimmunity(257).  CTLA-4 competes with CD28 on T cells for the co-
stimulatory ligand B7 on APCs to limit T cell activation. Whereas, PD-1/PD-L1 signaling 
regulates T cell function via direct attenuation of functional and proliferative capacity by 
the repression of TCR signaling and induction of genes such as BATF that regulate T cell 
function(258). Additionally, PD-1 expression has been implicated for the ability to limit 
T cell mobility, preventing target cell cytolysis in infected tissues(258). In the context of 
continued antigen stimulation, loss of T cell function usually coincides with increased 
expression of the inhibitory surface receptor PD-1. PD-1 and other inhibitory receptors 
such as LAG-3, 2B4 and Tim-3 can act synergistically due to non-redundant signaling 
pathways helping to establish the loss of function in responding T cells(259).  
Evidence has emerged indicating PD-1 as a major inhibitor of T cell function in 
the exhaustive state. Exhaustive T cells in the context of chronic viral infection have 
epigenetic variations in the Pdcd1 locus, resulting in long-term high expression of PD-1 
on virus specific T cells(260, 261). Additionally, antibody blockade of PD-1/PD-L1 has 
demonstrated a therapeutic benefit by increasing T cell function in vivo resulting in an 
increase in viral control in animal models of chronic viral infections(262). The 
effectiveness of PD-1 antibody blockade depends of the level of PD-1 expression of the 
exhaustive cell population since only T cells with intermediate PD-1 expression 
experienced reversible exhaustion, whereas PD-1high terminally differentiated cells did 
not(263). 
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T cell exhaustion is neither an irreversible terminal differentiated state nor a 
simple unresponsive T cell state, such as anergic T cells. The complete functional 
capacity of exhaustive cells in vivo has been difficult to determine due to the hierarchical 
loss of function during the progression of chronic viral infections but also due to the 
subtle variation in exhausted cells found during different contexts of infection(249). In 
studies of persistent antigen, T cell exhaustion can be defined by the inability of T cells to 
control pathogen infection or tumor progression in vivo or as the inability of T cells to 
exert effector functions measured during in vitro assays(264).  
These distinctions do not inherently differentiate between T cells that are continuously 
exerting effector functions in vivo, and have not had sufficient time to recover prior to 
analysis in ex vivo assays, versus T cells undergoing programmed T cell tolerance 
resulting in a lack of in vivo function.  
While exhaustion may be an adaptive state of hyper-responsiveness that is 
insufficient to control disseminated viral infection, it may also provide the host with the 
limited ability to control overwhelming viral replication without destructive T cell 
mediated immune pathology. The limited functional capacity of exhaustive T cells is 
supported by selection of T cell escape viruses in HIV patients, despite exhaustion of 
virus-specific T cells suggesting that these cells continue to exert some selective pressure 
during chronic infection(265). Furthermore, depletion of CD8 T cells during chronic 
viral infection of mice can result in a rapid increase of viremia(266, 267). Regulation of 
virus-specific T cell function by extrinsic factors such as regulatory T cells, IL-10, and 
TGF-β suggest that these are required to suppress ongoing T cell effector responses(249, 
254, 268).   
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Lymphocytic choriomeningitis virus model system 
Mouse models of viral infection have lead to the elucidation of a remarkable 
number of immunological properties. Specifically, infection of mice with Lymphocytic 
choriomeningitis virus (LCMV) has allowed the study of the immunological responses 
that contribute to the control of viral infection and disease(269). Animal studies utilizing 
the LCMV mouse model of infection have led to the description of the basis for MHC 
restriction of viral antigens(96, 270, 271), cross-presentation of epitopes by MHC 
proteins(272), how T cell effector mechanisms function to control virus infection(200, 
273, 274), the generation and maintenance of T cell memory(9, 221, 222), and 
exhaustion of T cell responses during persistent infection(238, 239, 249, 275, 276).  
Charles Armstrong unintentionally discovered LCMV during an outbreak of 
encephalitis in St Louis in 1933(277). It was further discovered that isolates of LCMV 
from infected humans were identical to isolates from naturally infected house mice (Mus 
musculus) in the United States and Europe highlighting the zoonotic potential of 
LCMV(269). LCMV is the prototypic Old World virus of the family Arenaviridae(278). 
The LCMV particle consists of an enveloped, bi-segmented ambisense single-stranded 
RNA (ssRNA) genome(278). The two segments of the LCMV genome contain only four 
genes and are designated as the long (L) segment and short (S) segment due to their 
respective lengths(279). The 7.2kb L segment encodes the viral RNA-dependent RNA 
polymerase (L) and a small structural or regulatory polypeptide that contains a zinc 
finger motif (Z)(280). The 3.4kb S segment encodes the structural proteins including the 
viral nucleoprotein (NP) and the glycoprotein precursor (GP-C) that is ultimately post-
transcriptionally cleaved into the mature GP-1 and GP-2 proteins(281, 282). 
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The ambisense coding strategy of arenaviruses requires that the NP and L coding 
regions located at the 3’ ends of the L and S segments are directly transcribed into 
genomic-complementary mRNA prior to translation, similar to other negative sense 
RNA viruses(278). In contrast, the GP and Z coding regions located at the 5’ ends of the 
L and S segments are transcribed into genomic-sense mRNA off of anti-genomic RNA 
generated during viral replication after NP and L translation occurs(283).  LCMV GP-1 
interacts with the cellular receptor α-Dystroglycan (α-DG) and the affinity of LCMV GP-1 
binding to α-DG has been implicated to determine viral tropism and the outcome of 
infection, acute or chronic, in mice (284). The LCMV model is particularly useful to 
study T cell responses due to the generation of transgenic mice encoding virus specific T 
cell subsets. The P14 transgenic mouse that generates CD8 T cells that express only TCR 
specific for the DbGP33-41 co-dominant epitope of LCMV is especially valuable in order 
to manipulate the number of antigen-specific naïve or memory CD8 T cells prior to viral 
challenge(285-288). Additionally, SMARTA transgenic mice that encode CD4 T cells 
specific for the GP61 epitope of LCMV(289) and B cell transgenic mice expressing the 
LCMV neutralizing KL25 antibody have been developed(290). 
 
Immune response to acute LCMV infection 
 There are several variants of LCMV that have been discovered in research 
laboratories that result in distinct pathological outcomes in laboratory mice after 
infection as illustrated in Figure 1.4(291, 292).  The following chapters employ two of 
the most popular strains utilized in mouse models for immunological research are the 
Armstrong and clone 13 strains. LCMV Armstrong is an acute infection after 
intraperitoneal (ip) or intravenous (iv) inoculation in adult mice.  
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Figure 1.4: The LCMV Armstrong and Clone 13 variants result in very 
different outcomes of infection in mice. [A] LCMV Armstrong infection of 
immune competent mice produces no overt clinical disease with undetectable viral titers 
in the serum by day 8 post infection due to the rapid and vigorous expansion of CD8 T 
cells followed by the formation of a stable LCMV specific memory population. [B] LCMV 
clone 13 infection of C57Bl/6 mice is characterized by diminished viral control resulting 
in high viral titers detectable in serum up to 60 days post infection. Persistence is due in 
part to dysfunctional CD8 T cell differentiation leading to exhaustion of the responding 
immunodominant CD8 T cells.  
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LCMV Armstrong infection of immune competent mice produces no overt clinical 
disease with undetectable viral titers in the serum by day 8 post infection due to the 
rapid and vigorous expansion of CD8 and CD4 T cells followed by the formation of a 
stable LCMV specific memory population(8, 200, 221). CD8 T cells are critical and 
necessary to control acute LCMV infection since mice deficient in the production of CD8 
T cells are unable to control viral replication after infection(293). Additionally, antibody 
production is presumably unnecessary for LCMV Armstrong viral clearance after 
primary infection because there is no measurable difference in the kinetics of viral 
clearance in B cell deficient mice(294, 295)  
 The majority of the responding CD8 T cells to LCMV Armstrong recognize either 
the immunodominant LCMV epitope from the viral nucleoprotein (H2Db, NP396-404) 
or the viral glycoprotein (H2-Db, GP33-41)(238). Although, the measured response to the 
GP33 peptide in in vitro assays is the total response of two separate populations because 
the GP33 peptide can also stimulate responding CD8 T cells that are specific for the 
GP34-41 (H-2Kb) epitope of LCMV. Table 1.1 summarizes additional GP or NP derived 
peptides such as GP276-286, GP118-125, GP92-101, and NP205-212 that have been 
measured to induce production of the greatest amount of IFNγ by CD8 T cells at the 
peak of the response post LCMV Armstrong infection(296). Further analysis of T cell 
responses to the entire LCMV Armstrong proteome has revealed measurable responses 
to 28 total LCMV epitopes including 15 subdominant responses to the viral 
polymerase(297). The resulting population of LCMV-specific CD8 T cells, after infection, 
is a broadly responsive polyclonal pool of memory cells. 
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Table 1.1: Summary of LCMV CD8 T cell epitopes and their relative 
immunodominance. Peptides utilized in this study are highlighted, percentage of 
LCMV T cell response for each peptide was derived from (Masopust, 2007). 
 
 
Peptide Sequence 
% IFNγ+ of CD8 T 
cells* 
day 8 day 90 
GP33/GP34 KAVYNFATM 27.54 5.29 
NP396 FQPQNGQFI 23.63 3.81 
GP276 SGVENPGGYCL 7.99 1.84 
NP166 SLLNNQFGTM 7.77 1.14 
GP118 ISHNFCNL 6.43 1.57 
NP205 YTVKYPNL 5.85 0.99 
GP92 CSANNSHHYI 1.17 0.25 
NP235 NISGYNFSL 1.07 - 
GP70 GVYQFKSV 0.77 0.27 
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However, the identical T cells responsible for controlling virus replication after ip 
inoculation in naive mice are also responsible for mediating lethal leptomeningitis when 
the virus is replicating in the brain post-intracranial (ic) inoculation leading to mortality 
6-8 days post infection(298-300). Pathology may be due to inflammatory conditions 
propagated by responding T cells either directly killing infected cells and producing 
cytokines such as TNF or the production of chemokines that result in the recruitment of 
innate immune cells such as macrophages and neutrophils that lead to increased 
vascular injury and lethal meningitis(301). The rapid control of viral replication in the 
brain after ic challenge due to the response of memory LCMV-specific CD8 T cells 
protects mice from lethal meningitis(302, 303). Thus demonstrating the importance of 
the kinetics in which virus can be eliminated from the host that can be affected by initial 
viral load, replication rates, and the effectiveness of responding T cells in order to limit 
severe pathology in critical tissues.  
Pathology observed during LCMV infection in mice may be dependent on virus 
strain, inoculum size and route of infection but ultimately pathology is mediated by the 
immune response (303-305). Congenital carrier mice with life-long LCMV infection in 
the absence of a LCMV-specific T cell response demonstrate limited pathology (273). 
This suggests that immune responses to LCMV, capable of generating protective 
responses to intracranial challenge or parental challenge with persistent stains, promote 
both virus clearance as well as immunopathology. 
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Immune response to persistent LCMV infection 
In contrast, the persistent LCMV clone 13 strain results in a protracted viral 
infection in wild type C57Bl/6 mice(292). Rafi Ahmed discovered LCMV clone 13 in 1984 
after observing sustained viral loads and suppression of LCMV-specific cytolytic activity 
in adult immunocompetent mice that received transfer of splenocytes from 2-month-old 
Balb/C WEHI mice infected at birth with LCMV Armstrong(292). Persistent LCMV clone 
13 infection in C57Bl/6 mice is characterized by diminished viral control, resulting in 
high viral titers detectable in serum up to 60 days post infection(238, 292). This is due 
to, in part, dysfunctional CD8 T cell differentiation leading to exhaustion of the 
responding immunodominant CD8 T cells (Figure 1.4B) (238).  In the absence of CD4 
T cell help, CD8 T cell dysfunction is exacerbated, resulting in life-long chronic infection 
in mice with long-term elevated viral titers in serum and tissues (218). Furthermore, the 
pathogenic difference between LCMV Armstrong and LCMV clone 13 infections is 
propagated by only three amino acid residue mutations between the two viruses(306). 
Two mutations occur within the viral spike GP-1 on the S segment at amino acid position 
176 and 260 and one occurs within the viral polymerase on the L segment at amino acid 
position 1076(307) as illustrated in Figure 1.5A.  
 The F260L mutation in the GP-1 protein in the LCMV clone- 13 variant results in 
an increased affinity for the cellular receptor, α-Dystroglycan, resulting in an increase in 
the relative infectivity of the virus. The K1079Q mutation in the viral polymerase of 
LCMV clone-13 results in an increase in replication rate of the virus (308). Importantly, 
these mutations that alter virus tropism and replication rates lead to stark differences in 
viral dissemination in the host, as illustrated in Figure 1.5B, yet they do not affect viral 
T cell epitopes(276).  
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Figure 1.5: LCMV clone 13 has two amino acid mutations that are critical for 
the pronounced difference in viral dissemination in vivo. [A] The F260L 
mutation in the GP-1 protein in the LCMV clone- 13 variant results in an increased 
affinity for the cellular receptor, α-Dystroglycan, resulting in an increase in the relative 
infectivity of the virus. The K1079Q mutation in the viral polymerase of LCMV clone-13 
results in an increase in replication rate of the virus. [B] LCMV Clone 13 mutations that 
alter virus tropism and replication rates lead to stark differences in viral dissemination. 
High virus is detectable in the serum and liver greater than 30 days post infection in 
Clone 13 infected mice. 
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The selection of the LCMV clone 13 genetic variant may have been a consequence of 
virus-host evolution towards balanced pathogenicity, since LCMV CTL activity is critical 
not only for viral control, but also fatal immunopathology mediated by responding CD8 
T cells after intracranial infection of adult mice. 
Naïve C57Bl/6 mice exhibit clinical disease symptoms after high dose (2x106 pfu) 
intravenous LCMV clone 13 challenge but they do not experience lethal 
immunopathology. Persistent but non-lethal infection is in part due to deletion of 
effector cells, such as T cells responding to the dominant NP396 peptide(238) or the 
progressive decrease in effector functions of exhausted effector cells, due to prolonged 
viral stimulation(239). Primary CD8 T cell responses to the persistent variant of LCMV 
can also result in fatal immunopathology due to alterations in the magnitude of T cell 
exhaustion. If the extent of exhaustion of the activated T cells is altered, due to either an 
increase in the number of naïve LCMV-specific CD8 T cells present before 
challenge(239) or a decrease in the initial viral load via a reduction in magnitude of the 
viral inoculum(275), it can result in two very different pathological outcomes.  
The increase in precursor frequency through the adoptive transfer of 106 LCMV-
specific CD8 T cells prior to high dose clone 13 challenge results in a robust effector 
response, increasing the kinetics of viral control, preventing T cell exhaustion and 
eliminating disease entirely. In contrast, a moderate increase in precursor frequency via 
adoptive transfer of 20,000-105 naïve LCMV-specific T cells prior to high dose clone 13, 
results in only partial exhaustion of the responding T cells. This can then cause fatal 
immunopathology via cytolysis and the production of inflammatory cytokines in the 
lungs.  
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A smaller increase in precursor frequency through the adoptive transfer of less than 
10,000 LCMV-specific CD8 T cells prior to high dose 13 challenge results in weaker 
magnitude responses, complete exhaustion, and elimination of increased 
immunopathology due to the absence of effector function of the responding cells(239, 
276). 
Consistent with the pathological outcomes due to varying precursor frequency of 
antigen-specific T cell subsets, the same phenomenon was observed after infection of 
naïve C57Bl/6 mice with decreasing magnitudes of LCMV. Infection with a 100-fold 
decrease of LCMV clone 13 (2x104 pfu) resulted in strong effector responses, early viral 
control, prevention of T cell exhaustion, and elimination of disease. LCMV clone 13 
challenge with an intermediate dose (2x105 pfu) resulted in only partial exhaustion of the 
responding T cells, yet without complete viral control allows the development of severe 
pathology, leading to death by 12 days post-infection. Lastly, high dose infection does not 
cause immunopathology due to the greater extent of exhaustion of responding T cells, 
resulting in loss of effector functions that mediated lethal lung and liver pathology(275). 
 
Memory CD8 T cell mediated immunopathology 
 The immunopathology mediated by LCMV specific CTL described above is not 
exclusive to the primary immune response. Memory CD8 T cells generated via 
immunization(303) or after heterologous infection(309, 310) have been shown to induce 
as severe immunopathology during secondary responses after viral challenge. Earlier 
studies by Oehen reported that narrow vaccination against one protein of LCMV (either 
NP or GP) followed by intracranial challenge with LCMV-WE, resulted in increased 
pathology as measured by mouse mortality (303).  
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Researchers predicted the observed pathology was a consequence of a narrow 
vaccination and could be avoided by induction of a broader immune response against 
more viral epitopes. Additionally, it has been reported that stimulation of immunized 
mice (with high levels of LCMV-specific CD8 T cells) with cognate peptide resulted in 
lethal immunopathology largely dependent on CD8 T cell production of TNF (305).  
The LCMV model system allows the isolated investigation of specific T cell 
factors, such as phenotype and effector function, that may contribute to virus control or 
pathology during an immune response. The easy manipulation of LCMV viral parameters 
such as replication rate and infectivity via use of LCMV variants allows the direct 
comparison and investigation of immune responses during acute or persistent viral 
settings. Furthermore, LCMV Armstrong can be used as a vaccine strain to generate 
memory T cell responses reactive to LCMV clone 13 epitopes that allow investigation into 
the characteristics of protective or pathologic memory T cell responses after exposure to 
chronic viral infections. 
 
Mathematical models predict immunopathology during LCMV infection  
Although considerable progress has been made towards understanding the 
molecular and cellular basis for immunopathogenesis during viral infection, it is often 
difficult in such situations to predict the outcome of infection due to exponentially 
expanding virus and immune cell populations(311-314). Mathematical models can help 
decipher these complex interactions, in part, by making predictions about which cells or 
pathways mediate immunopathology versus immune protection. LCMV infection of mice 
is also a useful system in which to mathematically model immunological responses, such 
as T cell exhaustion, that contributes to the control of viral infection versus disease (315).  
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This is due to the observation that CD8 T cell responses are required to mediate viral 
clearance (239). However, since LCMV is a non-cytolytic virus, the pathology observed 
during infection is mostly due to responding T cells. 
 An empirically based mathematical model of LCMV infection in mice has been 
developed using observations of T cell responses to LCMV. The ordinary differential 
equation model takes into account changes in virus, T cell responses, and exhaustion 
(276).  The developed model accurately describes both the viral dynamics and the 
immune response to infection. In particular, the model replicates the key features of 
persistent infection in which high numbers of virus-specific CD8 T cells rapidly control 
infection, while low numbers of virus-specific CD8 T cells are unable to control viral 
replication and become functionally exhausted(239, 276). Furthermore, the model 
reproduces the outcome that maximum T cell mediated pathology, without virus control, 
occurs when an intermediate number of naive virus-specific T cell precursors are 
present(239). The developed model incorporates immunopathology by modeling T cell 
production of TNF, resulting in severe vascular leakage, as seen in many hemorrhagic 
fever virus infections(316, 317).  
The developed model makes several key predictions about which immune or 
virus parameters are most important for resulting T cell mediated pathology. Specifically 
the model predicts that immunopathology, due to either infected cell cytolysis or 
cytokine production, is insensitive to the enhanced ability of memory CD8 T cells to 
respond to secondary infection. Additionally, the model predicts that enhancement of 
pathology is unaffected by the breadth of memory CD8 T cells responding. The model 
also suggests that the number of T cells that cause maximum immunopathology is 
proportional to the initial virus inoculum and that changes in virus inoculum will result 
in concomitant changes in the number of T cells that cause maximum disease. Chapter 2 
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directly tests the predictions of the developed mathematical model to determine how 
virus and immune system variables affect vaccine-enhanced disease during persistent 
viral infection.  
 
Historical perspective of vaccine-mediated immunopathology 
The outcome of vaccination ordinarily results in either protective or non-
protective immunity after subsequent exposure to a pathogen. Previous attempts to 
design vaccines for viral infection highlight the potential for vaccination (or prior 
exposure to a pathogen) to result in unintended immune mediated pathology (276, 303, 
318-322). The mechanism of vaccine induced immune mediated pathology can vary due 
to the type of immunizing agent utilized, demonstrated by the historical efforts of 
developing a vaccine for respiratory syncytial virus (RSV) (323). An experimental vaccine 
designed in 1966-67 consisting of intramuscular injection of concentrated formalin 
inactivated RSV to infants and children (2 months-9 years) resulted in a failure to offer 
protection during a subsequent outbreak of RSV. In addition to the vaccine 
demonstrating limited efficacy, an exaggerated clinical response was seen in 80 percent 
of young vaccine recipients, including two deaths (320, 324, 325). Follow up studies in 
animal models indicated that the inducement of T cells is crucial for the 
immunopathogenesis of vaccine enhanced RSV-disease.  
Particularly, the formalin inactivated RSV vaccine induces a Th2 bias that can 
result in increased lung inflammation and eosinophilia following subsequent infection 
(326). Surprisingly, researchers attempting to control the immune response towards 
nonpathogenic responses by selectively priming T cell subsets with recombinant RSV 
expressing prototypic Th1 cytokine IFNγ also reported enhanced weight loss and 
immunopathology due to pulmonary influx of RSV-specific CD8 T cells (327).  
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Whereas, mice that received a recombinant RSV expressing prototypic Th2 cytokine IL-4 
vaccine suffered no additional weight loss but demonstrated lung pathology and 
eosinophilia as expected (327). Moreover, further studies have demonstrated RSV- 
specific CD8 T cell induction of immunopathology during acute RSV infection after 
depletion of Tregs in mice (328).  
Other experimental settings have demonstrated vaccines designed to employ a 
cell-mediated immune response may also result in an unintended increase in disease 
(318, 319, 322).  Vaccine-mediated immunopathology occurs specifically when elicitation 
of only T cell responses or inappropriate versions of these responses to a pathogen occur. 
Therefore, determination of the circumstances in which memory T cell responses result 
in protection from persistent viral burden versus those that mediate immunopathology is 
critical for the design of safe and effective vaccines against diseases such as HIV/AIDS.  
 
Viruses have evolved to modulate host immunity 
Variola virus (VARV) is responsible for causing one of the most destructive 
diseases in human history. VARV, the causative agent of smallpox, is one of many 
double-stranded DNA viruses of the Poxviridae family that is best characterized by their 
large size, cytoplasmic replication and production of immune modulatory proteins(329). 
The World Heath Organization (WHO) declared smallpox eradicated in 1980 following 
the most successful vaccination program against a human pathogen in our history(330). 
The restricted use of VARV in scientific laboratories required the development of 
laboratory animal models of orthopoxvirus infection in order to study viral immune 
modulation and pathogenesis.  
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Poxviruses have been widely used to understand how the immune system responds to 
infection(331) and are currently being investigated for use as potential vaccine 
vectors(25) for many important human pathogens such as HIV(21). Recently, poxviruses 
have been broadly studied for use in oncolytic therapies and to reduce GVHD after bone 
marrow transplants(332).   
Poxvirus infection initiates a race between viral replication, transmission and the 
host’s immune response. Poxviruses have evolved several mechanisms to circumvent 
immune surveillance and subsequent immunological responses to infection(329). Type I 
interferons are potent antiviral cytokines responsible for production of a broad range of 
antiviral proteins and directly modulate adaptive immune responses(40). Consequently, 
poxviruses have evolved multiple strategies to suppress IFN-I production, modulate 
IFN-I signaling, and block the action of anti-viral proteins. One such mechanism is the 
sequestration of virally produced dsRNA in order to inhibit detection by host pattern 
recognition receptors that detect viral infection and initiate IFN-I production(333). The 
poxvirus protein E3L contains a highly conserved double-stranded RNA (dsRNA)-
binding domain that has been shown to be required for Vaccinia virus interferon 
resistance and pathogenesis in mice(334).  
In addition to intracellular blockade of IFN-I production, poxviruses also encode 
proteins to sequester extracellular IFN-I to limit IFN-I anti-viral effects in neighboring 
cells. Poxviruses produce a type I interferon binding protein (T1-IFNbp) that can bind to 
IFN-I with high affinity either in solution or associated with cell membranes to prevent 
IFN-I produced during infection to ligate with host type I interferon receptors(335). 
Intracellular and extracellular modulation of IFN-I is critical for poxvirus virulence as 
the deletion of either of these proteins reduce in vivo pathogenesis(333, 335). 
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Ectromelia virus model system 
Ectromelia virus (ECTV) was first discovered in the 1930s to cause a fatal disease 
in laboratory mice that mimicked smallpox disease in humans(336, 337). Similar to 
VARV in humans, ECTV is infectious at low doses and causes severe disease in mice with 
high mortality rates(338, 339). Experimental inoculation of susceptible mice with ECTV 
results in an acute, lethal disease corresponding with high viral replication in the liver 
and hepatic damage(337, 340). Inbred strains of laboratory mice are either susceptible 
or resistant to ECTV infection depending on specific genetic factors such as MHC 
genotype that ultimately influences the adaptive immune response after infection(341, 
342). Resistant C57Bl/6 mice have more rapid and stronger NK and CTL responses than 
susceptive mouse strains(336, 340).  
In addition to enhanced adaptive immune responses in resistant mice, 
production of IFNα/β has been shown to be important for the recovery of C57Bl/6 mice 
after ECTV infection(5, 338). Thus is supported by the observation that antibody 
blockade of ECTV T1-IFNbp in susceptible mice leads to increased survival(343). 
Interestingly, deletion of ECTV T1-IFNbp drastically reduces virulence in mice, but the 
ECTV T1-IFNbp has been found to only block the biological activity of mouse IFNα(5). 
However, ECTV is resistant to IFNβ treatment in vitro, suggesting that the ECTV E3L 
homolog is an important overlapping mechanism to circumvent the anti-viral affects of 
IFN-I production(344). The importance of IFN-I blockade during poxvirus infection is 
highlighted by the severe decrease in viral pathogenicity and replication in vivo after 
deletion of only one of the poxvirus immunomodulatory genes that block IFN-I(335).  
However, there is no known immunomodulatory protein that is shared by all poxviruses 
due to each virus species encoding a unique combination of proteins necessary to evade 
the immune response of its natural host(329).  
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Moreover, certain modulatory proteins are specifically limited to interact with host 
molecules(336, 345). ECTV infection of laboratory mice is useful in order to study 
orthopoxvirus immune modulation in its natural host(343).  
 
The immune system has evolved to maintain homeostasis with commensal 
microbiota 
 Significant progress has been made using a reductionist approach to understand 
host-microbe interactions in which specific cell populations and proteins are classified 
and dissected to determine their relative impact on immune responses. Therefore, the 
majority of microbiological research is performed in specific-pathogen-free, clean, and 
controlled environments that limit potential co-infection by heterologous pathogens.  
However, most “real-world” infections likely occur in the context of co-infection 
by heterologous pathogens or host microbiota(346). The collection of bacteria, viruses, 
parasites and fungi that compose the human microbiome is estimated to number over 
100 trillion microbes(347). Co-evolution between mammalian hosts and microbial 
communities has resulted in a symbiotic relationship. Commensal microbes, that do not 
normally cause disease, enhance digestion while benefiting from stable nutritional 
resources(348). Although, in order to prevent opportunistic invasion the human immune 
system has evolved to maintain homeostasis with host microbiota(349, 350). For 
example, germ-free mice that are born in a sterile environment do not develop lymphoid 
follicles in the small intestine, fail to secrete IgA antibodies, and lack intraepithelial 
lymphocytes(351), suggesting that co-evolution has also resulted in the dependence on 
host microbiota to influence immune development and immune cell regulation(348).  
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Alterations in host microbiota have been shown to influence, not only gut 
associated lymph tissue, but also influence peripheral immune responses. Parasitic 
helminths facilitate long-term survival in hosts by the regulation of immune responses 
via induction of regulatory CD4 T cell subsets and anti-inflammatory cytokines(352). 
Parasitic induced immune regulation extends beyond parasite-specific responses, since 
helminths infection can lower immune response to BCG vaccination(353) and reduce T 
cells responses during HCV infection(354). Parasitic modulation of systemic immunity 
highlights the potential consequences of microbial co-infection due to 
immunomodulatory mechanisms that can influence non-specific immune response and 
potentially alter disease(346). Therefore, implicating the potential alteration in immune 
responses during viral co-infection, due to virus evolution of an array of immune 
modulatory mechanisms. 
 
Consequences of viral co-infection of global health 
 Viral co-infection can occur by simultaneous exposure of two heterologous 
viruses that may share the same route of transmission or chronically infected individuals 
can become co-infected after independent exposure to circulating viral strains. Due to 
the success of highly active antiretroviral therapy in HIV-infected individuals that has 
decreased AIDS-related morbidity and mortality, HIV co-infection with Hepatitis virus 
has emerged as an additional source of morbidity and mortality(355). Co-infection with 
HCV and HIV is a relatively common event occurring in 15-30% of all HIV-infected 
individuals and 5-10% of all HCV-infected individuals(356, 357) (Figure 1.6). 
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Figure 1.6. Global prevalence of HIV and Hepatitis virus co-infection. Venn  
diagram illustrates prevalence of HIV, HBV or HCV co-infection. Area of circles and 
intersections is a to-scale representation of population prevalence. Sub-Saharan Africa 
accounts for ∼70% of global burden of HIV, and that around 10% of all those with HIV 
are HBV co-infected. 
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  HIV co-infection is associated with weaker HCV adaptive immune responses, 
increased liver fibrosis, higher HCV RNA levels, reduced response rates to anti-viral 
treatment, and worse HCV disease progression(356, 358). The differences in immunity 
and disease in co-infected individuals may be due to alterations in the intrahepatic 
cytokine milieu as a result of HIV infection(359, 360). Detection of cytokine mRNA in 
HIV/HCV co-infected patients revealed lower levels of TNF, IL-8, and IL-10 mRNA and 
increased levels of TGF-β compared to individuals infected with HCV alone(360). In 
addition, HBV co-infection has been reported to occur in up to 36% of all HIV-infected 
individuals in Africa, which currently accounts for 0ver 70 percent of global HIV-
infection(357, 361). HIV co-infection with HBV also correlates with higher rates of HBV 
persistence and increased risk of liver-related morbidity and mortality(355, 357, 362). 
  Another potential consequence of viral co-infection is co-evolution in which one 
virus may supply ancillary functions or suppress immune functions for another(345). 
Such a relationship has previously been described for Hepatitis B (HBV) and Hepatitis D 
(HDV) viruses. HDV cannot form mature virions without the presence of the Hepatitis B 
structural proteins(363). Furthermore, co-infection of HBV and HDV or super infection 
of persistently infected HBV patients with HDV also results in increased liver pathology 
and poorer prognosis in patients due to altered immune responses and type I interferon 
signaling in the host(364, 365). Chapter 3 investigates if alterations in innate signaling 
due to heterologous viral co-infection in a natural host will influence CD8 T cell 
responses and disease. Furthermore, chapter 4 assesses the consequence of viral co-
infection with persistent viral strains known to induce dysfunctional CTL response will 
alter CD8 T cell differentiation and potential CD8 T cell immunopathology. 
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Objectives 
Our current approach to develop a quantitative understanding of the dynamics of 
CD8 T cell responses during persistent viral infection involves the utilization of LCMV 
infection of mice. The LCMV model allows the study of specific components of the 
immunological responses that contribute to the control of infection versus those that 
mediate enhanced disease after vaccination, due to the capability of adoptive transfer of 
defined virus-specific T cell subsets into naive mice. The manipulation of T cell 
parameters (phenotype, functional capacity, breadth of response) and viral parameters 
(replication, infectivity) allow isolated investigation of multiple factors that may 
contribute to virus control and the reduction of pathology during an immune response.
 Our objective is to further inspect how the CD8 T cell response, responsible for 
viral clearance and/or immunopathology, can change due to alteration of the breadth of 
targeted epitopes, T cell effector function, and initial viral load. In addition, the 
consequence of viral co-infection during vaccination or infection on the resulting CD8 T 
cell effector response, memory differentiation, and protective capacity after secondary 
challenge will be examined. 
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CHAPTER 2 
 
A QUANTITATIVE UNDERSTANDING OF THE BALANCE BETWEEN PATHOLOGIC 
AND PROTECTIVE MEMORY T CELL RESPONSES DURING VIRAL INFECTION 
ABSTRACT 
Despite the development of vaccines for a wide range of viral diseases, efficacious 
vaccines for persistent viral infections have been elusive in part due to safety concerns 
for use of attenuated viruses and lack of efficacy for killed virus. Immunization against 
virus T cell epitopes has been proposed as an alternative vaccination strategy for 
persistent viral infections. However, vaccines that selectively engage T cell responses can 
potentially result in inappropriate immune responses that increase, rather than prevent, 
pathology after subsequent infection. Using dynamic quantitative models of virus 
infection and immune responses, we investigated the quantitative basis for pathologic 
versus protective T cell responses during disseminated viral infection, including which 
virus and immune system variables affect vaccine-enhanced disease. We found that an 
intermediate number of memory CD8 T cells prior to LCMV infection resulted in 
maximum T cell mediated pathology. Increased pathology at intermediate numbers of T 
cells was independent of the sensitivity or breadth of the T cell response but was 
dependent on T cell production of TNF and the magnitude of initial virus inoculum. In 
particular, abrogation of TNF signaling resulted in decreased pathology but no change in 
viral clearance, suggesting that TNF-blockade may be useful for minimizing pathology 
while maintaining protection during virus infection. Thus, mathematical models of virus 
and T cell immunity can be used to make useful predictions regarding which molecular 
and cellular pathways differentially mediate T cell protection versus pathology. 
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IMPORTANCE 
Vaccines remain the most effective method for preventing or treating viral 
diseases. Unfortunately, vaccines for many persistent viral infections have not shown 
efficacy. One strategy that has been widely employed to generate vaccines for persistent 
viral infections are recombinant vaccines expressing pathogen T cell epitopes. To better 
understand the quantitative relationship between memory T cell numbers and protection 
versus pathology resulting from such responses, we have developed quantitative 
mathematical models of virus infection and immune responses and used these to predict 
which molecular and cellular interactions mediate each of these outcomes. The following 
investigation demonstrates that memory T cell mediated pathology is independent of 
TCR sensitivity or breadth of the epitopes targeted, but is dependent on the magnitude of 
virus inoculum and T cell production of TNF. The blocking TNF signaling during 
disseminated virus infection, was able to abrogate pathology while maintaining T cell 
protection. These data suggest that TNF blockade intervention strategies may be useful 
for enhancing host survival during virus infection without preventing T cell protection. 
 
 
INTRODUCTION 
Four of the top ten leading global causes of premature death in humans are 
diseases due to infectious pathogens(11). Total deaths from HIV (1.6 million), 
tuberculosis (1.1 million) and malaria (627,000) infections totaled more than 3 million in 
2012(11). However, in the past decade there has been a global shift away from premature 
death due to infectious diseases, except in Africa where 70% of calculated years of life 
lost are due to infectious diseases, maternal, neonatal and nutritional causes(11).  
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One of the main reasons for this transition is that expanded vaccination coverage has 
significantly enhanced our ability to elicit effective memory immune responses to fight 
and prevent human diseases caused by infectious pathogens(12, 13). From 2000-2010 an 
estimated 2.5 million deaths were prevented each year among children less than 5 years 
old by the use of measles, polio and diphtheria-tetanus-pertussis vaccines(366).   
The vast majority of currently used vaccines against infectious diseases employ 
attenuated or killed versions of pathogens to induce protective immunity(367). Such 
vaccines induce antibodies that circulate the body as a first line of defense or induce 
populations of memory T and B cells(367, 368). Memory T cells are better able to rapidly 
respond to secondary infection via production of inflammatory cytokines and cytolysis of 
infected host cells to decrease the severity of disease(12, 13, 369-371). However, such T 
cell responses also have the potential to increase disease severity by production of 
inflammatory cytokines, in particular TNF, which can result in increased vascular 
leakage or cell death(316). 
Despite the success of current vaccines, inherent dangers associated with 
attenuated vaccines and ineffectiveness of killed vaccines for persistent viral infections 
has limited prevention of these diseases(17, 23, 24, 318, 372). One solution to this 
problem is the use of recombinant vectors expressing pathogen T cell epitopes as a 
means of inducing protective immunity(21, 22, 315, 373). Paradoxically, the production 
of a large number of memory T cells also has the potential to cause increased 
immunopathology and exacerbate disease compared to that observed in unvaccinated 
individuals(302, 318, 320, 321, 323-325, 374, 375). This was originally observed by 
Oehen et al., in which vaccination with recombinant viral vectors expressing lymphocytic 
choriomeningitis virus (LCMV) proteins resulted in enhanced disease, rather than 
protection, during subsequent virus challenge(303).  
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Previous studies have quantitated the relationship between naïve antigen-specific 
T cell precursors and the outcome of virus infection, showing that maximum pathology, 
but not protection, occurs at intermediate T cell numbers during chronic LCMV 
infection(239, 276). T cell enhancement pathology after viral infection has been reported 
in a variety of other animal models of virus infection including, LCMV(275, 276, 303, 
304, 376), influenza(377, 378) and respiratory syncytial virus(327, 379). Thus, a major 
goal of vaccination should be induction of immune responses that maximize elimination 
of infectious organisms while minimizing immunopathology. Therefore, determination 
of the circumstances in which memory T cell responses elicited by vaccination result in 
protection from virus infection versus those that mediate immunopathology is critical for 
the design of safe and effective recombinant vaccines against persistent viruses such as 
HIV. 
Although, considerable progress has been made towards understanding the 
molecular and cellular basis for immunopathogenesis during viral infection, it is often 
difficult in such situations to predict the outcome of infection due to exponentially 
expanding virus and immune cell populations(311-314). Mathematical models can help 
decipher these complex interactions by making predictions about which cells or 
pathways mediate immunopathology versus immune protection. Mathematical models 
that qualitatively describe previously observed dynamics of virus infection and naive T 
cell responses have been developed (276). These models make several key predictions 
about which immune or virus parameters are most important for T cell mediated 
pathology. Specifically, the models predict that immunopathology due to either cell loss 
or cytokine production is insensitive to the enhanced ability of memory T cells to 
respond to infection or to the breadth of the T cell response. 
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 However, the models do suggest that the number of T cells that cause maximum 
immunopathology is proportional to the initial virus inoculum dose. The following 
investigation brings the models into risky contact with experimental data and show that 
these predictions are supported in the LCMV mouse model of virus infection.  
The previously described ordinary differential equation mathematical model 
takes into account changes in virus, T cell responses, and exhaustion and recapitulates 
the dynamics of virus and CD8 T cell response during acute and persistent LCMV 
infection(276). In particular, the model replicates the key features of chronic infection in 
which high numbers of virus-specific CD8 T cells rapidly control chronic LCMV infection 
while low numbers of virus-specific CD8 T cells are unable to control viremia and 
become functionally exhausted(239, 276). Furthermore, the model reproduces the 
outcome that maximum T cell mediated pathology, without virus control, occurs when 
an intermediate number of virus-specific T cell precursors are present(239). Based on 
experimental results, immunopathology has been incorporated by modeling T cell 
production of TNF, resulting in severe vascular leakage, as seen in many hemorrhagic 
fever virus infections(316, 317).  
Further simulations of the developed model make key predictions regarding 
aspects of the virus and immune response that challenge current vaccinology dogma. 
Specifically, the model predicts that: 1) enhancement of pathology is unaffected by TCR 
sensitivity, 2) enhancement of pathology is unaffected by the breadth of the T cell 
response and 3) changes in virus inoculum dose result in concomitant changes in the 
number of T cells that cause maximum disease.  The following investigation tests each of 
these predictions using the developed experimental model of LCMV infection of mice. 
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MATERIALS AND METHODS 
Mice: 6-8 week old C57BL/6, TNFR-/- (p55-/-x p75-/-) and IFNγR-/- mice were 
purchased from Jackson laboratories (Bar Harbor, ME) and bred in our ASU animal 
facilities. P14 transgenic mice, in which CD8 T cells express TCR specific for the DbGP33-
41 epitope of LCMV, were obtained from Dr. Rafi Ahmed and bred in our animal 
facilities. All mice were maintained under specific-pathogen free conditions at The 
Biodesign Institute and experiments were performed in compliance with institutional 
guidelines as approved by Institutional Animal Care and Use Committee of Arizona State 
University. 
Cells: BHK cells were maintained in complete Eagles’ MEM (5% fetal bovine 
serum (FBS), 2mM L-glutamine (L-Q), 100 U/mL penicillin, 100 µg/ml streptomycin). 
Vero and MC57 cells were maintained in complete DMEM (10% FBS, 2mM L-Q, 100 
U/ml penicillin, 100 µg/mL streptomycin). 
Viruses and infections: Lymphocytic choriomeningitis virus clone-13 and 
Armstrong stocks were kindly provided by Rafi Ahmed (Emory University, Atlanta, GA) 
and produced in BHK cells as previously described (380). Viral stocks and serum viral 
titers were determined by plaque assay on Vero cell monolayers as previously 
described(292).  
Memory cell generation and adoptive transfer: Memory P14 cells were 
generated by adoptive transfer of 105 naive P14xThy1.1 cells into naïve Thy1.2 C57Bl/6 
(B6) donor mice followed by intraperitoneal (ip) immunization with 2x105 pfu LCMV 
Armstrong. After stable memory formation (typically >45 days post immunization), 
memory CD8 T cells were purified from splenocytes using Thy1.1 MACS magnetic beads 
purchased from Miltenyi Biotech (San Diego, CA) and adoptively transferred into Thy1.2 
B6 recipient mice.  
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Recipient mice were then challenged intravenously (iv) with 2x106 pfu LCMV clone-13 or 
varying doses as indicated. Mice were monitored daily for morbidity and mortality via 
clinical scoring (hunched posture, ruffled fur, non-motility) and weight loss. 
Peptides: Lymphocytic choriomeningitis virus CD8 T cell epitopes NP396, 
GP33, GP276, GP118, GP92 and NP205 were purchased from Genscript (Piscataway, 
NJ). Ex vivo peptide stimulations were done at a concentration of 1ug/ml as previously 
described(200). 
Cell surface antibody staining: Single cell suspensions were prepared from 
splenocytes as previously described(200). Erythrocytes were lysed with ammonium 
chloride lysis (ACK) buffer purchased from Lonza (Allendale, NJ and FACS staining was 
done as previously described(381) in 96 well plates with flurochrome-labeled 
monoclonal antibodies: anti-CD8 (clone 53-6.7), anti-Thy1.1 (clone X), anti-CD44 (clone 
IM7), antii-PD-1 (clone J43), anti-CD4 (clone GK1.5). Samples were then fixed in 1% 
paraformaldehyde solution and immediately acquired on a BD LSR II Fortessa flow 
cytometer (San Jose, CA) and analyzed using FlowJo Software (Tree-Star, Ashland, OR). 
All surface and intracellular monoclonal antibodies were purchased from BD Pharmigen 
(San Diego, CA) or eBiosciences (San Diego, CA). 
Intracellular cytokine staining: For quantification of LCMV-specific T cell 
responses, splenocytes (106/well) were stimulated with 1µM LCMV peptide as previously 
described(200). After 5 hours of stimulation, cells were permeabilized according to 
manufacturer’s instructions using the Cytofix/Cytoperm kit (BD Pharmigen) and 
intracellular cytokine producing cells were detected by staining with anti-IFNγ (clone 
XMG1.2) and anti-TNF (clone MP6-XT22) as previously described(200). The samples 
were acquired and analyzed as described above. 
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Histology: formalin fixed liver and lung tissue were cut into 4µm thick sections 
on a microtome. Liver and lung samples were stained with hematoxylin and eosin as 
previously described(382). 40x images were taken with a Nikon Eclipse E600 
microscope and evaluated by a veterinary pathologist.  
Statistics: Prism software (Graphpad, La Jolla, CA) was used to calculate t-test 
p values to determine significance or log-rank test to determine survival curve 
significance (* = p≤0.05, **= p≤0.01, ***= p≤0.001). 
 
 
RESULTS 
The increased sensitivity of memory CD8 T cells to viral antigens does 
not limit vaccine-induced pathology. Naïve and memory CD8 T cells differ in their 
requirements for activation, proliferative capacity and in vivo migration; memory CD8 T 
cells have an increased sensitivity to antigen stimulation allowing them to respond more 
rapidly to subsequent infections(223, 224). Additionally, memory CD8 T cells may be 
more tightly regulated than naïve CD8 T cells during disseminated LCMV infection 
causing them to be more prone to T cell exhaustion as a potential safety mechanism to 
limit pathology during recall responses(383).  As is often that case with complex biologic 
systems, it is difficult to intuit how this might impact resulting immunopathology during 
virus infection. Using the developed quantitative models, we make the prediction that 
the increased sensitivity of memory T cells to antigen is unlikely to affect the 
enhancement of disease at intermediate T cell responses (mathematical simulation 
results are relatively insensitive to the parameter that describes sensitivity).  
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 The overall strategy for testing whether intermediate numbers of memory CD8 T 
cells mediate maximum pathology during persistent viral infection is shown in Figure 
2.1. Briefly, memory P14 CD8 T cells specific for the GP33/34 epitope of LCMV were 
generated by LCMV Armstrong immunization. After a period of at least 45 days, 
P14xThy1.1 memory CD8 T cells were isolated and varying numbers were adoptively 
transferred into naïve mice two days prior to LCMV clone-13 challenge. As expected, 
mice receiving high numbers (>105) of memory P14 CD8 T cells followed by LCMV clone-
13 infection did not prevent initial viral seeding. LCMV viral titers in the serum at day 5 
post-infection were detectable in all groups tested (Figure 2.2). 
 However, as predicted by the quantitative model, transfer of an intermediate 
number of memory P14 CD8 T cells prior to LCMV challenge resulted in maximum 
immunopathology. Greater than 85% (7/8) of mice that received 7x104 P14 memory CD8 
T cells, and 60% (7/12) of mice that received 105 memory P14 CD8 T cells prior to LCMV 
clone-13 infection perished by 13 days post infection. In contrast, mice that received high 
(>105), low numbers (<20,000) and no p14 memory cells had no increase in mortality 
following LCMV clone 13 challenge (Figure 2.3). Additionally, mice that received a 
large number of memory p14 cells had markedly reduced disease in contrast to mice that 
received an intermediate number of memory p14 cells that had decidedly increased 
disease as measured by weight loss (Figure 2.4A) and subjective clinical scores 
(Figure 2.4B).  
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Figure 2.1: Overall strategy to test memory CD8 T cell capacity to mediate 
immunopathology during persistent viral infection. Memory P14 cells were 
generated by transfer of naïve p14 x thy1.1 cells into recipient C57Bl/6 x thy1.2 mice 
followed by immunization with 2x105 pfu LCMV Armstrong. After a period of at least 45 
days, P14 memory CD8 T cells were isolated and varying numbers were adoptively 
transferred into naïve C57Bl/6 mice followed two days post transfer with challenge of 
2x106 LCMV clone-13. 
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Figure 2.2: Adoptive transfer of LCMV-specific memory CD8 T cells does not 
prevent initial LCMV replication. Memory P14 cells were generated by transfer of 
naïve p14xthy1.1 cells into recipient C57Bl/6 thy1.2 mice followed by immunization with 
2x105 pfu LCMV Armstrong. After a period of at least 45 days, C57Bl/6 mice received 
adoptive transfer of varying numbers of memory p14 CD8 T cells followed by challenge 
with 2x106 LCMV clone-13. LCMV clone 13 viral titer in serum of C57Bl/6 recipient mice 
at day 5 post- infection (n= 3-5 mice per group). 
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Figure 2.3: Intermediate numbers of LCMV-specific memory CD8 T cells 
cause maximum pathology after subsequent infection with LCMV clone-13. 
Kinetics of survival of C57Bl/6 mice after adoptive transfer of varying numbers memory 
p14 CD8 T cells followed two days post transfer by LCMV clone-13 infection (n=3-5 
mice/group, three independent experiments). 
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Figure 2.4: Varying precursor frequency of LCMV-specific memory CD8 T 
cells alters pathology after subsequent infection with LCMV clone-13. 
C57Bl/6 mice received adoptive transfer of varying numbers of memory p14 CD8 T cells 
followed by challenge with 2x106 LCMV clone-13. [A] Representative example of weight 
loss of challenged mice that received varying numbers of p14 memory CD8 T cells 
measured as a percentage of weight change from weight at day 0 post infection. [B] 
Representative example of calculated clinical score of challenged mice that received 
varying numbers of p14 memory CD8 T cells determined by mouse morbidity, motility, 
respiration and overall appearance. 
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 The observed reduction of disease in mice that received a high number of 
memory p14 cells correlated with controlled viremia at day 8 post infection. Although, 
transfer of intermediate or low numbers of memory p14 CD8 T cells prior to LCMV clone 
13 challenge resulted in non-protective effector responses since all mice failed to control  
viremia at day 8 post infection regardless of an observed increase in pathology (Figure 
2.5). Additionally, LCMV persisted in the serum for up to 30 days in infected mice that 
received low dose transfer, indistinguishable from infected controls receiving no 
additional cells. Recipient mice that had a high precursor frequency of memory p14 cells 
after adoptive transfer maintained viral clearance up to 30 days post infection, with no 
detectable viral recrudescence (Figure 2.6).  
 Interestingly, LCMV viral variants that contain a mutated GP33 epitope are 
generated in 50 percent of mice that receive adoptive transfer of large numbers of naïve 
p14 cells prior to LCMV clone 13 infection. Generation of viral variants that are not 
recognized presumably occurs due to selective pressure by the responding donor p14 
cells(239). The absence of viral recrudescence after high dose memory p14 transfer 
suggests that the capacity of memory p14 cells to more rapidly produce effector 
responses after viral infection limits the potential generation of LCMV escape variants 
resulting in long term viral clearance.  
 The increase in immunopathology resulting in mortality due to memory p14 
transfer prior to LCMV clone 13 challenge was indistinguishable from survival data after 
transfer of an intermediate number of naïve P14 cells that has previously been shown to 
result in increased immunopathology(239, 276) (Figure 2.7).  
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Figure 2.5: High precursor frequency of LCMV-specific memory CD8 T cells 
protect mice from viral persistence after LCMV clone 13 infection. LCMV 
clone 13 viral titer in serum of memory p14 recipient mice at day 8 post infection (n=3-5 
mice per group, three independent experiments). 
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Figure 2.6: High precursor frequency of LCMV-specific memory CD8 T cells 
does not select for LCMV viral escape variants after LCMV clone 13 
infection. LCMV clone 13 viral titer in serum of memory p14 recipient mice at day 30 
post infection (n=3-5 mice per group, three independent experiments). 
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Figure 2.7: The increased sensitivity of memory CD8 T cells to viral antigens 
does not limit vaccine-induced pathology. Survival of C57Bl/6 mice after adoptive 
transfer of varying numbers of either memory p14 or naïve p14 CD8 T cells followed two 
days post transfer by LCMV clone-13 infection (n=3-5 mice/group, three independent 
experiments). 
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Intermediate numbers of both memory and naïve p14 CD8 T cells cause increased 
pathology after persistent LCMV infection.  Memory and naïve CD8 T cells differ in their 
requirements for activation, thus the sensitivity of the CD8 T cell to respond to antigen 
stimulation does not change the observed pathology. The observed similar increase in 
disease from varying precursor frequency of naïve or memory LCMV specific CD8 T cells 
support the previously described mathematical model prediction that TCR sensitivity is 
independent of the observed pathology. A key consideration highlighted by these 
experiments is why mice receiving lower doses of memory LCMV specific CD8 T cells do 
not suffer a similar enhancement of disease. 
 
Lose of CD8 T cell effector function and high PD-1 expression limits 
immunopathology at low precursor frequency of memory CD8 T cells. 
Previously it has been shown after naïve CD8 T cell adoptive transfer that exhaustion of 
the T cell response results in an inability to control infection but also limits T cell 
mediated immunopathology. Recent reports have shown that memory T cells have a 
lower threshold for exhaustion(383). Therefore, I investigated whether the exhaustion 
threshold of donor cells during persistent LCMV clone-13 infection was different in mice 
that initially received low numbers of donor memory P14 CD8 T cells versus mice that 
received high numbers of donor memory CD8 T cells. In order to measure exhaustion of 
donor cells, mice receiving less than 2x104 memory p14 cells or greater than 105 memory 
p14 cells were euthanized 30 days post LCMV clone 13 infection. P14 donor cells were 
analyzed for persistence and functional capacity to produce inflammatory cytokines after 
ex vivo peptide stimulation.  
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PD-1 expression of on donor cells was determined since high expression of the 
inhibitory receptor PD-1 is correlated with the exhaustive phenotype in CD8 T cells 
responding to LCMV clone 13 infection. Donor memory p14 cells in high dose recipient 
mice, that controlled LCMV clone 13 viral dissemination by day 8 post infection, 
persisted long-term. Greater than 8x105 p14 donor cells were detected (Figure 2.8A), 
accounting for more than 3% of total splenocytes in the spleen at day 30 post infection 
(Figure 2.8B, black bar). However, less than 103 memory p14 donor cells were 
detected (Figure 2.8A), accounting for less than 0.05% of total splenocytes in the 
spleen of mice that received low dose transfer at day 30 post LCMV clone 13 infection 
(Figure 2.8B, white bar). Thus indicating donor p14 cells underwent clonal deletion 
in mice initially receiving less than 2x104 memory p14 donor cells prior to LCMV clone 13 
infection. High expression of the inhibitory receptor PD-1, greater than 2000 MFI, was 
observed on detectable donor p14 cells that were not clonally deleted (Figure 2.9A, 
white). In contrast, memory donor cells isolated in mice that received high precursor 
frequency had very low expression of PD-1, less than 250MFI, with similar PD-1 
expression found on functional naïve CD8 T cells (Figure 2.9A, black).  
 Since exhausted T cells lose effector function in a hierarchical manner, the ability 
of CD8 T cells to produce both TNF and IFNγ in response to antigen stimulation ex vivo 
can be used as a measure of the level of exhaustion of the cell. Isolated donor cells from 
mice that received low dose transfer were unable to produce TNF in any capacity. 
Additionally, only 34% of detectable donor cells produced IFNΥ (Figure 2.9B, white). 
In contrast, almost 90% of memory donor p14 cells isolated in mice that received high 
precursor frequency had full functional capacity to produce both effector cytokines TNF 
and IFNγ (Figure 2.9B, black). Thus, the CD8 T cell response in mice starting with 
low numbers of memory LCMV-specific CD8 T cells underwent T cell exhaustion.  
  70 
 
 
 
Figure 2.8: CD8 T cell exhaustion limits pathology at low precursor 
frequency. [A] Representative FACS plot of percentage of donor p14 cells in the spleen 
at day 30 post-infection in mice that received low dose (103) adoptive transfer or high 
dose (106) adoptive transfer of p14 memory cells prior to LCMV clone 13 challenge (n=3-
5 mice/group). [B] Mean absolute number of memory p14 donor cells recovered from 
the spleen at day 30 post-infection in mice that received either low dose (103) adoptive 
transfer or high dose (106) adoptive transfer of p14 memory cells prior to LCMV clone 13 
challenge (n=3-5 mice/group).  
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Figure 2.9: High PD-1 expression and loss of cytokine production limits 
pathology at low precursor frequency. [A] Left panel: Representative FACS 
histogram of PD-1 expression on donor p14 cells in the spleen at day 30 post-infection in 
mice that received low dose (103) adoptive transfer or high dose (106) adoptive transfer of 
p14 memory cells prior to LCMV clone 13 challenge. Right panel: MFI of PD-1 expression 
on donor p14 cells (n=3-5 mice/group). [B] Left panel: Representative FACS plot of TNF 
and IFNγ production after peptide stimulation of donor p14 cells in the spleen at day 30 
post-infection in mice that received low dose (103) adoptive transfer or high dose (106) 
adoptive transfer of p14 memory cells prior to LCMV clone 13 challenge. Right panel: 
Mean absolute number of IFNγ producing memory p14 donor cells recovered from the 
spleen at day 30 post-infection (n=3-5 mice/group).  
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The extent of T cell exhaustion limited the ability of challenged mice to control viral 
replication, since all mice that received low precursor frequency of donor CD8 T cells 
could not eliminate virus, as seen by high serum viral titers at day 30 post infection, but 
the loss of T cell function also limited T cell mediated immunopathology preventing 
mortality seen in mice that received an intermediate precursor frequency.   
 
Qualitative differences between naïve and memory CD8 T cell mediated 
pathology. Although mice receiving either memory LCMV-specific CD8 T cells or naïve 
LCMV-specific T cells both underwent a similar enhancement of pathology at 
intermediate precursor frequency, there was an observed qualitative difference in the 
pathology in mice that received memory CD8 T cells versus naïve CD8 T cells. Tissue 
samples harvested at time of euthanasia were cut to 4μm thick formalin fixed sections 
and stained with hematoxylin and eosin (H&E). Histological analysis of tissue in mice 
receiving a pathogenic dose of either naïve of memory cells were compared to one 
another and to healthy mouse tissue. Mice that received a pathogenic dose of donor 
memory p14 cells displayed necrotic lesions and cell infiltration primarily localized in the 
liver. Whereas lung sections of mice receiving donor memory p14 cells showed limited 
vascular leakage and cell infiltration. In contrast, mice that received a pathogenic dose of 
naïve P14 recipients had extreme lung pathology including breakdown of the vascular 
architecture, fluid build-up and cell infiltration. However, these mice displayed no 
detectable necrotic lesions in the liver (Figure 2.10A).  
 
 
 
  73 
In order to investigate if the qualitative difference in tissue damage was due to 
variation in the recruitment of donor cells to infected tissues, the number of donor cells 
in each tissue at day 6 post infection (prior to day of required euthanasia) was 
determined. Since naïve and memory CD8 T cells differ in their proliferative capacity 
and sensitivity for antigen stimulation, the number of memory or naïve donor cells 
detected in the liver or lung was compared to the total response of donor p14 cells in the 
spleen. There was a significant difference in the ratio of donor cells trafficking to the lung 
and liver between naïve and memory cells. 
As expected due to histological analysis, mice receiving a pathogenic dose of 
naive p14 cells had a greater proportion of the donor response traffic to the lung 
presumably causing destruction of the vascular architecture. In contrast, mice receiving 
a pathogenic dose of memory P14 cells had a greater proportion of the donor response 
traffic to the liver, presumably resulting in the observed necrotic lesions via CTL activity 
(Figure 2.10B). Consistent between naïve and memory donor p14 cells, the greater 
proportion of the response trafficking to either the lung or the liver correlated with the 
organ exhibiting maximum pathology. However, it is not known from these experiments 
whether production of inflammatory cytokines or direct killing of target cells in infected 
tissues is responsible for mediated the observed lethal pathology. 
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Figure 2.10: Qualitative differences between pathology from memory CD8 T 
cells and naïve CD8 T cells after subsequent infection with LCMV clone-13. 
C57Bl/6 mice received adoptive transfer of varying numbers of memory or naive p14 
CD8 T cells followed by challenge with 2x106 LCMV clone-13. [A] 40X view of 
hematoxylin and eosin stained 4μm thick formalin fixed liver and lung tissue sections 
collected at time of death for pathogenic doses after transfer of naïve or memory p14 
CD8 T cells as compared to healthy mouse tissue [B] Ratio of donor p14 memory or p14 
naive CD8 T cells harvested from the lung or liver as compared to total donor expansion 
in the spleen at day 5 post infection (n=3-5 mice per group, two independent 
experiments). 
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Pathology is mediated by TNF production. In order to inform the safe 
design of vaccines, it is necessary to determine which T cell parameters of the CD8 T cell 
response are responsible for vaccine induced pathology versus those that mediate virus 
control. To investigate whether pathology in this setting arises from the production of 
pro-inflammatory cytokines, we transferred LCMV specific memory CD8 T cells into wild 
type, TNF-R deficient mice (p55-/- x p75-/-) or IFNγ-R deficient mice prior to LCMV 
clone-13 challenge. Consistent with previous experiments, 75 percent of wild-type 
recipient mice that received the maximal pathogenic dose (7x104) of memory p14 cells 
experienced an increase in disease requiring euthanasia by day 12 post infection. In 
contrast, recipient mice deficient in both TNF receptors demonstrated no detectable 
increase in disease after LCMV clone 13 challenge at any dose of memory CD8 T cells 
tested (Figure 2.11, open square).  
Surprisingly, we observed identical control of LCMV clone replication by 8 days 
post infection in both wild-type and TNF-R deficient recipient mice that received high 
dose transfer of memory LCMV specific CD8 T cells (Figure 2.12). This suggests that 
not only does TNF mediate pathology in this setting; it is also dispensable for virus 
control due to the CD8 effector T cell response. In stark contrast, mice deficient in the 
IFNγ-receptor experienced a further enhancement of pathology after LCMV clone 13 
infection due to increased precursor frequency of LCMV specific CD8 T cells. The 
adoptive transfer of greater than 103 memory p14 cells resulted in 100% mortality after 
LCMV clone-13 challenge (Figure 2.11, open circle). Furthermore, recipient mice 
were unable to control infection prior to the day required for euthanasia (Figure 2.12, 
open circle).  
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Figure 2.11: Pathology during persistent LCMV infection is dependent on 
memory T cell production of TNF. C57Bl/6 mice, TNFR-/- mice or IFNγR-/- mice 
received adoptive transfer of varying doses of p14 memory CD8 T cells followed by 2x106 
pfu LCMV clone-13 infection. Percent survival of recipient mice (C57Bl/6 solid circle, 
IFNγR-/- open circle, TNFR-/- open square) versus number of donor cells transferred 
after LCMV clone-13 infection (n=3-10 mice/group).  
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Figure 2.12: High precursor frequency of memory cells protect mice from 
LCMV persistence in both wild-type and TNF-R deficient mice. C57Bl/6 mice, 
TNFR-/- mice or IFNγR-/- mice received adoptive transfer of varying doses of p14 
memory CD8 T cells followed by 2x106 pfu LCMV clone-13 infection. LCMV viral titer in 
serum of recipient mice at day 6 (IFNγR/-) or day 8 post infection (TNFR-/- & B6), n=3-
5 mice per group, two independent experiments. 
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Thus, IFNγ production by LCMV specific CD8 T cells is important for CD8 T cell 
mediated protection from viral dissemination, but is not the major source of pathology in 
these mice. Taken together, these result show that blockade of different cytokines such as 
TNF may be possible to prevent pathology while retaining protective effects of vaccine-
induced memory T cells. 
However, the elimination of pathology could be a result of differences in the in 
vivo expansion of wild-type donor p14 cells in LCMV infected TNF-receptor deficient 
hosts. In order to confirm the pathogenic dose of wild-type p14 donor cells expanded in a 
similar fashion after LCMV infection, the magnitude and functional capacity of donor 
memory p14 cells were determined after LCMV clone 13 infection. There was no 
statistical difference between the magnitude of the donor memory p14 response between 
recipient wild-type and TNF-receptor deficient mice in the spleen at day 7 post infection 
(Figure 2.13A). Greater than 106 memory p14 donor cells were detected in both wild-
type and TNF-R deficient mice. In addition, the functional capacity of the donor cells 
were similar, over 40 percent of donor cells were able to produce TNF and IFNγ after 
peptide stimulation (Figure 2.13B).  
Therefore, the elimination of pathology observed in TNF-R deficient mice is not 
due to a alteration in donor cell expansion, indicating immunopathology in this model is 
likely due to CD8 T cell production of TNF. Although, it has previously been 
hypothesized that vaccine induced CD8 T cell mediated pathology may be due in part to 
the limited breadth of the T cell response, induction of T cells specific for only 1-2 viral 
epitopes, following vaccination. Therefore, the impact of the breadth of the LCMV-
specific memory CD8 T cell population has on the resulting immunopathology observed 
during secondary infection needs to be determined. 
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Figure 2.13: Memory CD8 T cell expansion does not change in TNF-R 
deficient hosts. C57Bl/6 mice or TNF-R-/- mice received adoptive transfer of 70,000 
p14 memory CD8 T cells followed by 2x106 pfu LCMV clone-13 infection. [A] Number of 
donor memory cells isolated from wildtype or TNFR-/- recipient mice 7 days post LCMV 
clone-13 infection. [B] Functional capacity of donor memory cells isolated from wildtype 
or TNFR-/- recipient mice 7 days post LCMV clone-13 infection (n=3-5 mice/group). 
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 Increasing the breadth of the CD8 T cell response does not limit 
vaccine-induced pathology. In the landmark studies by Oehen et al, vaccination with 
recombinant vaccinia virus vectors expressing LCMV protein antigens resulted in 
increased pathology during subsequent infection with LCMV compared to non-
vaccinated animals. One main hypothesis from these studies was that T cell mediated 
immunopathology was a result of the limited breadth of the CD8 T cell response after 
vaccination using recombinant vectors(303).  However, the developed quantitative 
model predicts that increasing the breadth of the CD8 T cell response should have no 
impact on resulting immunopathology. The model predicts that, similar to disease 
caused by donor CD8 T cells from a transgenic mouse specific for one epitope of LCMV, 
maximum enhancement of disease will occur at intermediate precursor frequency of 
memory CD8 T cells specific for a multitude of LCMV epitopes. 
 In order to test the impact of the breadth of the CD8 T cell response on resulting 
immunopathology during infection, varying numbers of polyclonal LCMV-specific 
memory CD8 T cells were adoptively transferred into recipient mice prior to LCMV clone 
13 infection. Polyclonal memory LCMV-specific CD8 T cells were generated by 
immunization of naïve C57Bl/6xThy1.1 congenic mice with LCMV Armstrong (Figure 
2.14A). The number of polyclonal LCMV-specific memory cells present in the sample of 
pooled splenocytes harvested from multiple LCMV Armstrong immunized mice was 
enumerated by intracellular cytokine staining after ex-vivo stimulation with 
immunodominant LCMV peptides (Figure 2.14B). Six LCMV peptides derived from 
the LCMV glycoprotein or nucleoprotein were used to estimate the number of polyclonal 
memory CD8 T cells since they have been found to make up over 88 percent of the well 
characterized CD8 T cell response following LCMV Armstrong infection. 
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Figure 2.14: General strategy for LCMV polyclonal memory CD8 T cell 
generation and adoptive transfer. [A] Polyclonal memory cells were generated by 
immunization of C57Bl/6 Thy1.1 mice with 2x105 pfu LCMV Armstrong. After a period of 
at least 45 days, C57Bl/6 mice received adoptive transfer of varying numbers of 
polyclonal memory CD8 T cells followed by challenge with 2x106 LCMV clone-13. [B] 
Input breadth of donor polyclonal  memory CD8 T cells as measured by IFNγ production 
after peptide stimulation.  
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 Consistent with model predictions, mice that received intermediate numbers of 
polyclonal LCMV-specific CD8 T cells experienced high mortality. Greater than 80% of 
mice receiving intermediate numbers (7x104, 2x104) of polyclonal LCMV-specific 
memory CD8 T cells required euthanasia by day 13 post LCMV clone-13 challenge 
(Figure 2.15). Whereas, no increase in mortality was seen in mice receiving low 
(<20,000) or high (>105) numbers of polyclonal memory cells prior to LCMV clone 13 
challenge. Similar to results after memory p14 transfer, low precursor frequency of 
polyclonal LCMV-specific CD8 T cells prior to persistent LCMV infection resulted in a 
non-protective response and uncontrolled viral replication. LCMV titer, up to 105 
pfu/mL, was measured in the serum at day 8 post-infection in mice receiving less than 
2x105 donor polyclonal memory CD8 T cells. Whereas, transfer of a high number of 
polyclonal memory CD8 T cells (>105) prior to LCMV clone 13 resulted rapid viral 
control by day 8 post infection and minimal disease (Figure 2.16). Additionally, LCMV 
persisted in the serum for up to 30 days in infected mice that received low dose transfer, 
indistinguishable from infected controls receiving no additional cells. Recipient mice 
that had a high precursor frequency of polyclonal memory CD8 T cells after adoptive 
transfer maintained viral clearance up to 30 days post infection, with no detectable viral 
recrudescence (Figure 2.17). 
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Figure 2.15: Intermediate numbers of antigen specific polyclonal memory 
CD8 T cells cause maximum pathology after subsequent LCMV clone-13 
infection. Percent survival of C57Bl/6 recipient mice of varying numbers of polyclonal 
memory CD8 T cells followed by LCMV clone-13 infection (n=3-5 mice/group).  
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Figure 2.16: High precursor frequency of polyclonal LCMV-specific memory 
CD8 T cells protect mice from viral persistence after LCMV clone 13 
infection. C57Bl/6 mice received adoptive transfer of varying numbers of polyclonal 
memory CD8 T cells followed by challenge with 2x106 LCMV clone-13. LCMV viral titer 
in serum of polyclonal memory recipient mice at day 8 post infection (n=3-5 
mice/group). 
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Figure 2.17: High precursor frequency of polyclonal LCMV-specific memory 
CD8 T cells does not select for LCMV viral escape variants after LCMV clone 
13 infection. C57Bl/6 mice received adoptive transfer of varying numbers of polyclonal 
memory CD8 T cells followed by challenge with 2x106 LCMV clone-13. LCMV viral titer 
in serum of polyclonal memory recipient mice at day 30 post infection (n=3-5 
mice/group). 
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 The increase in immunopathology resulting in mortality due to transfer of 
polyclonal LCMV-specific memory cells prior to LCMV clone 13 challenge was 
indistinguishable from survival data generated after transfer of an intermediate number 
of monoclonal-transgenic memory P14 cells (Figure 2.18). Therefore, intermediate 
numbers of both polyclonal and monoclonal memory CD8 T cell populations can result 
in unattended increase in disease during persistent LCMV infection. The observed 
increase in disease from varying precursor frequency of polyclonal or monoclonal 
memory LCMV specific CD8 T cells support the previously described mathematical 
model prediction that the breadth of the T cell response induced by vaccination is 
independent of the observed pathology. Thus, the breadth of the T cell response has no 
impact on the dose of cells that cause maximum pathology. The breadth of the memory 
CD8 T cell response does not impact generation of viral escape variants since neither 
transfer of high dose monoclonal or polyclonal LCMV-specific CD8 T cells resulted in 
viral recrudescence. However, broader vaccine responses are likely to be useful in 
preventing virus escape observed for other infections with more mutable viruses. An 
additional suggestion from the developed model, which was not immediately intuitive, 
was that inoculation with decreased viral inoculum should result in maximum pathology 
at lower numbers of T cells and at slightly later times post infection. 
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Figure 2.18: Increasing the breadth of the CD8 T cell response does not limit 
vaccine-induced pathology. Percent survival of C57Bl/6 mice that received varying 
numbers of either p14 memory or LCMV-specific polyclonal memory CD8 T cells 
followed by LCMV clone-13 infection (n=5-10 mice/group).  
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 The precursor frequency of memory CD8 T cells that enhances 
pathology is dependent on the magnitude of initial viral load. The model 
predicts that inoculation with decreased viral inoculum should result in maximum 
pathology at lower numbers of T cells. Presumably, this is due to CD8 T cell expansion 
outpacing virus that quickly reaches carrying capacity in a given host. In order to test 
how CD8 T cell pathology depends on the initial viral load, varying numbers of LCMV-
specific P14 CD8 T cells were transferred into recipient mice followed by infection with 
increasing or decreasing doses of persistent LCMV clone 13. As shown in Figure 2.19, 
the dose of T cells causing the maximum amount of pathology scaled with the virus 
inoculum.  
 Infection with 2x105 pfu LCMV clone 13  (10-fold lower than the standard virus 
challenge dose) did not induce pathology in mice that received 7x104 donor cells, but 
instead caused maximum pathology in mice that received 10-fold lower (7x103) donor 
cells. Survival of recipient mice decreased from 80% to 50% in mice receiving low (7x103) 
precursor frequency of LCMV-specific donor cells after challenge with 2x105 pfu LCMV 
clone 13. In addition, survival increased from 0% to 100% in mice receiving intermediate 
(7x104) precursor frequency of LCMV-specific donor cells after challenge with 2x105 pfu 
LCMV clone 13. On the other hand, mice challenged with a 5-fold higher dose (107) of 
LCMV clone 13 displayed increased mortality at higher numbers of (106) donor cells, 
(100% to 80% survival) and decreased pathology (0% to 40% survival) at intermediate 
doses (7x104) (Figure 2.19).  
In all cases, maximum pathology occurred at a dose of donor CD8 T cells just 
below the amount that was able to clear infection at 8 days post-infection (Figure 
2.20).  
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This suggests that decreasing the amount of initial virus inoculum resulted in a higher 
threshold for exhaustion of donor CD8 T cells leading to greater survival at intermediate 
cell number correlating with increased viral control. Whereas, increasing the amount of 
the initial inoculum resulted in a lower threshold for exhaustion of donor CD8 T cells 
leading to greater survival at intermediate cell number due to loss of TNF production. 
However, leading to decreased survival at high donor CD8 T cell number due to partial 
exhaustion, lack of early viral control, and T cell production of TNF. 
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Figure 2.19: Pathology during persistent LCMV infection is dependent on 
initial viral load. Percent survival of C57Bl/6 mice that received varying doses (103-
107) of naïve p14 CD8 T cells followed by infection with three different doses (2x105-107 
pfu) of LCMV clone-13 (n=3-5 mice per group, two independent experiments).    
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Figure 2.20: Maximum pathology occurs at precursor frequency of antigen-
specific CD8 T cells just below the amount that is able to control infection. 
C57Bl/6 mice received varying doses (103-107) of naïve p14 CD8 T cells followed by 
infection with three different doses (2x105-107 pfu) of LCMV clone-13. LCMV clone-13 
titer in the serum of recipient mice on day 8 post infection. Grey bars indicate dose that 
resulted in maximum pathology (n=3-5 mice per group, two independent experiments). 
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DISCUSSION 
A previously developed mathematical model of LCMV infection in mice has 
generated predictions about which virus and host immune parameters can differentially 
affect pathology versus protection during persistent viral infection. We have tested these 
predictions experimentally and our findings indicate that CD8 T cell pathology due to an 
intermediate precursor of antigen-specific CD8 T cells is largely independent of T cell 
sensitivity or the breadth of TCR diversity. However, pathology was observed to be 
dependent on TNF production and initial virus load. These results indicate that variation 
in precursor frequency of memory CD8 T cells as well as initial viral load drastically 
alters disease outcome due to changes in the level of T cell exhaustion.  
The initial amount of stimulation by varying the magnitude of viral infection 
alters the frequency at which the responding T cells can result in pathogenic responses.  
These results are consistent with published data indicating that T cell exhaustion may be 
a mechanism to limit immunopathology of naïve CD8 T cells(275, 384) and an increase 
in pathology can occur due to partial exhaustion of the T cell response as mediated by 
initial viral dose. Our experimental results expand on these findings and support the 
predictions of the developed mathematical model. Demonstrated by the findings that 
memory cells (specific to one epitope or multiple epitopes) are also prone to increased 
pathology dependent on the total number of memory CD8 T cells and the extent of 
exhaustion these cells experience, due to initial viral load and the magnitude of the 
response determines pathological or protective outcomes.  
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Mice that had high numbers of memory CD8 T cells (polyclonal or monoclonal) 
prior to high dose viral infection did not develop immunopathology because the 
magnitude of the response was great enough to control viral replication by 8 days post 
infection. Whereas mice that had an intermediate number of memory CD8 T cells prior 
to high dose viral infection developed severe pathology due to partial T cell exhaustion of 
the response resulting in ongoing high viral titers and pathology presumed due to 
continued production of TNF. The ability of memory CD8 T cells to respond to viral 
infection with greater sensitivity than naive did not alter the observation that 
intermediate precursor frequency of antigen specific T cells prior to persistent viral 
infection can increase disease. 
Pathology does not occur at low precursor frequency of memory LCMV specific T 
cells prior to LCMV clone 13 infection. Analysis of T cell persistence and functional 
capacity support the hypothesis that T cell exhaustion is a mechanism during persistent 
viral infection to avoid pathology, since responding T cells lose the ability to proliferate 
and produce inflammatory cytokines such as TNF. Mice that had low numbers of 
memory CD8 T cells or no memory CD8 T cells prior to high dose infection did not 
develop immunopathology because the responding CD8 T cells were highly exhausted 
and unable to cause pathology. However, when the initial viral dose decreases by one log, 
to an intermediate viral infection, lower numbers of memory CD8 T cells become only 
partially exhausted leading to an increase in pathology at a low dose of cells, similar to 
mice receiving intermediate numbers of CD8 T cells after high dose infection. Indicating 
there is a fine balance between the magnitude and functionality of the memory CD8 T 
cell response and initial viral dose, that is not due dependent on TCR diversity of the 
CD8 T cell response. 
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Pathology was found to be mediated by CD8 T cell production of TNF since 
pathology, due to intermediate precursor frequency of LCMV specific memory CD8 T 
cells, was eliminated in TNF-R mice infected with LCMV clone 13. Although, histological 
analysis indicated memory CD8 T cells mediated a qualitatively different pathology than 
that seen mediated by effector responses originating from LCMV-specific naïve CD8 T 
cells. Pathology due to naïve-originating CD8 T cell responses was found to be primarily 
localized in the lungs, whereas pathology due to memory-originating CD8 T cell 
responses was found to be in the liver. The difference in the tissue pathology could be 
attributed to the kinetics of the T cell response(238). Memory CD8 T cells respond 
rapidly upon subsequent exposure and may traffic to the liver, an early site of viral 
replication, whereas naïve cells may traffic to the lungs a secondary site of viral 
replication(273). Although the reason for the increase in pathology is unchanged, 
pathology is due to partial exhaustion of the responding T cells.  
Furthermore, variation of antigen-specific memory CD8 T cell precursor 
frequency in TNF-R deficient and IFNγ-R deficient mice indicated that although T cell 
production of TNF mediates pathology, it is not required for viral control. TNF-R 
deficient mice that received high dose LCMV-specific memory CD8 T cells were able to 
control LCMV viral load by day 8 post infection, similar to wild-type mice receiving high 
dose p14 memory transfer. Whereas, a high precursor frequency of LCMV-specific CD8 T 
cells in IFNγ-R deficient mice prior to persistent LCMV infection did control viral 
replication and mice experienced an increase in mortality. Thus, highlighting the 
importance of the anti-viral effects of IFNγ produced by responding CD8 T cells to 
control initial viral replication and promote immune response. 
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Although, precursor frequency of memory or naive antigen specific cells alters 
disease outcome to the same extent at an intermediate dose resulting in mouse mortality, 
the same cannot be said after high dose transfer. Mice that receive high numbers of naïve 
T cells show viral escape 50 percent of the time; with viral recrudescence and high viral 
loads in the serum 30 days post infection(239). However, we have not observed virus 
escape after transfer of high dose p14 memory cells (n=15 mice) followed by LCMV 
clone-13 infection. In addition to a lack of viral escape after transfer of high dose 
monoclonal memory cells, no escape was seen after polyclonal transfer (n=10 mice). 
Indicating that immune responses generated from memory CD8 T cells are superior in 
virus control due to the absence of variant escape viruses. Presumably due to the kinetics 
of the response, T cells controlling viral loads before selective pressure results in an 
escape mutant.  
Pathology can be due to low precursor frequency or intermediate precursor 
frequency memory CD8 T cells dependent on the initial viral dose. Therefore, a wide 
range of precursor frequencies could potentially cause pathology depending on viral 
dose. Therefore, the strength of the vaccine response for an individual may or may not be 
pathogenic dependent on the individual’s subsequent viral exposure. In order to avoid 
potential vaccine induced pathology the CD8 T cell response must be above a critical 
threshold to limit pathology due to early viral control. In addition, vaccines that only 
elicit one arm of the immune system should be avoided over vaccine candidates that also 
stimulate antibody production and CD4 T cell help, since the combination of responding 
immune cells may influence early viral control decreasing the chance of pathology. 
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Recently it has been published that vaccine induced CD4 memory T cells specific 
for LCMV can also cause immunopathology and mortality after challenge with LCMV 
clone-13(385). The investigators found that the pathology was mediated by antigen 
driven hyper stimulation and activation of LCMV specific memory CD4 T cells that do 
not undergo traditional T cell exhaustion, seen in our model with LCMV-specific 
memory CD8 T cells. Pathology was ablated by the addition of high does of P14 cells that 
resulted in virus control by day 7 post infection and pathology remained after blockade of 
CD8 T cells during immunization. CD4 mediated pathology was presumably caused by 
cytokine production, but not by TNF indicated in our results for causing the 
immunopathology from responding memory CD8 T cells. Our results in conjunction with 
these results indicate that both memory CD8 and CD4 T cells after immunization can 
cause immunopathology when the vaccine induced immune response is not sufficient to 
immediately control virus early after infection. Thereby, allowing the responding cells 
that do not completely lose functionality due to an exhausted phenotype, continue to 
exert effector function due to persistent viral load. These studies highlight the 
importance for future vaccine design to induce both CD4 and CD8 T cell memory 
responses. 
Vaccine induced pathology has been reported as early as the 1960s during an 
experimental vaccine trial for respiratory syncytial virus (RSV). The candidate vaccine, 
formalin inactivated RSV given intramuscularly to infants and children, resulted in a 
failure to offer protection during a subsequent outbreak of RSV. In addition to the 
vaccine demonstrating limited efficacy, an exaggerated clinical response was seen in 80 
percent of young vaccine recipients including two deaths(320, 324). 
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 Thus, a major goal of vaccination should be induction of immune responses that 
maximize elimination of infectious organisms while minimizing immunopathology. 
Historical examples of vaccine induced pathology highlight the need to understand the 
relationship between virus infection, immune responses and immune exhaustion that 
have been difficult to determine due to the complex non-linear interactions that occur 
between these variables.  
We have developed a model of virus infection and immune responses that can 
help to decipher these interactions and to make predictions about which features of the 
virus or immune response contribute to immunopathology. The mathematical 
framework for analyzing the complex non-linear interactions between immune cells and 
virus infection can then be useful for maximizing vaccine protection to chronic infections 
while minimizing enhancement of disease due to elevated immune response, in order to 
design vaccines that maximize protection while minimizing enhancement of disease.  
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CHAPTER 3 
INTERACTION BETWEEN UNRELATED VIRUSES DURING IN-VIVO CO-INFECTION 
TO LIMIT PATHOLOGY AND IMMUNITY 
ABSTRACT 
Great progress has been made in understanding the requirements for immunity 
to viral infection. However, outside of laboratory experiments, most “real-world” 
infections occur in the context of co-infection by heterologous pathogens that have the 
potential to modulate immune responses and/or disease. In order to begin to understand 
the complex relationships that may occur during heterologous virus co-infection, we 
have studied co-infection of mice with Ectromelia virus (ECTV) and Lymphocytic 
Choriomeningitis virus (LCMV), two unrelated viruses that are endemic to mice. 
Experimental inoculation of mice with ECTV results in a lethal infection with high virus 
replication in the liver, due in part to a number of ECTV proteins that block the 
production of and signaling from Type I interferons (IFN-I). Conversely, LCMV 
Armstrong infection results in an acute viral infection that is rapidly controlled by a 
potent CD8 T cell response, which is reliant on the induction of Type I interferon. We 
show that ECTV/LCMV co-infection of mice results in decreased ECTV viral load and 
amelioration of ECTV-induced disease. Our data suggest that this is due to Type I IFN 
induction by LCMV that suppresses ECTV replication. However, immune responses to 
LCMV in ECTV co-infected mice were also lower compared to mice infected with LCMV 
alone, and biased toward IFNγ producing effector-memory cells. Thus, we provide 
evidence for bi-directional effects of unrelated viruses during co-infection to modulate 
disease and immunity. Such observations likely have important implications for the 
maintenance and spread of these viruses in wild mouse populations. 
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IMPORTANCE 
1. Novel finding of interaction between unrelated viruses during co-infection to 
limit disease and modulate immunity. 
2. Findings suggest that co-infection in wild populations may have important 
implications for understanding the spread and maintenance of these viruses in endemic 
populations by increasing host survival and decreasing immunity to facilitate 
transmission. 
3. Data suggest that heterogeneity in responses during vaccination with viral 
vectors or virus infection may be in part due to heterologous virus infection or vaccine 
usage. 
 
INTRODUCTION 
Tremendous progress has been made in our understanding of the requirements 
for immunity to viral infection(315, 386). In particular, animal studies utilizing the 
Lymphocytic Choriomeningitis (LCMV) mouse model of infection have led to the 
description of numerous fundamental properties of the immune system including the 
basis for MHC restriction of viral antigens(96, 270, 271), cross-presentation of epitopes 
by MHC proteins(272), how T cell effector mechanisms function to control virus 
infection(200, 273, 274), the generation and maintenance of T cell memory(9, 221, 222), 
and exhaustion of T cell responses during persistent infection(238, 239, 249, 275, 276). 
Poxviruses have also been widely used to understand how the immune system responds 
to infection(331) and are currently being investigated for use as potential vaccine 
vectors(25) for many important human pathogens such as HIV(21).  
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Despite this progress, an important caveat to such illuminating laboratory 
experiments is that they are almost always done in isolation, under specific pathogen-
free (SPF) conditions. Whereas most “real-world” infections likely occur in the context of 
co-infection by heterologous pathogens that have the potential to modulate immune 
responses and/or alter disease(346). Current studies suggest co-infection with different 
pathogens is a common occurrence that can alter the progression of disease(346, 387-
390).  One example of such interaction is exacerbation of Listeriosis in mice to lethal 
disease during co-infection with LCMV(391, 392). Recent studies have also shown that 
enteric bacterial strains promote infection by poliovirus via mucosal routes(393).  
Another potential consequence of viral co-infection is viral co-evolution in which one 
virus may supply ancillary functions or suppress immune functions for another(345). 
Such a relationship has previously been described for Hepatitis B (HBV) and Hepatitis D 
(HDV) viruses. HDV cannot form mature virions without the presence of the Hepatitis B 
structural proteins(363). Co-infection of HBV and HDV or super infection of persistently 
infected HBV patients with HDV also results in increased liver pathology and poorer 
prognosis in patients due to altered immune responses and type I interferon signaling in 
the host(364, 365).  
In order to understand the complex relationships that may occur during 
heterologous virus co-infection, we have studied co-infection of mice with ECTV and 
LCMV, two unrelated viruses that are endemic to mice. Although previous studies of co-
infection with the related vaccinia virus (VACV) and LCMV have shown no alteration in 
either LCMV CD8 T cell responses or disease, such studies may minimize the role of 
these interactions(394, 395), as VACV is not endemic to mice. ECTV is a DNA virus of 
the orthopoxvirus family and encodes a number of proteins that block the production of 
and signaling by Type I interferons (IFN-I)(5, 338). 
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 Experimental inoculation of mice with ECTV typically results in a lethal infection 
due to high virus replication in the liver and acute hepatic disease(337, 340). Conversely, 
LCMV infection of mice results in the rapid expansion of virus-specific CD8 T cells that 
limit viremia resulting in viral control and clearance within 7 days post infection(238, 
396). In striking contrast to ECTV, LCMV induces robust Type I IFN production in mice 
with peak production during the first 12-48 hours of infection(397, 398). Furthermore, 
CD8 T cell responses to LCMV in mice are highly dependent on IFN-I signaling for 
sustained expansion(60, 399); infection of Interferon receptor deficient (IFNAR-/-) mice 
with LCMV results in a defective CD8 T cell response that is unable to control 
infection(400). Therefore, we hypothesize that co-infection with ECTV and LCMV has 
the potential for bi-directional effects on disease and immunity by suppression of ECTV 
replication and disease while limiting LCMV-specific CD8 T cell responses. 
We show here that ECTV/LCMV co-infection of mice results in decreased ECTV 
viral load and ameliorates ECTV-induced disease. Furthermore, we show that this effect 
is likely due to Type I IFN induction by LCMV that is able to overwhelm ECTV 
mechanisms for suppression of Type I IFN production and signaling. Conversely, we also 
show that ECTV partial suppression of type I IFN production during co-infection with 
LCMV results in diminished CD8 T cell responses to LCMV. Additionally, the LCMV 
response is biased towards the formation of memory CD8 T cells with a TNF-deficient 
effector-memory phenotype that has been shown to be less protective in other 
studies(230, 401, 402). Thus, we provide the first experimental evidence for bi-
directional effects of these two unrelated viruses during co-infection to modulate disease 
and immunity. These findings likely have implications for disease and transmission of 
these viruses in wild mouse populations, and may in part explain the heterogeneity that 
is typically observed in LCMV immune responses in the wild(403, 404).  
  102 
More importantly, our data suggest heterogeneity in responses during vaccination, with 
viral vectors, or viral infection may be in part due to heterologous virus infection or 
vaccine usage(405, 406).  
 
MATERIALS AND METHODS 
Mice: 6-8 week old female C57Bl/6J mice were purchased from Jackson 
laboratories (Bar Harbor, Maine). IFNAR1-deficient mice (IFNAR-/-) were purchased 
from Jackson laboratories (Bar Harbor, Maine) and bred in our ASU animal facilities. All 
studies were conducted according to animal protocol 12-1229R under the approval and 
guidance of the Arizona State University Institute for Animal Care and Use Committee. 
Cells and viruses: BHK cells were maintained in complete Eagles’s MEM (5% 
fetal bovine serum (FBS), 2mM L-glutamine (L-Q), 100 U/mL penicillin, 100 µg/ml 
streptomycin). Vero and MC57 cells were maintained in complete DMEM (10% FBS, 
2mM L-Q, 100 U/ml penicillin, 100 µg/mL streptomycin). LCMV Armstrong and LCMV 
clone-13 stocks were kindly provided by Rafi Ahmed (Emory University, Atlanta GA) and 
produced in BHK cells as previously described(380). The titer of LCMV stocks and 
mouse serum samples were determined by plaque assay on Vero cell monolayers as 
previously described(380). ECTV expressing the β-gal gene in the CHO locus (US17-βgal) 
was a gift from Dr. Mark Buller (St Louis University, St Louis MO). ECTV stocks were 
propagated in Vero cells as previously described(407). ECTV titers in mouse liver 
homogenates were determined on VERO cell monolayers. Briefly, liver samples were 
weighed and homogenized in PBS to 10% w/v. Vero monolayers were infected following 
three freeze-thaw cycles for 1 hour prior to overlay with a 1:1 ratio of 1% agarose and 2X-
MEM supplemented with 10% fetal bovine serum.  
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After three days at 37oC, a second overlay of a 1:1 ratio of 1% Agarose and 2X-MEM 
supplemented with 10% fetal bovine serum and X-gal (20mg/ml) was applied. Four days 
after the secondary overlay blue ECTV plaques were counted.  
In vivo infections: Unless otherwise stated, LCMV and ECTV stocks were 
diluted to 106 pfu/ml in 1X PBS prior to intraperitoneal infection in a volume of 100ul, 
delivering a total of 105 pfu per mouse. Unless otherwise indicated, co-infected mice 
received ECTV immediately followed by LCMV inoculation. Mice were monitored daily 
for clinical disease (hunched posture, ruffled fur, non-motility) and euthanized at the 
indicated times post infection. 
Peptides: Lymphocytic choriomeningitis virus CD8 T cell epitopes GP33 (H-
2Db, KAVYNFATC) and NP396 (H-2Db, FQPQNGQFI) were purchased from Genscript 
(Piscataway, NJ). 
Cell surface antibody staining: Single cell suspensions were prepared from 
splenocytes as previously described(200). Erythrocytes were lysed with ammonium 
chloride lysis (ACK) buffer purchased from Lonza (Allendale, NJ) and FACS staining was 
done as previously described(200) in 96 well plates with fluorochrome-labeled 
monoclonal antibodies: anti-CD8 (clone 53-6.7), anti-CD44 (clone IM7), anti-PD-1 
(clone J43), anti-CD4(clone GK1.5) and anti-CD62L (clone MEL-14) or APC labeled 
GP33-tetramer(238). Samples were then fixed in 1% paraformaldehyde solution and 
immediately acquired on a BD LSR II Fortessa flow cytometer (San Jose, CA) and 
analyzed using FlowJo software (Tree-Star, Ashland, OR). All surface monoclonal 
antibodies were purchased from BD Pharmigen (San Diego, CA) or eBiosciences (San 
Diego, CA). 
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Intracellular cytokine staining: For quantitation of ECTV-specific T cell 
responses, splenocytes (106/well) were stimulated with uninfected MC57 cells or with 
ECTV infected MC57 cells (MOI:1, at 24 hours post infection). For quantitation of 
LCMV-specific T cell responses, splenocytes were cultured alone or with 1mM LCMV 
peptide epitopes as previously described(200). After 5 hours of stimulation, cells were 
permeabilized and intracellular cytokine producing cells detected by staining with anti-
IFNγ (clone XMG1.2) and anti-TNF (clone MP6-XT22) antibodies purchased from BD 
Pharmigen (San Diego, CA) or eBiosciences (San Diego, CA). The samples were acquired 
and analyzed as described above. 
Interferon-I ELISA: Mouse interferon beta and interferon alpha ELISA kits 
were purchased from PBL Assay Science (Piscataway, NJ) and used according to 
manufacturers instructions to detect serum Type I IFN levels. 
Histology: Formalin fixed liver sections were cut into 20µm thick tissue sections 
on a microtome. Liver samples were stained with x-gal (20mg/mL) using the β-
galactosidase reporter gene staining kit purchased from Sigma (St Louis, MO) following 
the manufacturers instructions. Adjacent sections of formalin fixed liver tissue were 
stained with hematoxylin and eosin as previously described(382). 20x images were taken 
with a Zeiss Axioskop (Thornwood, NJ) and evaluated for pathology and punctate blue x-
gal staining. 
Statistics: Prism software (Graphpad, La Jolla, CA) was used to calculate t-test 
p values to determine significance or log-rank test to determine survival curve 
significance (* = p≤0.05, **= p≤0.01, ***= p≤0.001). 
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RESULTS: 
ECTV/LCMV co-infection reduces ECTV disease and viral load. We first 
determined if ECTV/LCMV co-infection alters disease in mice compared to ECTV 
infection alone, by monitoring physical symptoms and mouse survival. As expected, 
ECTV-only infected mice exhibited extreme disease symptoms starting at 5 days post 
infection and required euthanasia by 7 days post-infection (Figure 3.1). Surprisingly, 6 
week-old ECTV/LCMV co-infected mice exhibited a delay in ECTV-induced disease, with 
survival between 12-17 days post infection, more than twice that observed in mice 
infected with ECTV alone.  
Orthopoxvirus infections have been shown to be age and immune status 
dependent, with older mice typically having reduced poxvirus replication and less severe 
disease(336), we also compared mice infected with ECTV alone to ECTV/LCMV co-
infection in 8-week old mice. We observed no difference in ECTV disease in older mice 
compared to younger mice, presumably due to the high dose of inoculation used, since 
all mice infected with ECTV alone required euthanasia by 7 days post-infection. In 
striking contrast, ~70% of 8 week-old ECTV/LCMV co-infected mice exhibited long-
term, disease-free survival. Overall, ECTV/LCMV co-infection resulted in 50% survival 
of mice, with no detectable ECTV in liver homogenates at greater than 60 days post-
infection compared to 0% survival after mice infected with ECTV alone. Thus, these 
results demonstrate that ECTV/LCMV co-infection can ameliorate ECTV disease in mice.  
ECTV induced mortality in mice is known to correlate with high viral titers in the 
liver that result in in acute hepatic failure(336, 343). In order to determine whether the 
delay in and/or amelioration of ECTV-induced disease in ECTV/LCMV co-infected mice 
was due to suppression of ECTV viral loads, we next measured ECTV viral titers in the 
liver of ECTV/LCMV co-infected mice compared to mice infected with ECTV alone. 
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Figure 3.1: ECTV/LCMV co-infection reduces ECTV disease. 6-8 week old 
female C57Bl/6 mice were injected with 105 pfu ECTV-US17-βgal ip. Immediately 
following ECTV infection co-infected mice were injected with 105 pfu LCMV Armstrong 
ip. All mice were monitored daily for morbidity and mortality. Survival curve of all ECTV 
infected (n=34), LCMV infected (n=20) and ECTV/ LCMV co-infected (n=47) 6-8 week-
old mice. Survival curve breakdown of ECTV/LCMV co-infected by age indicates 8-week 
and older mice experience complete rescue of mortality. 
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Mice infected with ECTV alone exhibited high liver viral titers, with up to 109 pfu/gram 
by 6 days post-infection (Figure 3.2A). However, ECTV/LCMV co-infected mice 
exhibited a ~1000 to 100-fold decrease in ECTV liver viral load, remaining below 107 
pfu/gram up to 9 days post-infection. Thereafter, ECTV/LCMV co-infected mice were 
either able to completely able to control ECTV infection or succumb to lethal disease.  
Notably, in analysis of liver tissue sections directly ex vivo, mice infected with 
ECTV alone displayed punctate x-gal staining across the entire liver section, whereas x-
gal staining was undetectable in ECTV/LCMV co-infected mice at day 5 post infection 
(Figure 3.2B, upper panel). These findings were also consistent with histological 
staining (H&E stain) in which liver tissues at 5 days post infection from mice infected 
with ECTV alone showed multiple necrotic lesions, whereas liver sections from 
ECTV/LCMV co-infected mice did not exhibit any detectable necrotic lesions (Figure 
3.2, lower panel). Taken together, these results show that ECTV/LCMV co-infection 
reduces ECTV virus load in the liver and therefore ameliorates disease. 
 In order to investigate if the reduced disease in ECTV/LCMV co-infected mice 
was due to LCMV prevention of initial ECTV infection of cells, versus suppression of 
ECTV replication, we tested whether infection of mice with decreasing doses of ECTV 
during LCMV co-infection had a similar effect on disease. We reasoned that if LCMV 
inhibited initial seeding of ECTV in the liver we would expect mice receiving lower doses 
of ECTV to also have less disease and enhanced survival in the absence of LCMV 
infection. Mice that received up to 1000-fold lower doses of ECTV exhibited similar 
disease at 5 days post-infection compared to the high dose inoculation used above, and 
100% of these mice required euthanasia by 7 days post-infection.  
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Figure 3.2: ECTV/LCMV co-infection reduces ECTV viral load in the liver. 6-
8 week old female C57Bl/6 mice were injected with 105 pfu ECTV-US17-βgal ip. 
Immediately following ECTV infection co-infected mice were injected with 105 pfu LCMV 
Armstrong ip. All mice were monitored daily for morbidity and mortality. [A] Mean 
ECTV viral load (pfu/gram) in the liver of ECTV infected and ECTV/LCMV co-infected 
mice on days indicated post infection (n=3-5 mice/group, 3 independent experiments). 
[B] Top panel: 20X view of formalin fixed liver section stained with X-gal at day 5 post 
infection, blue color indicates presence of ECTV infection. Bottom panel: Histological 
stain (H&E) of formalin fixed liver sections at day 5 post infection, red arrows point to 
necrotic lesions (n= 3-5 mice/group). 
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Surprisingly, decreasing the dose of ECTV during ECTV/LCMV co-infection had 
no impact on suppression of disease: ECTV/LCMV co-infected mice at all doses of ECTV 
demonstrated delayed disease until day 16 post infection similar to that observed during 
high dose infection (Figure 3.3). These data are consistent with the hypothesis that the 
observed suppression of ECTV disease in ECTV/LCMV co-infected mice is not due to 
competition for target cells or blockade of initial ECTV seeding in the liver, but rather 
suppression of ECTV replication or infection after initial seeding.  
 
The timing of LCMV infection is crucial for reducing disease during 
ECTV co-infection. We next hypothesized that the observed reduction in ECTV 
replication and disease during LCMV co-infection may be dependent on the timing 
(prior exposure or post exposure) of co-infection due to the potential for enhancement of 
early innate events by LCMV to suppress ECTV infection. Infection with LCMV up to 2 
days prior to ECTV infection resulted in similarly reduced ECTV viral loads and disease 
as observed during concurrent ECTV/LCMV co-infection (Figure 3.4A). Mice infected 
with LCMV 3 days prior to ECTV infection demonstrated a minor delay in disease 
progression, with mice surviving on average 3 days longer than mice infected with ECTV 
alone. In striking contrast, mice inoculated with LCMV 1 or 2 days post ECTV infection 
showed no reduction in ECTV viral loads or disease compared to mice infected with 
ECTV alone, with 100% of these mice exhibiting lethal disease symptoms by 7 days post-
infection (Figure 3.4B). Thus, the timing of co-infection for the suppression of ECTV 
replication and disease suggests that the effects of LCMV on ECTV are to enhance early 
innate events to suppress ECTV viral infection in the liver.  
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Figure 3.3: LCMV does not prevent initial seeding of ECTV in the liver 
during co-infection. 8-week old female C57Bl/6 mice infected with 105, 104 or 103 pfu 
ECTV-US17-βgal ip. Immediately following ECTV infection co-infected mice were 
injected with 105 pfu LCMV Armstrong ip. Survival curve of mice infected with ECTV 
alone or co-infected with ECTV and LCMV at varying infectious doses of ECTV (n= 3-5 
mice/group). 
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Figure 3.4: The timing of LCMV infection is crucial for reducing disease 
during ECTV co-infection. [A] Survival of 6 week-old mice infected with 105 LCMV 
Armstrong (ip) 1, 2 or 3 days prior to ECTV-US17-βgal (ip) infection. [B] Survival of 
ECTV-US17-βgal infected 8-week old mice (d0) that received LCMV Armstrong 
immunization 1 or 2 days post ECTV exposure (n=3-5 mice/group). 
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ECTV/LCMV co-infection nullifies ECTV abrogation of IFN-I 
production. Because LCMV is known to induce potent Type I Interferon 
responses(398), and ECTV is sensitive to Type I Interferons(338, 343), we next  
hypothesized that the early innate immune suppression of ECTV could be due to an 
overwhelming Type I IFN response. This would be consistent with the observation that 
LCMV inoculation 1-2 days prior to ECTV infection resulted in similar reduction in 
disease and ECTV liver titers, as Type I IFN production is maximal at 1-2 days post 
LCMV infection and is curtailed thereafter(397).  
Serum levels of total IFNα and IFNβ in ECTV infected mice were undetectable, 
as expected, presumably due to the ability of ECTV viral proteins to completely shut 
down Type I IFN production(336). In contrast, mice infected with LCMV alone induced 
potent Type I IFN responses, with >12,000 pg/mL total IFNα and >500 pg/mL IFNβ in 
the serum of mice infected with LCMV alone by 24 hours post infection. Thereafter, 
IFNα and IFNβ levels decreased to 9000 pg/mL and 100pg/mL respectively by 48 hours 
in mice infected with LCMV alone and were low to undetectable thereafter (Figure 3.5). 
ECTV/LCMV co-infected mice exhibited an increase in serum levels of both IFNα and 
IFNβ, compared to mice infected with ECTV alone (which were undetectable). Serum 
IFNα levels were not statistically different between LCMV and co-infected animals 
(Figure 3.5A). Whereas, IFNβ levels were lower in ECTV/LCMV co-infected mice 
compared to mice infected with LCMV alone (Figure 3.5B). Thus, these results suggest 
that although ECTV is able to partially attenuate IFNβ production during LCMV co-
infection, sufficient Type I IFN levels remain to suppress ECTV replication and 
ameliorate disease. 
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Figure 3.5: ECTV/LCMV co-infection nullifies ECTV abrogation of IFN-I 
production. 6-8 week old female C57Bl/6 mice were injected with 105 pfu ECTV-US17-
βgal ip (100ul). Immediately following ECTV infection co-infected mice were injected 
with 105 pfu LCMV Armstrong ip. [A] IFNαlevels in serum of ECTV/LCMV co-infected 
mice as compared to LCMV only and ECTV only control mice at 24 and 48 hours post 
infection (n=3-5 mice/group). [B] IFNβlevels in serum of ECTV/LCMV co-infected mice 
as compared to LCMV only and ECTV only control mice at 24 and 48 hours post 
infection (n=3-5 mice/group).  
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In order to directly test the role of Type I IFN in suppression of ECTV replication 
and disease during ECTV/LCMV co-infection, we tested whether ECTV/LCMV co-
infection could rescue IFNAR-/- mice from disease. Mice infected with ECTV alone and 
ECTV/LCMV co-infected infected mice had indistinguishable ECTV viral loads and  
exhibited similar disease, requiring euthanasia by 7 days post-infection (Figure 3.6). 
Thus, LCMV co-infection does not rescue IFNAR-/- mice from lethal ECTV disease. These 
results suggest that Type I IFN signaling is the main mechanism for LCMV suppression 
of ECTV replication and disease.  
 
LCMV co-infection does not significantly enhance ECTV-specific CD8 
T cell responses. Resistance to mousepox has been shown to correlate with rapid, 
more enhanced cytotoxic responses(340, 408). Therefore, an alternative explanation for 
the observed decrease in ECTV disease during LCMV co-infection is that LCMV alters 
ECTV-specific adaptive immune responses, and thus attenuates immunopathology. It 
should be noted, that although no studies have shown a dependence on Type I IFN for 
induction of ECTV T cell responses, as has been shown with LCMV, other 
orthopoxviruses do not require Type I IFN for induction of CD8 T cell immunity(394). 
We observed no difference in the total magnitude of the ECTV-specific CD8 T cell 
response in the spleen, measured by CD8 T cell production of IFNγ after culture with 
ECTV infected-MC57 cells directly ex-vivo, between mice infected with ECTV alone and 
ECTV/LCMV co-infected mice.  
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Figure 3.6: LCMV reduction of ECTV mediated disease during ECTV/LCMV 
co-infection is dependent on Type I interferon signaling. Survival curve of 8-10 
week old female IFNAR-/- mice infected with 105 pfu ECTV-US17-βgal ip. Immediately 
following ECTV infection co-infected mice were infected with 105 pfu LCMV Armstrong 
ip (n= 3-5 mice/group). 
  
  116 
The ECTV CD8 T cell response was evaluated at a time point preceding 
presentation of disease symptoms that required euthanasia. Moreover, in both groups of 
mice the CD8 T cells had equivalent production of IFNγ and TNF (Figure 3.7A). Thus, 
LCMV co-infection does not appear to increase survival in co-infected mice due to 
alteration of the initial ECTV CD8 T cell response or immunopathology resulting from 
these cells. Thus, suggesting that the observed effects on reduction of ECTV replication 
and amelioration of disease due to LCMV co-infection are driven by the increase in 
innate immune production of Type I IFN. However, the increase in survival seen in co- 
infected mice past 6 days post infection may allow greater development of the ECTV CTL 
response, which may further influence ECTV viral replication. In order to investigate the 
potential bi-directional effects of alterations in IFN-I production during co-infection, we 
next determined if there were variations in the LCMV-specific T cell response in 
ECTV/LCMV co-infected mice. 
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Figure 3.7: ECTV/LCMV co-infection does not significantly enhance 
magnitude of ECTV-specific CD8 T cell response. 6-8 week old female C57Bl/6 
mice were injected with 105 pfu ECTV-US17-βgal ip (100ul). Immediately following 
ECTV infection co-infected mice were injected with 105 pfu LCMV Armstrong ip. At the 
indicated time post infection, splenocytes were harvested, processed to single cell 
suspensions and stimulated for 6 hours with ECTV infected MC57 cells prior to 
intracellular cytokine staining. [A] Representative FACS plots showing the proportion of 
CD8 T cells, isolated on day 5 post infection from the spleen of ECTV infected and 
ECTV/LCMV co-infected mice, capable of producing TNF and IFNγ after stimulation 
with ECTV-MC57 cells. [B] Left panel: mean percentage of ECTV-specific IFNγ 
producing T cells out of all CD8 T cells in the spleen on day 5 post infection. Right panel: 
Average number of ECTV-specific CD8 T cells in the spleen on day 5 post infection (n=3-
5 mice/group). 
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Decreased IFN-I during ECTV/LCMV co-infection limits LCMV-
specific CD8 T cell expansion. In addition to the effect of LCMV/ECTV co-infection 
to reduce ECTV replication and disease, we next hypothesized that production of ECTV 
proteins that suppress Type I IFN production(5) may impair the generation of LCMV-
specific CD8 T cell responses that are critically dependent on Type-I IFN for sustained 
proliferation(60, 399). In order to determine if ECTV/LCMV co-infection impaired 
LCMV-specific CD8 T cell expansion, we compared LCMV effector CD8 T cell generation 
between co-infected mice and mice infected with LCMV alone (Figure 3.8A). Peak 
LCMV CD8 T cell responses to the immunodominant GP33 and NP396 epitopes(238) at 
9 days post-infection in the spleen of mice infected with LCMV alone were >35% of the 
total CD8 T cell population, consisting of on average >6 x106 LCMV-specific cells 
(Figure 3.8B, black bars). However, ECTV/LCMV co-infection decreased the peak 
LCMV response by 2-3 fold as GP33 and NP396 epitope-specific CD8 T cells comprised 
<20% of the total CD8 T cell population with on average <2x106 LCMV-specific CD8 T 
cells (Figure 3.8B, white bars). This effect was not due to differences in the timing of 
expansion of the LCMV-specific CD8 T cells, as a similar reduction in the effector T cell 
response was also seen at day 7 post ECTV/LCMV-infection (Figure 3.8C).   
  Moreover, and consistent with previous reports that show that Type I IFN are 
necessary for sustained proliferation of CD8 T cells but not the initial activation and 
early proliferation of these cells(60), we observed no difference in the CD8 T cell 
response to LCMV between mice infected with LCMV alone and ECTV/LCMV co-
infected mice at 5 days post-infection (Figure 3.8C). Thus, incomplete ECTV 
suppression of Type I IFN during LCMV co-infection results in reduced LCMV-specific 
CD8 T cell expansion.  
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Additionally, although not statistically significant with the number of mice used in these 
studies, the percentage of LCMV-specific memory CD8 T cells in ECTV/LCMV co-
infected mice was consistently lower than that observed in mice infected with LCMV 
alone at >35 days post infection. Thus, memory CD8 T cells specific for the 
immunodominant NP396 and GP33 epitopes appeared to be proportional to peak 
effector T cell responses in both groups. (Figure 3.8C).   
 
 Decreased CD8 T cell responses to LCMV during ECTV/LCMV co-
infection do not impair control of LCMV or CD8 T cell memory function. We 
next asked whether the observed reduction in the LCMV-specific CD8 T cell response 
during ECTV/LCMV co-infection impaired immune control of LCMV. Surprisingly, we 
observed no difference in serum LCMV titers at 7 days post-infection between LCMV-
only and ECTV/LCMV co-infected mice, with neither group having detectable LCMV 
levels at this time. However, we cannot rule out that there were small differences in the 
kinetics of control of LCMV. Many studies have suggested that the strength or duration 
of the initial stimulus has a dramatic impact on the generation and function of CD8 T cell 
memory(9, 238, 400). Although we observed no impact of ECTV/LCMV co-infection on 
CD8 T cell mediated control of LCMV, we reasoned that if the diminished CD8 T cell 
responses in ECTV/LCMV co-infected mice resulted in slight impairment of LCMV-
specific immunity, then this might alter the bias generation of LCMV-specific memory T 
cells or their function. To test whether LCMV-specific memory CD8 T cells in 
ECTV/LCMV co-infected mice were impaired in their effector functions we next 
measured the ability of memory cells from mice infected with LCMV alone or 
ECTV/LCMV co-infected mice to produce the key inflammatory cytokines IFNγ and 
TNF.   
  120 
 
 
Figure 3.8: Decreased IFN-I during ECTV/LCMV co-infection limits LCMV-
specific CD8 T cell expansion. 6-8 week old female C57Bl/6 mice were injected with 
105 pfu ECTV-US17-βgal ip (100ul). Immediately following ECTV infection co-infected 
mice were injected with 105 pfu LCMV ip. At the indicated times post infection, 
splenocytes were harvested, processed to single cell suspensions and stimulated for 6 
hours with cognate LCMV peptides prior to intracellular cytokine staining. [A] 
Representative FACS plots of the LCMV-specific (GP33 peptide stimulated) CD8 T cell 
response in the spleen at day 9 post infection of LCMV infected and ECTV/LCMV co-
infected mice. [B] Mean total number of LCMV-specific (GP33 and NP396) CD8 T cells 
in the spleen on day 9 post infection (n=3-5 mice/group). [C] Kinetics of LCMV-specific 
(GP33 and NP396) CD8 T cell response as a percentage of total CD8 T cells in the spleen 
in ECTV/LCMV co-infected mice and LCMV infected mice (n=3-5 mice/group). 
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  We observed a decrease in the relative proportions of LCMV-specific memory 
cells, specific for NP396 and GP33 epitopes that were able to produce both IFNγ and 
TNF after stimulation. 89% of CD8 T cells isolated from mice infected with LCMV alone 
that produced IFNγ in response to these epitopes were double-positive for TNF. In 
contrast, only 41% of CD8 T cells in ECTV/LCMV co-infected mice that produced IFNγ 
also produced TNF (Figure 3.9A). The magnitude of LCMV-specific (GP33 and NP396 
epitopes) memory CD8 T cells capable of producing TNF and IFNγ in the spleen also 
decreased from 8% of all CD8 T cells in the spleen of mice infected with LCMV alone to 
less than 4% of CD8 T cells in the spleen of ECTV/LCMV co-infected mice (Figure 
3.9B). In addition, the percentage of central-memory (CD62Lhigh) CD8 T cells specific 
for the LCMV epitope GP33 was decreased almost three-fold (>95% CD62Lhigh to ~35% 
CD62Lhigh) in ECTV/LCMV co-infected mice compared to mice infected with LCMV 
alone (Figure 3.9C). Taken together, these results suggest that CD8 T cell control of 
LCMV is partially impaired in ECTV co-infected mice resulting in fewer multi-functional 
memory cells biased toward an effector-memory (CD62Llow) phenotype. Finally, we 
tested whether the reduced cytokine production and effector-memory bias of CD8 T cell 
populations in ECTV/LCMV co-infected mice impacted the ability of these mice to 
control subsequent LCMV infection.  
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Figure 3.9: Decreased CD8 T cell responses to LCMV during ECTV/LCMV co- 
infection bias T cell effector memory formation. 6-8 week old female C57Bl/6 
mice were infected with 105 pfu ECTV-US17-βgal ip. Immediately following ECTV 
infection co-infected mice were injected with 105 pfu LCMV ip. After a period of at least 
35 days surviving co-infected mice were euthanized to enumerate LCMV CD8 T cell 
memory formation and function. [A] Functional analysis of GP33 and NP396 memory 
CD8 T cells at day 35 post infection. White bar indicates ability to produce IFNγ only, 
black sections indicates ability to produce both TNF and IFNγ after peptide stimulation 
(n=3-5 mice/group). [B] Mean percentage of TNF and IFNγ producing LCMV-specific 
memory cells in the CD8 T cell splenic population at day 35 post infection. [C] Left 
panel: representative FACS histogram of CD62L expression on GP33-tetramer positive 
cells in the spleen. Right panel: percentage of GP33-tetramer positive, LCMV-specific 
central memory (CD62Lhigh) CD8 T cells in the spleen in LCMV infected and 
ECTV/LCMV co-infected mice (n=3-5 mice/group). 
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We challenged ECTV/LCMV co-infected or mice infected with LCMV at 35 days 
post-infection with the virulent clone-13 strain of LCMV(284, 292, 308). Non-
immunized mice infected with LCMV clone-13 are unable to control LCMV replication 
and present with high viral titers (~105 pfu/ml) in the serum at 7 days post-infection. 
Additionally, naïve mice challenged with LCMV clone 13 undergo T cell exhaustion 
resulting in decreased cytokine production and increased expression of the inhibitory 
receptor PD-1(239). Both groups of immunized mice, whether previously infected with 
LCMV alone or co-infected with ECTV/LCMV, had undetectable LCMV viral titers in the 
serum at 7 days post LCMV clone 13 challenge (Figure 3.10A).  
In addition, LCMV-specific CD8 T cells in ECTV/LCMV co-infected mice did not 
experience T cell exhaustion, since capacity to produce IFNγ and TNF after stimulation 
was greater than naive challenged mice and indistinguishable from LCMV immunized 
mice at day 15 post challenge (Figure 3.10B). Furthermore, CD8 T cells isolated from 
either ECTV/LCMV co-infected or LCMV-immunized mice at day 15 post LCMV clone 13 
challenge expressed low levels of PD-1 (Figure 3.10B). Thus, suggesting that even 
though ECTV co-infection reduced the generation, function and central memory 
phenotype of LCMV specific CD8 T cells, which has been shown to be less protective 
during LCMV challenge(230, 402), sufficient memory T cells persisted in both groups to 
mount protective responses to LCMV clone-13 challenge. 
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Figure 3.10: ECTV/LCMV c0-infection has no impact on secondary 
responses and protection after LCMV clone-13 challenge. 6-8 week old female 
C57Bl/6 mice were infected with 105 pfu ECTV-US17-βgal ip. Immediately following 
ECTV infection co-infected mice were injected with 105 pfu LCMV ip. After a period of at 
least 35 days surviving co-infected mice were challenged with 2x106 pfu LCMV clone-13 
iv. [A] LCMV clone 13 viral load (pfu/mL) in the serum of LCMV clone-13 challenged 
mice at day 7 post infection. [B] Mean percentage of TNF and IFNγ producing 
secondary effector LCMV-specific CD8 T cells at day 15 post challenge [C] Percentage of 
PD-1high GP33-tetramer positive cells at day 15 post challenge in LCMV immune, 
ECTV/LCMV co-infected and naïve mice (n=3-5 mice/group).  
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DISCUSSION 
Our results demonstrate interaction between endemic but unrelated viruses 
during co-infection of mice to limit disease and immunity. Mice co-infected with LCMV 
and ECTV demonstrated reduced ECTV replication resulting in reduced disease and 
enhanced survival. Conversely, ECTV co-infection resulted in reduced LCMV-specific 
CD8 T cell responses. The data suggest that these effects are primarily due to modulation 
of Type I IFN levels, with primarily lower IFNβ levels in ECTV/LCMV co-infected mice 
compared to mice infected with LCMV alone and no difference in disease progression 
during ECTV/LCMV co-infection in IFNAR-/- mice compared to mice infected with ECTV 
alone. This is further supported by more striking amelioration of disease in ECTV/LCMV 
co-infected older mice in which Type I IFN signaling has previously been shown to limit 
Orthopoxvirus replication(343). 
Our results implicate Type I IFN production and/or signaling as the main 
mechanism by which LCMV suppresses ECTV replication and disease in ECTV/LCMV 
co-infected mice. The kinetics of LCMV infection and induction of Type I IFN responses 
in this model appears to be critically important as co-infection with LCMV 3 days prior 
had minimal impact on ECTV disease while inoculation with LCMV >1 day after ECTV 
infection showed no effect. We suggest in the former case LCMV-induced Type I IFN 
production is curtailed after 3 days to levels that are effectively blocked by ECTV 
proteins. In contrast, LCMV infection after establishment of ECTV infection is likely 
ineffective as ECTV proteins have effectively shut down Type I IFN signaling(336, 341). 
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Our results also show that ECTV modulation of Type I IFN production during 
ECTV/LCMV co-infection attenuates LCMV-specific CD8 T cell responses that are 
dependent on direct signaling via Type I IFN for sustained proliferation. It is unlikely in 
this context that ECTV is modulating Type I IFN intracellular signaling as ECTV is not 
known to directly infect CD8 T cells(341). Although we find minimal differences in IFNα 
in ECTV/LCMV co-infected mice compared to mice infected with LCMV alone, we did 
observe significantly and consistently lower levels of systemic IFNβ in co-infected mice. 
Therefore, our data suggests that IFNβ, rather than IFNα, plays a larger role in 
supporting sustained CD8 T cell proliferation during LCMV infection. In addition to 
lower overall effector and memory T cell responses in ECTV/LCMV co-infected mice, we 
also show that ECTV partial suppression of Type I IFN during LCMV co-infection results 
in decreased memory CD8 T cell functionality and biasing towards an effector-memory 
phenotype. While we observed no difference in the ability of memory cells in either 
group to control subsequent LCMV infection, it has been shown that central-memory are 
better able to control LCMV infection compared to effector-memory cells(9). Taken 
together with the decreased TNF production by these cells, our results suggest that ECTV 
co-infection results in a slight impairment of LCMV-specific immunity.  
The importance of type I interferon to limit ECTV disease is well known(5, 338). 
It has previously been shown that antibody blockade of ECTV type I interferon-binding 
protein, C12R, during ECTV infection drastically reduces ECTV disease(343). Therefore, 
our results indicate that Type I IFN produced after LCMV infection may be 
overwhelming the ability of C12R to block signaling, mimicking antibody blockade. It is 
currently unknown which ECTV-encoded proteins provide the suppressive effects on 
Type I IFN production that result in attenuation and alteration of LCMV-specific CD8 T 
cell immunity.  
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We propose that the most likely candidate in this case is the ECTV dsRNA binding 
protein (homolog of Vaccinia virus E3L) that would be able to limit type I interferons 
during co-infection(5, 334, 344). The ECTV IFN-I binding protein has been shown to 
only block the action of mouse IFNα(5). Our results suggest there is only a decrease in 
systemic IFNβ, indicating a different mechanism other than ECTV expression of an IFN-
I binding protein, is responsible for limiting LCMV-specific CD8 T cell immunity. 
Interestingly, previous reports that showed no alteration of LCMV-specific immune 
responses during co-infection with the orthopoxvirus, vaccinia virus, utilized the highly 
attenuated “Lancy” vaccine strain that has low virulence in mice(394).  
The discovery of viral genomes incorporated within mammalian genomes 
indicates that viral families are much older than previously believed(409). The newly 
predicted timescale increases the frequency of potential viral co-divergence with hosts in 
order for the virus to survive(345). In addition, hosts that are infected with multiple 
viruses or host that are persistently infected and undergo additional infection with a 
heterologous virus could result in further viral co-evolution. The beneficial interplay via 
modulation of IFN-I between LCMV and ECTV suggest that there may have been co-
evolution of ECTV and LCMV in wild mouse populations due to the potential increase in 
viral transmission of both viruses. 
An important point that these studies raise is whether co-infection alters either 
ECTV or LCMV transmission in wild mouse populations. ECTV is suspected to be easily 
transmitted among naturally infected wild populations of mice(336, 339). Multiple ECTV 
strains with varying disease severity have been isolated from outbreaks in European and 
North American laboratory mouse colonies(410-412). The delayed progression of ECTV 
disease during LCMV co-infection that results in continued host survival may lead to 
greater potential for transmission of ECTV to subsequent hosts.  
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In addition, decreased CD8 T cell immunity and function during ECTV co-infection 
could also result in a decreased ability to control infection, potentially leading to 
increased transmission of both ECTV and LCMV. Although we observed no difference in 
LCMV control in this experimental setting using the acute Armstrong strain of LCMV, 
circulating LCMV strains in the wild also include persistent strains (396, 413, 414).  
Future experiments will need to address how ECTV modulates Type I IFN during 
infection during co-infection with persistent strains of LCMV or in established carrier 
mice infected at birth with the virus. However, recent data suggest that Type I IFNs 
produced during later time points of persistent LCMV infection actually contribute to 
persistence by suppressing immune responses (398). Therefore, our results would be 
consistent with a more important role for ECTV suppression of LCMV Type I IFNs 
during co-infection resulting in early suppression of immunity. In addition, an important 
observation in these studies is that ECTV/LCMV co-infection alters the magnitude, 
function, and phenotype of CD8 T cell responses. One implication of this observation is 
that heterogeneity in T cell responses during vaccination and/or viral infection (415) may 
be in part explained by the context of other infections. This is particularly relevant for 
vaccination studies using recombinant orthopoxviruses as vaccine vectors for other 
pathogens (25), as individuals with other infections (or other vaccinations) may 
attenuate the effectiveness of such strategies.  
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CHAPTER 4 
LCMV VIRUS PERSITENCE ABROGATES THE BENEFICAL EFFECT OF IFN-I 
INDUCTION ON DISEASE DURING ECTV CO-INFECTION 
ABSTRACT 
Human Immunodeficiency virus (HIV) and Hepatitis C virus (HCV) co-infection 
is estimated to occur in 15-30% of all HIV-infected individuals and 5-10% of all HCV-
infected individuals. In the last decade, due to the success of highly active antiretroviral 
therapy, HIV/HCV co-infection has emerged as a major source of morbidity and 
mortality in HIV-infected individuals. HIV/HCV co-infection is associated with weaker 
HCV immune response, increased liver fibrosis, higher HCV RNA levels, and worse HCV 
disease progression. Thus, highlighting the potential consequence of co-infection with 
persistent viruses that may bi-directionally modulate viral persistence and immune 
responses. We have studied co-infection of mice with persistent and acute variants of 
Lymphocytic choriomeningitis virus (LCMV) with Ectromelia virus (ECTV). 
Experimental inoculation of mice with ECTV results in a lethal infection with high virus 
replication in the liver, due in part to a number of ECTV proteins that block the 
production of and signaling from Type I interferons (IFN-I). We show that ECTV co-
infection of mice with persistent or acute LCMV results in differential impacts on ECTV 
viral load and amelioration of ECTV-induced disease. CD8 T cell responses to both acute 
and persistent LCMV in ECTV co-infected mice were attenuated. However, the resulting 
effect on LCMV viral control and pathology was different between co-infection with 
either acute or persistent variants of LCMV. Thus, we provide evidence for differential 
effects of acute versus persistent co-infection that modulate disease and immunity.  
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INTRODUCTION 
 
Due to the success of highly active antiretroviral therapy in HIV-infected 
individuals that has decreased AIDS-related morbidity and mortality, HIV co-infection 
with Hepatitis virus has emerged as a major source of morbidity and mortality in HIV-
infected individuals(355). Co- infection with HCV and HIV is a relatively common event, 
occurring in 15-30% of all HIV-infected individuals and 5-10% of all HCV-infected 
individuals(356, 357). Viral co-infection can occur by simultaneous exposure of two 
heterologous viruses, that may share the same route of transmission, or a chronically 
infected individual can become co-infected after independent exposure to circulating 
viral strains. 
  HIV co-infection is associated with weaker HCV immune response, increased 
liver fibrosis, higher HCV RNA levels, reduced response rates to anti-viral treatment, and 
worse HCV disease progression(356, 358). The differences in immunity and disease in 
co-infected individuals may be due to alterations in the intrahepatic cytokine milieu as a 
result of HIV infection(359, 360). Detection of cytokine mRNA in HIV/HCV co-infected 
patients revealed lower levels of TNF, IL-8, and IL-10 mRNA and increased levels of 
TGF-β compared to individuals infected with HCV alone(360). In addition, HBV co-
infection has been reported to occur in up to 36% of all HIV-infected individuals in 
Africa, which currently accounts for 0ver 70 percent of global HIV-infection(357, 361). 
HIV co-infection with HBV also correlates with higher rates of HBV persistence and 
increased risk of liver-related morbidity and mortality(355, 357, 362). 
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In order to understand the complex relationships that may occur during heterologous 
virus co-infection, we have studied the impact on viral persistence during co-infection of 
mice with ECTV and LCMV. ECTV is a DNA virus of the orthopoxvirus family and 
encodes a number of proteins that block the production of and signaling by Type I 
interferons (IFN-I)(5, 338). Experimental inoculation of mice with ECTV typically 
results in a lethal infection due to high virus replication in the liver and acute hepatic 
disease(337, 340). Acute LCMV infection of mice results in the rapid expansion of virus-
specific CD8 T cells, viral control and clearance by 7 days post infection(238, 396). 
Previous findings highlight the interaction between endemic but unrelated LCMV 
and ECTV during co-infection of mice to limit disease and immunity. Mice co-infected 
with the acute strain of LCMV and ECTV demonstrated reduced ECTV replication 
resulting in reduced disease and enhanced survival. Conversely, ECTV co-infection 
resulted in reduced LCMV-specific CD8 T cell responses. The data suggest that these 
effects are primarily due to modulation of Type I IFN levels, with primarily lower IFNβ 
levels in ECTV/LCMV co-infected mice compared to mice infected with LCMV alone. 
 In striking contrast to acute LCMV Armstrong infection, persistent LCMV clone 13 
infection in C57Bl/6 mice is characterized by diminished viral control, resulting in high 
viral titers detectable in serum up to 60 days post infection(238, 292). This is due to, in 
part, dysfunctional CD8 T cell differentiation leading to exhaustion of the responding 
immunodominant CD8 T cells (238).  In the absence of CD4 T cell help, CD8 T cell 
dysfunction is exacerbated, resulting in life-long chronic infection in mice with long-term 
elevated viral titers in serum and tissues (218). In addition, LCMV clone 13 has also been 
shown to produce ~4x the amount of IFNβ in the serum(398).  
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The marked difference between LCMV Armstrong and LCMV clone 13 infections 
is propagated by only three amino acid residue mutations between the two viruses(306). 
Two mutations occur within the viral spike GP-1 on the S segment at amino acid position 
176 and 260 and one occurs within the viral polymerase on the L segment at amino acid 
position 1076(307) The identified mutations in the LCMV clone- 13 GP protein results in 
an increased affinity for the cellular receptor, α-Dystroglycan, resulting in an increase in 
the relative infectivity of the virus. While the mutation in the viral polymerase of LCMV 
clone-13 results in an increase in replication rate of the virus (308). The selection of the 
LCMV clone 13 variant may have been a consequence of virus-host evolution towards 
balanced pathogenicity, since LCMV CTL activity is critical not only for viral control, but 
also fatal immunopathology mediated by responding CD8 T cells after intracranial 
infection of adult mice. Therefore, we hypothesize that co-infection with ECTV and 
persistent LCMV has the potential for differential effects on disease and immunity due to 
differences in the speed of replication, induction of T cell exhaustion and greater initial 
magnitude IFN-I production. 
Our results demonstrate that ECTV/CL13 co-infection of mice results in 
differential outcomes in T cell immunity and disease. We observed a modest 3 day 
increase in survival during ECTV/Clone 13 co-infection as compared to co-infection with 
acute LCMV presumably due to IFN-I production by LCMV before progression of ECTV-
induced liver pathology. Furthermore, co-infection did not result in control of ECTV 
replication in the liver past 8 days post infection. We also show that ECTV co-infection 
results in diminished LCMV-specific CD8 T cell effector expansion and a complementary 
10-fold increase in LCMV viral load. Thus, we provide experimental evidence for 
differential effects of acute versus persistent viruses during co-infection that modulate 
disease and immunity. 
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MATERIALS AND METHODS 
Mice: 6-8 week old female C57Bl/6J mice were purchased from Jackson 
laboratories (Bar Harbor, Maine). P14 transgenic mice, in which CD8 T cells express 
TCR specific for the DbGP33-41 epitope of LCMV, were obtained from Dr. Rafi Ahmed 
and bred in our animal facilities. All studies were conducted according to animal 
protocol 12-1229R under the approval and guidance of the Arizona State University 
Institute for Animal Care and Use Committee. 
Cells and viruses: BHK cells were maintained in complete Eagles’s MEM (5% 
fetal bovine serum (FBS), 2mM L-glutamine (L-Q), 100 U/mL penicillin, 100 µg/ml 
streptomycin). Vero and MC57 cells were maintained in complete DMEM (10% FBS, 
2mM L-Q, 100 U/ml penicillin, 100 µg/mL streptomycin). LCMV Armstrong and LCMV 
clone-13 stocks were kindly provided by Rafi Ahmed (Emory University, Atlanta GA) and 
produced in BHK cells as previously described(380). The titer of LCMV stocks and 
mouse serum samples were determined by plaque assay on Vero cell monolayers as 
previously described(380). ECTV expressing the β-gal gene in the CHO locus (US17-βgal) 
was a gift from Dr. Mark Buller (St Louis University, St Louis MO). ECTV stocks were 
propagated in Vero cells as previously described(407). ECTV titers in mouse liver 
homogenates were determined on VERO cell monolayers. Briefly, liver samples were 
weighed and homogenized in PBS to 10% w/v. Vero monolayers were infected following 
three freeze-thaw cycles for 1 hour prior to overlay with a 1:1 ratio of 1% agarose and 2X-
MEM supplemented with 10% fetal bovine serum. After three days at 37oC, a second 
overlay of a 1:1 ratio of 1% Agarose and 2X-MEM supplemented with 10% fetal bovine 
serum and X-gal (20mg/ml) was applied. Four days after the secondary overlay blue 
ECTV plaques were counted.  
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In vivo infections: Unless otherwise stated, ECTV stocks were diluted to 106 
pfu/ml in 1X PBS prior to intraperitoneal infection in a volume of 100ul, delivering a 
total of 105 pfu per mouse. LCMV Clone 13 stocks were diluted to 107 pfu/ml in 1X PBS 
prior to intravenous infection in a volume of 200ul, delivering a total of 2x106 pfu per 
mouse. Unless otherwise indicated, co-infected mice received ECTV immediately 
followed by LCMV inoculation. Mice were monitored daily for clinical disease (hunched 
posture, ruffled fur, non-motility) and euthanized at the indicated times post infection.  
Peptides: Lymphocytic choriomeningitis virus CD8 T cell epitopes GP33 (H-
2Db, KAVYNFATC) and NP396 (H-2Db, FQPQNGQFI) were purchased from Genscript 
(Piscataway, NJ). 
Cell surface antibody staining: Single cell suspensions were prepared from 
splenocytes as previously described(200). Erythrocytes were lysed with ammonium 
chloride lysis (ACK) buffer purchased from Lonza (Allendale, NJ) and FACS staining was 
done as previously described(200) in 96 well plates with fluorochrome-labeled 
monoclonal antibodies: anti-CD8 (clone 53-6.7), anti-CD44 (clone IM7), anti-PD-1 
(clone J43), anti-CD4(clone GK1.5) and anti-CD62L (clone MEL-14) or APC labeled 
GP33-tetramer(238). Samples were then fixed in 1% paraformaldehyde solution and 
immediately acquired on a BD LSR II Fortessa flow cytometer (San Jose, CA) and 
analyzed using FlowJo software (Tree-Star, Ashland, OR). All surface monoclonal 
antibodies were purchased from BD Pharmigen (San Diego, CA) or eBiosciences (San 
Diego, CA). 
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Intracellular cytokine staining: For quantitation of LCMV-specific T cell 
responses, splenocytes were cultured alone or with 1mM LCMV peptide epitopes as 
previously described(200). After 5 hours of stimulation, cells were permeabilized and 
intracellular cytokine producing cells detected by staining with anti-IFNγ (clone 
XMG1.2) and anti-TNF (clone MP6-XT22) antibodies purchased from BD Pharmigen 
(San Diego, CA) or eBiosciences (San Diego, CA). The samples were acquired and 
analyzed as described above. 
Statistics: Prism software (Graphpad, La Jolla, CA) was used to calculate t-test 
p values to determine significance or log-rank test to determine survival curve 
significance (* = p≤0.05, **= p≤0.01, ***= p≤0.001). 
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RESULTS 
Persistent variant of LCMV does not rescue mice from lethal 
pathology during ECTV/LCMV co-infection. The persistent variant of LCMV, 
LCMV clone-13, induces greater amounts of systemic IFN-I during the first 12-48 hours 
post infection than LCMV Armstrong(397, 398). We hypothesized that LCMV-clone 13 
co-infection would be able reduce ECTV induced mortality and viral loads to the same or 
greater extent as co-infection with the acute variant of LCMV. 8- week old female mice 
were infected with ECTV alone, co-infected with ECTV and LCMV Armstrong 
(ECTV/ARM) or co-infected with ECTV and LCMV Clone-13 (ECTV/Cl13). Mice were 
evaluated for disease by monitoring physical symptoms, viral loads and survival. As 
expected, mice infected with ECTV alone exhibited extreme disease symptoms starting at 
5 days post infection and required euthanasia by day 6 post-infection.  
Mice co-infected with the acute strain of LCMV exhibited a significant delay in 
morbidity and complete rescue in ~70% of 8-week old mice, consistent with previous 
experiments. Surprisingly, 8-week old ECTV/LCMV-13 co-infected mice exhibited only a 
slight delay in disease progression and mortality. 100% of ECTV/LCMV-13 co-infected 
mice succumbed to disease on day 9 post infection (Figure 4.1). Lethal ECTV infection 
in mice is known to correlate with high viral titers in the liver resulting in in acute 
hepatic failure(336, 343). Furthermore, the delay in and/or amelioration of ECTV-
induced disease in ECTV/ARM co-infected mice was previously found to correlate with 
suppression of ECTV viral replication in the liver. 
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Figure 4.1: Persistent variant of LCMV does not rescue mice from lethal 
pathology during ECTV/LCMV co-infection. 8-week old female C57Bl/6 mice were 
injected with 105 pfu ECTV-US17-βgal ip. Immediately following ECTV infection co-
infected mice were injected with 2x106 pfu LCMV Clone 13 iv or 105 pfu LCMV 
Armstrong ip. All mice were monitored daily for morbidity and mortality. Survival curve 
of ECTV infected (n=6), LCMV clone 13 infected (n=6), ECTV/ARM (n=7) co-infected, 
and ECTV/ CL13 co-infected (n=6). 
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Persistent variant of LCMV does not reduce ECTV viral load in the 
liver during ECTV/LCMV co-infection. In order to determine whether the 
mortality seen after ECTV/Cl13 co-infection was due to ECTV replication in the liver, we 
next measured ECTV viral titers in the liver of ECTV/Cl13 co-infected mice one day prior 
to evident morbidity requiring euthanasia. Mice infected with ECTV alone exhibited high 
liver viral titers, on average 5x107 pfu/gram, one day prior to death at day 5 post-
infection (Figure 4.2, black bar). In comparison, ECTV/Cl13 co-infected mice 
exhibited high ECTV titer, on average 107 pfu/gram, in the liver one day prior to death at 
day 8 post infection (Figure 4.2, gray bar). In contrast, ECTV/ARM co-infected mice 
with long-term survival had a  ~1000 to 100-fold decrease in ECTV liver viral load, 
measured below 105 pfu/gram at day 8 post infection (Figure 4.2, white bar). Thus, 
suggesting that ECTV/Cl13 co-infected mice succumbed to ECTV mediated disease due 
to uncontrolled ECTV viral replication in the liver.  
Prior investigation of ECTV co-infection with LCMV Armstrong demonstrated, in 
addition to suppression of ECTV replication, a bi-directional effect on LCMV immunity 
by suppression of LCMV-specific CD8 T cell effector expansion and bias towards 
CD62Llow effector memory cell generation. Therefore, we determined if ECTV 
immunomodulatory proteins limit primary CD8 T cell effector expansion during 
ECTV/CL13 co-infection.  It is unknown if T cell dysfunction observed during LCMV 
clone 13 infection due to viral persistence will alter the potential impact of decreased 
IFN-I on effector expansion.  
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Figure 4.2: Persistent variant of LCMV does not reduce ECTV viral load in 
the liver during ECTV/LCMV co-infection. 8-week old female C57Bl/6 mice were 
injected with 105 pfu ECTV-US17-βgal ip. Immediately following ECTV infection co-
infected mice were injected with 2x106 pfu LCMV Clone 13 iv. Mean ECTV viral load 
(pfu/gram) in the liver of ECTV infected and ECTV/Cl13 co-infected mice on day 8 
indicated post infection (n=3 mice/group, 2 independent experiments). 
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ECTV limits LCMV-specific CD8 T cell expansion during co-infection 
with persistent variant of LCMV. In order to determine if ECTV/Cl13 co-infection 
impaired LCMV-specific CD8 T cell expansion, we compared LCMV effector CD8 T cell 
generation between co-infected mice and mice infected with LCMV clone 13 alone. 
Magnitude of the LCMV CD8 T cell response to the immunodominant GP33 
epitope(238) on day 8 post Clone 13 infection of mice infected with LCMV alone 
consisted of on average of 6 x105 cells in the spleen (Figure 4.3, black bar). As 
expected, ECTV/13 co-infection decreased the LCMV response by over 2-fold, LCMV 
GP33 epitope-specific CD8 T cells comprised on average <3x105 cells in the spleen 
(Figure 4.3, white bars). Thus, suggesting that ECTV suppression of Type I IFN 
during LCMV Clone 13 infection is significant enough to limit LCMV-specific CD8 T cell 
effector expansion.  
However, the significant decrease in effector cell expansion observed after acute 
LCMV infection did not alter LCMV Armstrong viral control or the protective capacity of 
immunized mice to limit LCMV clone 13 dissemination after clone 13 challenge. 
Although, the ability of co-infected mice to protect against LCMV clone 13 challenge may 
have been due to proliferation of central memory CD8 T cells and/or the presence of 
LCMV-specific CD4 memory T cells. Therefore, we hypothesize that the significant 
reduction in the primary LCMV effector response during LCMV clone 13 infection will 
also result in decreased control of LCMV replication.  
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Figure 4.3: ECTV limits LCMV-specific CD8 T cell expansion during co-
infection with persistent variant of LCMV. 8-week old female C57Bl/6 mice were 
injected with 105 pfu ECTV-US17-βgal ip. Immediately following ECTV infection co-
infected mice were injected with 2x106 pfu LCMV Clone 13 iv.  Mean total number of 
LCMV-specific (GP33 epitope) CD8 T cells in the spleen on day 8 post infection (n=3-5 
mice/group). 
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ECTV co-infection increases LCMV clone 13 viral load. In order to test 
whether the reduced expansion of LCMV CD8 T cell effectors in ECTV/Cl13 co-infected 
mice impacted the ability of these mice to limit overwhelming LCMV viral loads, we 
measured virus load in the serum of co-infected and Clone 13 infected mice. Naive mice 
infected with LCMV clone-13 are unable to control LCMV replication and present with 
viral titers around (~105 pfu/ml) in the serum at day 8 post-infection (Figure 4.4, 
black bar). As expected, ECTV/CL13 co-infected mice had 10-fold higher LCMV viral 
titer, greater than 106 pfu/ml, in the serum at day 8 post infection (Figure 4.4, white 
bar). Thus indicating, ECTV/Cl13 co-infection impacts not only LCMV- specific CD8 T 
cell response, but also initial LCMV replication.  
IFN-I signaling can induce expression of hundreds of inflammatory genes 
resulting in pleiotropic effects on multiple cellular processes(37, 40). In some settings of 
persistent viral infection, IFN-I has sustained production that can result in lymphoid 
tissue disorganization(398). IFN-I levels in LCMV clone 13 infected mice are consistently 
higher than in LCMV Armstrong infected mice. LCMV clone 13 has been shown to 
produce ~4x the amount of IFNβ in the serum(398). Although, IFN-I production during 
LCMV clone 13/ECTV co-infection did not substantially increase mouse survival or limit 
ECTV viral replication. However, ECTV/Cl13 co-infection did reduce LCMV immunity, 
suggesting there is a significant reduction in IFN-I in ECTV/Cl13 co-infected mice. 
Additionally, blockade of IFN-I signaling with antibodies against IFNAR-/- can result in 
restoration of splenic architecture and an increase in viral control of Clone 13 infected 
mice(398). Therefore, we hypothesized that infection of persistently infected LCMV 
clone 13 mice with ECTV could potentially increase viral control due to production of 
ECTV immunomodulatory proteins that block IFN-I signaling if sustained IFN-I was 
great enough to limit overwhelming ECTV replication and disease.  
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Figure 4.4: ECTV co-infection increases LCMV clone 13 viral load. 8-week old 
female C57Bl/6 mice were injected with 105 pfu ECTV-US17-βgal ip. Immediately 
following ECTV infection co-infected mice were injected with 2x106 pfu LCMV Clone 13 
iv.  Mean LCMV viral load (pfu/mL) in the serum of LCMV clone 13 infected and 
ECTV/Cl13 co-infected mice on day 8 indicated post infection (n=3 mice/group, 2 
independent experiments). 
 
 
 
 
  
  144 
Sustained IFN-I production in persistently infected mice does not 
limit ECTV replication or disease after exposure. In order to test the therapeutic 
potential of ECTV infection in persistently infected mice, C57Bl/6 mice persistently 
infected with LCMV clone 13 (30 days prior) were co-infected with 102 pfu ECTV ip. All 
mice were monitored for physical symptoms, viral load and mouse survival. LCMV clone 
13 infection in naïve mice results in sustained viral titers up to 60 days post infection, but 
it does not cause overwhelming pathology due to exhaustion of the responding T cells. 
Surprisingly, age matched naive mice infected intraperitoneal with 100 pfu ECTV 
succumbed to ECTV mediated disease at day 8 post ECTV exposure. Thus, highlighting 
the virulence of ECTV infection given intraperitoneally in C57Bl/6 mice. LCMV clone 13 
persistently infected mice also succumbed to disease 8 days post infection ETCV 
infection. Indicating that the sustained IFN-I produced during clone 13 infection is not 
great enough to limit ECTV replication and promote survival.  
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Figure 4.5: Sustained IFN-I production in persistently infected mice does 
not limit ECTV replication or disease after exposure. C57Bl/6 mice persistently 
infected with LCMV clone 13 (30 days prior) were co-infected with 102 pfu ECTV ip. All 
mice were monitored for morbidity and mortality. Percent survival of age matched mice 
infected with 100 pfu ECTV and LCMV clone 13 persistently infected mice co-infected 
with 102 pfu ECTV. 
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DISCUSSION 
Our results highlight the potential consequence of virus-virus co-infection that 
can result in modulation of T cell immunity and influence disease. However, the ability 
of the secondary virus to persist in the host dramatically alters the bi-directional affects 
on immunity and pathology. Mice co-infected with acute LCMV and ECTV demonstrate 
reduced ECTV replication, resulting in rescue of disease, and enhanced survival. 
Conversely, mice co-infected with the persistent strain of LCMV and ECTV could not 
control ECTV replication and perished by 9 days post infection. ECTV viral load in the 
liver of ECTV/CL13 co-infected mice was of equal magnitude to ECTV viral load in the 
liver of mice infected with ECTV alone (one day prior to onset of morbidity requiring 
euthanasia). Maximum viral load was not reached until day nine, resulting in a modest 
three-day increase in survival prior to fatal disease progression.  
One similar outcome of co-infection between acute and persistent strains of 
LCMV and ECTV was ECTV modulation of Type I IFN production resulting in 
attenuation of LCMV-specific CD8 T cell effector expansion. The dramatic difference in 
viral dissemination between Armstrong and Clone 13 due to two amino acid mutations 
increasing replication rate and viral tropism does not impact the sequence of T cell 
epitopes presented to virus-specific T cells(276). Therefore, the observed decrease in 
effector expansion was not unexpected, because LCMV responses are known to be 
dependent on direct signaling via Type I IFN for sustained proliferation(60, 399). 
However, the attenuation in the primary response to acute LCMV did not alter initial 
viral control, nor the protective capacity of LCMV-specific, effector memory biased, CD8 
T cells to persistent viral challenge.  
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The ability of ECTV/ARM co-infected mice to protect against LCMV clone 13 challenge 
may have been due to proliferation of the small proportion of central memory CD8 T 
cells and/or the presence of LCMV-specific CD4 memory T cells. On the other hand, 
attenuation of naïve-originating LCMV-specific CD8 T cell effector expansion by ECTV 
during persistent LCMV infection results in 10-fold greater LCMV viral load in the serum 
prior to mice succumbing to liver pathology.  
Prior investigation into the mechanism in which LCMV Armstrong influences 
ECTV replication and disease determined that systemic IFN-I levels changed during co-
infection. Serum levels of total IFNα and IFNβ in ECTV infected mice were undetectable, 
presumably due to the action of ECTV immunomodulatory viral proteins, such as E3L 
and IFN-I binding protein, that effectively shut down Type I IFN production(336). In  
contrast, ECTV/ARM co-infection resulted in an increase in serum levels of both IFNα 
and IFNβ, compared to mice infected with ECTV. However, Serum IFNβ was found to be 
significantly lower in ECTV/ARM co-infected mice compared to mice infected with 
LCMV Armstrong alone. LCMV clone 13 has been shown to produce ~4x the amount of 
IFNβ in the serum(398). Although, the presumed increase in IFN-I during LCMV clone 
13 co-infection did not increase survival or limit ECTV viral replication. 
 However, ECTV/Cl13 co-infection did reduce LCMV immunity, implicating there 
is a significant reduction in IFN-I in co-infected mice. Additionally, ECTV/Cl13 infected 
mice had 10-fold greater LCMV viral load in the serum. It is unknown whether the 
increase in LCMV replication and decrease in viral control was due to lower magnitude T 
cell responses or if altered IFN-I production between 12-24 hours significantly impacts 
control of LCMV clone 13, more so than LCMV Armstrong.  
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Although, the three-day increase in survival in ECTV/Cl13 co-infected mice could be due 
to the anti-viral effects of Type I interferon during peak induction, between 12-24 hours 
post infection, initially limiting ECTV replication. 
The use of poxvirus vectors to decrease IFN-I signaling in a setting of persistent 
viral infection that has detrimental sustained IFN-I production is inconclusive. Mice 
persistently infected with LCMV clone 13 thirty days prior to ECTV exposure succumbed 
to ECTV mediated disease. Indicating that the sustained IFN-I produced during clone 13 
infection was not high enough to overcome lethality of ECTV infection. Mortality due to 
ECTV viral replication did not allow the determination of the therapeutic potential of 
ECTV immunomodulatory proteins to limit IFN-I produced during persistent LCMV 
infection. Future experiments should investigate if less pathogenic ECTV mutants can 
mediate blockade of IFN-I, without leading to overwhelming pathology in the liver. 
Persistent viral infection is characterized by chronic antigen stimulation and 
persistent inflammation due to continued viral replication over time(234, 237). Under 
conditions of chronic antigen stimulation, CD8 T cells do not undergo traditional 
differentiation into functional memory cells(232, 238). There are multiple alterations to 
the T cell response that occur under situations of chronic antigen stimulation such as T 
cell localization, functionality, and breadth of response(232, 239). It is unknown at this 
time how the combination of normal T cell dysfunction, due to increased antigen 
stimulation, and the attenuation of the CD8 T cell response, due to ECTV alteration of 
IFN-I production and signaling, is responsible for the decrease in LCMV immunity and 
viral control during co-infection.  
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Future studies should investigate if the decreased effector expansion of LCMV 
specific T cells due to IFN-I modulation affects the level of exhaustion of those cells 
resulting in decreased viral control. Particularly in settings when the precursor frequency 
of antigen-specific memory cells can induce increased pathology, due to partial T cell 
exhaustion(239). The results presented above demonstrate an additional consequence 
between disease outcomes due to persistent versus acute viral infections. 
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CHAPTER 5 
DISCUSSION 
Through the use of mouse-models of acute and persistent virus infection, we have 
investigated how both virus and immune system variables influence pathogenic versus 
protective CD8 T cell responses generated during viral infection or after vaccination. In 
addition, an interdisciplinary collaboration with mathematical modelers has allowed us 
to provided experimental evidence that validate quantitative mathematical models of 
viral infection and immune response, which predict the molecular and cellular pathways 
that mediate T cell protection versus pathology. We have examined the variations in CD8 
T cell immunity and disease that may occur during the context of heterologous viral co-
infection and we have shown another consequence of viral persistence in the context of 
viral co-infection. We have shown antigen persistence influences the interplay between 
two viruses that result in modulation of immune response and disease during co-
infection. 
 Our results have furthered our understanding of potential vaccine-mediated 
increase in disease, due to variations in antigen-specific T cell precursor frequency that 
changes the threshold of T cell exhaustion of responding cells. Furthermore, Type I 
interferon produced during acute viral co-infection can overcome poxvirus 
immunomodulatory proteins, enhancing survival in co-infected mice. Additionally, viral 
persistence eliminates the beneficial effects of co-infection between LCMV and ECTV, 
highlighting the immense difference in T cell responses during persistent versus acute 
infection.  
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Immune memory was utilized to decrease disease burden in humans long before 
the adaptive immune cells responsible for providing the observed protection from 
subsequent exposure were discovered and meticulously evaluated(1, 2). One of the most 
relevant and impactful contributions of immunology to human health is the ability to 
utilize immune memory for the design of vaccines against infectious diseases(7, 10). 
Expanded vaccination coverage has significantly enhanced our ability to limit or prevent 
human diseases caused by infectious pathogens(12, 13). Vaccines designed against 
smallpox, polio and measles are excellent examples of the remarkable impact vaccination 
can make towards the reduction of the global disease burden(1, 14).  Although, the 
extensive study and characterization of pre-programmed immune cells that respond 
faster and with greater magnitude to secondary infection to limit disease(7-9), has not 
facilitated the elimination of all infectious pathogens that cause premature death and 
disease in humans(11). In 2013, four of the top ten leading global causes of premature 
death in humans are diseases were due to infectious pathogens(11).  
The failure to design a vaccine to prevent HIV/AIDS in humans is leading 
example of the need to continue to dissect the intricacies of immunity to persistent viral 
infection. In 2013, 35 million people were estimated to be living with HIV resulting in an 
estimated 1.5 million deaths due to HIV-related causes(11). Effective antiretroviral 
therapy has increased the quality and longevity of life in HIV-infected individuals(20). 
However, in 2o13, 2.1 million people worldwide became newly infected with HIV(11), 
emphasizing the need for a vaccine that prevents infection in order to eliminate 
HIV/AIDS in humans(21).The traditional approach in order to design a vaccine against 
HIV has been challenging (17, 21-23).  
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Therefore, vaccination for T cell responses using recombinant vectors has been 
proposed as an alternative strategy to elicit immune responses and continues to be the 
focus of future vaccine candidates(21, 24, 25). However, our data suggest that vaccines 
designed to only generate T cell responses for persistent viral infections known to induce 
T cell exhaustion, may result in unintended increases in disease due to partial T 
exhaustion of responding memory CD8 T cells.  
Initial studies have been able to model increased pathology during persistent 
infection due to changes in antigen-specific CD8 T cell precursor frequency. However, 
adoptive transfer of naïve transgenic CD8 T cells to study potential vaccine induced 
pathology is limited by the use of naïve CD8 T cells and transgenic T cells specific for 
only one epitope of LCMV. The adoptive transfer of naïve T cells is a limitation because 
vaccination induces the formation of memory CD8 T cells that differ from naïve CD8 T 
cell subsets. Memory CD8 T cells undergo additional changes in phenotype, function and 
gene expression during differentiation 1-2 months after infection. This results in the 
establishment of a pool of antigen-specific T cells that can be maintained without 
continued antigen stimulation(9).  
Memory CD8 T cells can rapidly respond to secondary infection primarily due to 
a simple increase in precursor frequency of antigen-specific cells and the retained 
potential to rapidly kill infected cells(223). Memory CD8 T cells can release 
perforin/granzyme B and produce large amounts of IFNγ and TNF after exposure to an 
antigen without the activation and proliferation via traditional stimulation from APCs in 
draining lymph nodes(9, 211, 224). These differences enable memory CD8 T cells to 
respond more rapidly to subsequent infections.  
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 Previous studies regarding immunopathology during persistent LCMV infection 
have not compared the ability of naïve and memory CD8 T cells to mediate similar 
enhancement of pathology during responses to persistent LCMV infection. In addition, 
the previously developed mathematical model of LCMV infection in mice has generated 
predictions about which virus and host immune parameters can differentially affect 
pathology versus protection during persistent viral infection. The model predicts that 
increased sensitivity to viral infection by memory CD8 T cells should not change the 
potential for maximum disease, due to an intermediate precursor frequency, because 
simulations generated from the model are relatively insensitive to the parameter that 
describes sensitivity. We have tested this prediction and our results indicate that CD8 T 
cell pathology, due to an intermediate precursor of antigen-specific CD8 T cells, is largely 
independent of CD8 T cell sensitivity. Morbidity and mortality after adoptive transfer of 
an intermediate number of transgenic memory antigen-specific or transgenic naïve- 
antigen specific CD8 T cells was indistinguishable. 
 However, qualitative differences between the location of pathology indicate the 
kinetics of the response to virus (influenced by sensitivity) do have a marginal impact. 
Memory CD8 T cells resulted in pathology contained to the liver, whereas naïve CD8 T 
cells induced maximum pathology in the lungs. Since memory CD8 T cells respond 
rapidly upon secondary infection, they may traffic to the liver, an early site of viral 
replication. Whereas naïve cells may traffic to the lungs, a secondary site of viral 
replication(273).  
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Although in either scenario maximum pathology is due to an intermediate number of 
antigen-specific cells, regardless of antigen-experience. Mice that had high numbers of 
memory CD8 T cells prior to high dose viral infection did not develop immunopathology 
because the magnitude of the response was great enough to control viral replication by 8 
days post infection. Additionally, pathology did not occur from low precursor frequency 
of memory LCMV specific T cells prior to LCMV clone 13 infection.  
Analysis of T cell persistence and functional capacity support the hypothesis that 
T cell exhaustion is a mechanism during persistent viral infection to avoid pathology, 
since responding T cells lose the ability to proliferate and produce inflammatory 
cytokines such as TNF. Mice that had low numbers of memory CD8 T cells or no memory 
CD8 T cells prior to high dose infection did not develop immunopathology because the 
responding CD8 T cells were highly exhausted and unable exert effector function. 
Whereas mice that had an intermediate number of memory CD8 T cells prior to high 
dose viral infection developed severe pathology due to partial T cell exhaustion of the 
response resulting in ongoing high viral titers and pathology presumed due to continued 
production of TNF.  
However, when the initial viral dose decreases by one log, lower numbers of 
memory CD8 T cells became only partially exhausted, leading to an increase in pathology 
at a low dose of cells similar to mice receiving intermediate numbers of CD8 T cells after 
high dose infection. Decreasing the initial amount of stimulation provided to the T cells, 
by varying the magnitude of viral infection, alters the frequency at which the responding 
T cells can result in pathogenic responses.  These results are consistent with published 
data indicating that T cell exhaustion may be a mechanism to limit immunopathology of 
naïve CD8 T cells(275, 384). Increase in pathology can occur due to partial exhaustion of 
the T cell response, as mediated by initial viral dose.  
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Our experimental results expand on these findings, indicating there is a fine balance 
between the magnitude and functionality of the memory CD8 T cell response in addition 
to initial viral dose (Figure 5.1). Although, the use of transgenic memory T cells specific 
for one LCMV epitope can limit the investigation of T cell pathology to only very narrow 
T cell responses to viral infection. 
Initial studies by Oehen et al, demonstrated vaccination with recombinant 
vaccinia virus vectors expressing LCMV protein antigens resulted in increased pathology 
during subsequent infection with LCMV, compared to non-vaccinated animals. One 
main hypothesis from these studies was that T cell mediated immunopathology was a 
result of the limited breadth of the CD8 T cell response after vaccination using 
recombinant vectors(303).  However, the developed quantitative model predicts that 
increasing the breadth of the CD8 T cell response should have no impact on resulting 
immunopathology. Our data showed the increase in immunopathology resulting in 
mortality, due to transfer of polyclonal LCMV-specific memory cells prior to LCMV clone 
13 challenge, was indistinguishable from survival data generated after transfer of an 
intermediate number of monoclonal-transgenic memory P14 cells. Therefore, TCR 
diversity does not eliminate the potential for pathology due to partial exhaustion of 
responding CD8 T cells. 
The observed increase in disease from varying precursor frequency of polyclonal 
or monoclonal memory LCMV specific CD8 T cells validate the mathematical model 
prediction that the breadth of the T cell response induced by vaccination is independent 
of the observed pathology. Thus, the breadth of the T cell response has no impact on the 
dose of cells that cause maximum pathology. Furthermore, generation of LCMV viral 
variants that evade T cell recognition were not observed after high dose memory transfer 
(polyclonal or transgenic p14).  
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Indicating that immune responses generated from memory CD8 T cells are superior in 
virus control due to the absence of variant escape viruses. Presumably due to the kinetics 
of the response, indicating memory T cells can control viral loads before selective 
pressure results in an escape mutant.  
Our results indicate a wide range of precursor frequencies could potentially cause 
pathology depending on viral dose of subsequent exposure. Therefore, the strength of the 
vaccine response for an individual may or may not be pathogenic depending on the 
individual’s subsequent viral exposure. In order to avoid potential vaccine induced 
pathology the CD8 T cell response must be above a critical threshold to limit pathology 
due to early viral control. In addition, vaccines that only elicit one arm of the immune 
system should be avoided over vaccine candidates that also stimulate antibody 
production and CD4 T cell help. Since the combination of responding immune cells may 
influence early viral control decreasing the chance of pathology at a wider range of 
precursor frequency.  
In addition, pathology was observed to be dependent on TNF production by 
responding CD8 T cells. However, abrogation of TNF signaling did not alter the capacity 
for effector responses originating after high dose transfer to protect from persistent viral 
infection. Implicating that blockade of TNF could be a potential treatment for T cell 
pathology during persistent infection that would not severely impact the ability of T cells 
to mediate viral control. Our results will provide empirical refinements of the developed 
mathematical model of LCMV infection and vaccine-induced T cell responses. The 
refined model may then be used to make predictions about vaccine-induced pathology 
that might occur during immunization against other pathogens, in particular with 
vaccines that employ T-cell epitope based approaches.  
  
  157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Model of vaccine-induced immunopathology due to intermediate 
CD8 T cell immunity levels prior to persistent viral challenge. Virus-specific 
memory CD8 T cells primed by vaccination can induce unintended pathology during 
persistent viral challenge due to high initial viral load and partial exhaustion of CD8 T 
cells. Thus resulting in greater cytokine production and a corresponding increase in 
disease compared to naïve infected or low precursor frequency infected individuals that 
undergo greater T cell exhaustion and loss of effector function. High precursor frequency 
of virus-specific memory CD8 T cells does not cause disease due to early viral control 
resulting in contraction of T cell response prior to unintended tissue damage. 
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The majority of mouse models of persistent viral infection have used a 
reductionist approach to understand virus-host interactions in which specific cell 
populations and proteins are classified and dissected to determine their relative impact 
on the immune response. Therefore, the majority of microbiological research is 
performed in specific-pathogen-free, clean, and controlled environments that limit 
potential co-infection by heterologous pathogens. However, most “real-world” infections 
likely occur in the context of co-infection by heterologous pathogens or host 
microbiota(346) Viral co-infection can occur by simultaneous exposure of two 
heterologous viruses that may share the same route of transmission or chronically 
infected individuals can become co-infected after independent exposure to circulating 
viral strains. Our results indicating there is a fine balance between pathogenic and 
protective T cell responses during viral infection, which is dictated by the magnitude and 
functionality of the memory CD8 T cell response similarly disregarded the potential 
impact of immune modulation due to heterologous co-infection.  
However, HIV co-infection with Hepatitis virus has emerged as a major source of 
morbidity and mortality in HIV-infected individuals(355). Co-infection with HCV and 
HIV is a relatively common event occurring in 15-30% of all HIV-infected individuals 
and 5-10% of all HCV-infected individuals(356, 357). HIV co-infection is associated with 
weaker HCV adaptive immune responses, increased liver fibrosis, higher HCV RNA 
levels, reduced response rates to anti-viral treatment, and worse HCV disease 
progression(356, 358). The differences in immunity and disease in co-infected 
individuals may be due to alterations in the intrahepatic cytokine milieu as a result of 
HIV infection(359, 360).  
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Our results demonstrate interaction between endemic but unrelated viruses 
during co-infection of mice may limit disease and immunity. Mice co-infected with 
LCMV and ECTV demonstrated reduced ECTV replication resulting in reduced disease 
and enhanced survival. Conversely, ECTV co-infection resulted in reduced LCMV-
specific CD8 T cell responses. The data suggest that these effects are primarily due to 
modulation of Type I IFN levels, with primarily lower IFNβ levels in ECTV/LCMV co-
infected mice compared to mice infected with LCMV alone. Our results implicate Type I 
IFN production and/or signaling as the main mechanism by which LCMV suppresses 
ECTV replication and disease in ECTV/LCMV co-infected mice. LCMV infection post 
ECTV exposure was likely ineffective as ECTV proteins have effectively shut down Type I 
IFN signaling(336, 341). Although, treatment with IFN-I prior to 24 hours post ECTV 
exposure may allow for prophylactic IFN-I induction by LCMV. 
Our results also show that ECTV modulation of Type I IFN production during 
ECTV/LCMV co-infection attenuates LCMV-specific CD8 T cell responses that are 
dependent on direct signaling via Type I IFN for sustained proliferation. Although we 
found minimal differences in IFNα in ECTV/LCMV co-infected mice compared to mice 
infected with LCMV alone, we did observe significantly and consistently lower levels of 
systemic IFNβ in co-infected mice. Therefore, our data suggests that IFNβ, rather than 
IFNα, plays a larger role in supporting sustained CD8 T cell proliferation during LCMV 
infection. We also show that ECTV partial suppression of Type I IFN during LCMV co-
infection results in decreased memory CD8 T cell functionality and biasing towards an 
effector-memory phenotype (Figure 5.2).  
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Figure 5.2: Bi-directional effects of viral co-infection on disease and 
immunity. Mice co-infected with LCMV and ECTV demonstrated reduced ECTV 
replication resulting in reduced disease and enhanced survival. Conversely, ECTV co-
infection resulted in reduced LCMV-specific CD8 T cell responses. The data suggest that 
these effects are primarily due to modulation of Type I IFN levels, with primarily lower 
IFNβ levels in ECTV/LCMV co-infected mice compared to mice infected with LCMV 
alone. Our results implicate Type I IFN production and/or signaling as the main 
mechanism by which LCMV suppresses ECTV replication and disease in ECTV/LCMV 
co-infected mice. 
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While we observed no difference in the ability of memory cells in either group to control 
subsequent LCMV infection, it has been shown that central-memory are better able to 
control LCMV infection compared to effector-memory cells(9). Taken together with the 
decreased TNF production by these cells, our results suggest that ECTV co-infection 
results in a slight impairment of LCMV-specific immunity.  
The critical finding of these studies is that ECTV/LCMV co-infection alters the 
magnitude, function, and phenotype of CD8 T cell responses. One implication of this 
observation is that heterogeneity in T cell responses during vaccination and/or viral 
infection(415) may be in part explained by the context of other infections. This is 
particularly relevant for vaccination studies using recombinant orthopoxviruses as 
vaccine vectors for other pathogens(25), as individuals with other infections (or other 
vaccinations) may attenuate the effectiveness of such strategies. Furthermore, extension 
of this model to compare the effect of viral immunomodulatory proteins altering the 
cytokine milieu during co-infection with persistent strains rather than acute strains 
highlight additional consequences of viral persistence on immunity.  
Our results demonstrate that ECTV/CL13 co-infection of mice results in 
differential outcomes in T cell immunity and disease. Persistent Clone 13 co-infection 
with ECTV induced only a marginal increase in survival, as compared to complete rescue 
in 70% of older Armstrong co-infected mice. Indicating there may be a lower threshold 
for ECTV-replication mediated liver pathology. This may be due to persistent LCMV 
Clone 13 in the liver also driving liver pathology, due to responding LCMV-specific CD8 
T cells. We also show that ECTV co-infection with persistent LCMV results in diminished 
LCMV-specific CD8 T cell effector expansion. However, the attenuation in the primary 
response to acute LCMV did not alter initial viral control, nor the protective capacity of 
LCMV-specific, effector memory biased, CD8 T cells to persistent viral challenge. 
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Although, the ability of ECTV/ARM co-infected mice to protect against LCMV clone 13 
challenge may have been due to proliferation of the small proportion of central memory 
CD8 T cells and/or the presence of LCMV-specific CD4 memory T cells.  
On the other hand, attenuation of naïve-originating LCMV-specific CD8 T cell effector 
expansion by ECTV during persistent LCMV infection results in 10-fold greater LCMV 
viral load in the serum prior to mice succumbing to liver pathology.  
Together our data provide experimental evidence for differential effects of acute 
versus persistent viruses during virus infection and viral co-infection that modulate 
disease and immunity. Intermediate precursor frequency of virus-specific memory CD8 
T cells prior to LCMV infection resulted in maximum T cell mediated pathology and the 
threshold for exhaustion of responding CD8 T cells ultimately influenced the precursor 
frequency that causes enhanced disease. Furthermore, we also show that ECTV co-
infection with persistent LCMV results in diminished LCMV-specific CD8 T cell effector 
expansion. Thus, suggesting viral co-infection may influence pathogenic and protective T 
cell responses that are dictated by the magnitude and functionality of the memory CD8 T 
cell response. Furthermore, co-infection could either abrogate pathology, via reduction 
of the magnitude of an intermediate response, or induce pathology, via reduction of the 
magnitude of a high precursor response of antigen-specific memory CD8 T cells. 
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